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Allergic diseases are the result of a complex interaction of environmental 
factors and genetic susceptibilities that lead to the induction of improper T 
helper 2 (Th2) responses and production of specific immunoglobulin E (IgE) 
antibodies to harmless environmental antigens 1. The prevalence of allergic 
diseases has dramatically increased during the last four decades and is still 
increasing worldwide, affecting the quality of life of a significant proportion 
of the world’s population 2;3. While the reasons for this increase are largely 
unknown, changes in environmental factors including vast changes in life-
style are thought to play an important role 4. The following changes in 
environmental factors coincided with the increase in allergic diseases, and 
may offer explanations for their increased prevalence: (i) reduced exposure 
to microbial infection as stated in the hygiene hypothesis 5, (ii) increased 
exposure to perennial allergens 4, (iii) decline in physical exercise and changes 
in diet such as decreased proportion of the vitamins in the food and increased 
usage of iron intake by infants in affluent societies 4;6-8. However, any causal 
association between the mentioned hypotheses and increased prevalence of 
allergic disease remains to be elucidated.
Given the high level of discomfort caused by allergic diseases, the high 
number of affected patients worldwide and the lack of options for disease 
prevention, an efficient treatment that modifies the deleterious immune 
reaction to allergens appears to be the best resolution for allergic diseases 9. A 
wide range of pharmaceutical therapies are available for treatment of different 
allergic diseases 10. Most of these therapies aim at reducing the symptoms of 
the disease while leaving the root immunological cause of the disease intact 
10. Currently, allergen specific immunotherapy (SIT) is the only treatment 
for allergic diseases that targets the root immunological base of the disease 
and leads to long-lasting relief of allergic symptoms 11. However, despite 
the high efficacy in allergic rhinitis and venom allergies, the efficacy of SIT 
in allergic asthma and patients with multiple allergies is controversial and 
requires improvement 10-13. Rational improvement of SIT requires a detailed 
knowledge of the mechanism of action of SIT in inducing allergen tolerance. 
This detailed mechanistic understanding of the mechanism of action of SIT 
is currently lacking. 
In this dissertation, we will first address the role of high iron intake in 
exacerbating the symptoms of allergic asthma, thereby testing the hypothesis 
that increased iron intake by infants could contribute to the increased prevalence 
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of allergic diseases during the past four decades. Next, we will disclose the 
results of studies that we have performed to unravel the mechanisms of SIT-
induced tolerance and its effector functions during allergen inhalation as well 
as two strategies that we used to improve the efficacy of SIT in a mouse 
model of ovalbumin-based SIT. 
Allergic reaction: course of actions
Environmental antigens are constantly being sampled by local dendritic cells 
in the lungs, gastrointestinal tract and skin, and presented to T cells in the 
regional draining lymph nodes 14. Allergen, at the first encounter, elicits an 
antigen specific Th2 response in susceptible individuals in regional lymph 
nodes followed by migration of the allergen specific Th2 cells to the location 
of allergen exposure 15. Consequently, allergen specific Th2 cells instruct B 
cells to produce allergen specific IgE by secreting IL-4 and IL-13 16.  IgE 
circulates in the blood and causes allergic sensitization by binding to high 
affinity IgE receptors (FCεRI) expressed by mast cells and basophils enabling 
these cells to respond to the allergen. Subsequent exposure to the allergen 
results in cross-linking of the cell-surface bound IgE and degranulation of 
mast cells and basophils, leading to the early-phase allergic reaction 15. Early-
phase allergic reaction occurs within minutes after allergen exposure due to 
the contents of mast cell granules such as histamine and newly synthesized 
lipid mediators including prostaglandin D2 and leukotrienes 15;17. Vasodilation, 
increased vascular permeability, bronchoconstriction and airway mucus 
secretion are some of the features of early phase reaction which can last 
for a few hours 15;18. Allergen presentation to Th2 memory cells by antigen 
presenting cells induces the late-phase allergic reaction. During the late phase 
reaction, which starts within a few hours of allergen exposure and lasts for 
several hours, cytokine contents of mast cell granules enhance activation 
and recruitments of Th2 cells, eosinophils, basophils to the site of allergen 
exposure 15;18. Edema, skin erythema, airway narrowing and mucus hyper-
production at the site of allergen are the features of the late allergic reaction 19. 
Allergic asthma
Allergic asthma is a chronic allergic disease of the lungs characterized by 
airway inflammation, airway hyperreactivity (AHR) and excess mucus 
production in the airways 20. While the prevalence of asthma is increased by 
approximately 50% every decade, it is estimated that more than 300 million 
people suffer from asthma worldwide 21;22. Now it has become clear that the 




cause of asthma 23. However, pointing out only Th2 cells in the pathogenesis 
of asthma seems to be an oversimplification and there may be a role for other 
T cell subsets in the pathogenesis of asthma 24;25. Moreover, there appear to 
be asthma subphenotypes including a Th2-high phenotype in approximately 
50% of the patients 26-28. 
Allergen specific immunotherapy
SIT is currently the only treatment for allergic diseases that aims to restore the 
loss of allergen tolerance by targeting the root cause of allergic diseases 11;29. 
The clinical efficacy was first documented by Noon and colleagues in 1911 30. 
SIT is performed by repeated administration of high doses of the sensitizing 
allergen for a period of three to five years. In order to reduce the risk of 
side-effects such as anaphylactic reactions, the treatment starts with an initial 
period of low but gradually increasing doses of allergen administration 31. 
Currently, SIT treatment has some disadvantages, including the need for long-
term treatment, potential risk of anaphylactic reactions and variable efficacy 
in the treatment outcome in different patients. 32-34. There is an urgent need 
for improving SIT in a way that lower doses of allergen and shorter treatment 
protocols can induce optimal tolerogenic efficacy in a short period of time 
in all treated patients. Rational improvement of SIT requires of an exact and 
detailed understanding of the mechanism of action of SIT. The mechanism(s) 
by which SIT generates or restores tolerance to the sensitizing allergen is 
incompletely understood to date 35. 
Routes of SIT
Subcutaneous immunotherapy (SCIT)
SCIT is the classical form of SIT 36, in which the allergen is administered 
to the hypo-dermal layer of the skin where it can be captured by in situ 
antigen presenting cells such as skin conventional dendritic cells (DCs) and 
macrophages or by skin recruited plasmacytoid DCs 37. Captured allergen is 
then conveyed by the APCs and presented to T cells in the draining lymph 
nodes 37. SCIT is accompanied by a potential risk of anaphylactic reactions 
and therefore, it needs to be performed by authorized health care professionals. 
Requirement for repeated referral to the clinic for a period of 3-5 years in 




Sublingual immunotherapy has been developed as a less invasive alternative 
for SCIT that could be performed outside the clinic 38. In this method of 
SIT, allergen is given to the patients in the form of oral tablets and droplets 
which have to be used under the tongue at specified intervals 39;40. Presence of 
patients in the clinic is not required in SLIT 39. The type of APCs involved in 
SLIT has yet to be determined, however, mucosal langerhans cells in humans 
and oral macrophage-like cells in mouse model have been implicated 41;42. 
The efficacy of SLIT in suppressing the allergic symptoms has been shown in 
several studies 43-46. 
Other methods
Beside SLIT and SCIT other methods of SIT have been suggested. Senti and 
colleagues have shown that intra-lymphatic application of SIT requires lower 
doses of allergen and less frequent need for injection than SLIT while still 
being highly efficient in suppressing the symptoms of the disease 47. The use 
of skin patches has also been suggested as a safe method of SIT. Applied 
allergen to the skin using skin patches could be captured by Langerhans cells 
that are highly tolerogenic 48. The efficacy and safety of intra-lymphatic SIT 
and skin patches have yet to be further elucidated. 
Potential mechanisms of allergen immunotherapy
Successful SIT leads to allergen tolerance as evident by suppressed Th2 as 
well as effector cells such as eosinophils and basophils. In addition, allergen-
specific immunoglobulin responses display a shift from IgE to IgG and IgA 
35. Different hypotheses have been postulated to explain the mechanism of 
SIT-induced allergen tolerance. Generation of inducible regulatory T cells, 
blocking IgG antibodies, clonal deletion and anergy of allergen-specific Th2 
cells are the major mechanisms of action that are thought to contribute to 
clinical efficacy of SIT 35. The long-term efficacy of SIT indicates the presence 
of immunological memory, implicating  either B or T cell subsets in SIT-
induced allergen tolerance 49.  
B cell mediated tolerance induction: Regulatory B cells and 
Blocking IgG
B cells can contribute to SIT-induced allergen tolerance by playing two roles. 
The first role is the acquisition of suppressive regulatory activities. It has 




capable of suppressing the allergic airway inflammation 50. Interestingly, it 
has been shown that regulatory B cells induce their suppressive effects by 
producing interleukin-10 (IL-10) 51, the tolerance associated cytokine that 
has also been implicated in SIT-induced allergen tolerance 35;52. However, 
the role of regulatory B cells in SIT-induced allergen tolerance has yet to be 
elucidated.   
The second potential role of B cells in SIT-induced allergen tolerance is by 
producing blocking IgG antibodies 53. Induction of allergen specific IgG, 
especially IgG4, and IgA has been observed after successful SIT in human 
patients 52;54;55. SIT-induced allergen-specific IgG antibodies can contribute to 
the therapeutic effects of SIT by two mechanisms. These antibodies can bind 
to the allergen, thereby effectively competing with the specific IgE for the 
allergen, preventing IgE cross linking and subsequent mast cell and basophil 
degranulation as well as preventing IgE facilitated antigen presentation 53;56;57. 
Moreover, the specific IgG antibodies can bind to FcγRIIB expressed by 
B cells, mast cells and basophils, which upon allergen-mediated IgG cross 
linking provides a negative intracellular signal and prevents cell activation, 
even upon co-aggregation with FcεRI 58.  
T cell mediated tolerance induction: Regulatory T cells
Role of DCs in the induction of tolerance by allergen immunotherapy
To elicit an efficient T cell mediated immune response, antigen presentation 
is the first key step. DCs are heterogeneous population of specialized antigen 
presenting cells that have the unique capability of presenting antigens to naïve T 
cells in an immunogenic fashion 59;60. Nevertheless, DCs can, like other subsets 
of APCs, also induce tolerance in naïve T cells. DCs can induce functional T 
cell responses by providing two signals, while determining the phenotype of 
the T cell response by a third signal 61;62.  The first signal is antigen specific, 
and delivered to CD4+ T cells by presenting antigen in the context of MHC-II 
molecules. The second signal is given through co-stimulatory molecules such 
as CD80 and CD86 (B7 molecules). A third signal is provided by cytokines 
produced by the DC or present in the microenvironment, and determines the 
nature of the induced T cell phenotype, such as Th1, Th2 or Th17 63;64. DCs can 
contribute to the induction of allergen tolerance through several mechanisms. 
Tissue resident DCs including epidermal langerhans cells and dermal DCs 
show an immature profile by expressing low level of major histocompatibility 
complex-II (MHC-II) and the absence of co-stimulatory molecules 65;66. 
Antigen presentation by immature DCs can induce T cells anergy 67 or the 
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induction of IL-10 producing iTreg cells 68. DCs exposed to an antigen under 
non-inflammatory conditions acquire a semi-mature phenotype by expressing 
high levels of MHC-II and low levels of co-stimulatory molecules. Similar to 
immature DCs, semi-mature DCs can induce iTreg cells, while mature DCs 
induce effector T cells 69. Approaches that restrain the maturation of DCs such 
as application of vitamin D3 facilitate the induction of tolerance and may 
have therapeutic implications 70. 
Different sub-types of DCs including plasmacytoid and conventional DCs 
play distinct roles in the induction of tolerance or immunity 71. Plasmacytoid 
DCs (pDCs) express the immune-regulating and tryptophan degrading 
enzyme indoleamine 2, 3-dioxygenase (IDO) and have been associated with 
tolerance induction 72. De Heer and colleagues have shown that pDCs play 
an essential role in maintaining tolerance in the lungs to a harmless antigen 
in a mouse model 73. In contrast, conventional DCs have been associated 
with the induction of Th2 and Th1 responses 74, as well as Treg cells 75. 
Surprisingly, there is little known about the role of different subtypes of DCs 
in SIT-induced allergen tolerance 35.
Regulatory T cells
Regulatory T cells (Treg) are key elements of the immune system playing 
crucial roles in controlling immune responses to pathogens and eliciting 
immunological tolerance to self as well as to harmless environmental antigens 
76. Based on the origin and the conditions of their generation, Treg cells are 
classified as naturally occurring (nTreg) and inducible regulatory T cells 
(iTreg) 76. nTreg cells represent a distinct lineage during T cell differentiation 
in the thymus, and constitutively express Forkhead Box P3 (FOXP3), 
Cytotoxic T-Lymphocyte Antigen 4 (CD152) and high levels of interleukin-2 
receptor α-chain (CD25) 77. nTreg cells are thought to have a specificity 
towards, not yet identified self antigens, facilitate the induction of iTreg cells 
and suppress self-reacting effector T cells 78. iTreg cells are generated from 
naïve T cells in the periphery in an antigen-specific manner and these can only 
be induced under certain conditions during antigen presentation, and could 
therefore potentially play important roles in SIT-induced allergen tolerance 76. 
Different subtypes of CD4+ iTreg cells with suppressive capacities have been 
described: (i) FOXP3+ iTreg cells 79, (ii) IL-10 producing Tr-1 cells that do not 
express FOXP3 80, (iii) IL-10 producing FOXP3+ iTreg cells 81 and (iv) TGF-β 
producing iTreg cells called Th3 cells 82. 
There is an increasing body of evidence indicating that iTreg cells contribute to 




54;55;83-86. Several studies have reported that FOXP3+ 87, IL-10 producing 
55, FOXP3+IL-10 producing 88 or TGF-β secreting 89 T cells  are increased 
after SIT in human subjects suggesting that SIT generates allergen-specific 
inducible Treg cells that contribute to the therapeutic effects of SIT in humans. 
FOXP3+ regulatory T cells in SIT
Several clinical studies have provided evidence for a possible role of FOXP3+ 
Treg cells in SIT-induced generation of allergen tolerance. Kerstan and 
colleagues have observed that venom SIT induces activation and homing of 
circulating CD4+CD25+FOXP3+ Treg cells to the secondary lymphoid organs 
leading to a transient decrease of these cells in the circulation one month 
after initiating the treatment 90. During this time, venom-stimulated T cell 
proliferation and IFN-γ production was decreased suggesting a functional 
role for CD4+CD25+FOXP3+ Treg cells in controlling both specific Th2 and 
Th1 immune responses. A different study has reported that at six months after 
the treatment, venom SIT increases the number of circulating CD4+FOXP3+ 
Treg cells which significantly correlates with venom-specific IgG4/IgE ratio 
shift, suggesting a therapeutic role for CD4+FOXP3+ Treg cells 87. It seems 
that after venom-SIT, initially FOXP3+ Treg cells home to the lymphoid 
organs where antigen presentation occurs, followed by their later expansion. 
Radulovic and colleagues have observed that there is an increased number of 
CD4+CD25+FOXP3+ Treg cells in nasal mucosa two years after the initiation 
of grass pollen SIT, suggesting a putative role for these cells also in the local 
suppression of allergic manifestations upon allergen exposure 85. However, 
the functional importance of the observed increase in FOXP3+ Treg numbers 
for the therapeutic effects of SIT has not been clearly shown. 
IL-10, an important tolerance mediator in SIT
IL-10 production has been frequently reported during and after SIT 44;89;91-
93, underscoring the role of this anti-inflammatory cytokine for the induction 
of allergen tolerance by SIT.  IL-10 can induce its anti-inflammatory effects 
through different mechanisms. IL-10 can directly inhibit the activation of Th2 
cells. It has been shown that IL-10 inhibits CD28 costimulatory signaling, 
which is the second signal necessary to elicit a T cell response when the 
first signal is given through T cell receptor 94. IL-10 skews the production 
of antigen specific IgE towards production of IgG4 antibodies  94. Moreover, 
it has been shown that IL-10 can directly dampen the mast cell sensitization 
by inhibiting the expression of FCεRI on mast cells which is a high affinity 
receptor for IgE 95. Different immune cells can produce IL-10 including B 
cells 51, T cells 80 and dendritic cells 96.
16
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IL-10 producing Treg cells in SIT
Several lines of research have provided evidence for IL-10 producing 
Treg cells in SIT. IL-10 production by CD4+CD25+T cells has been 
observed in ex vivo stimulated PBMCs after venom 97, grass pollen 
91, house dust mite 98 and birch pollen SIT 84. It has been shown that 
IL-10 producing CD4+CD25+T cells suppress the allergen induced T cell 
proliferation in ex vivo stimulated PBMCs through an IL-10 dependent 
mechanism 97. Induction of IL-10 producing CD4+CD25+T cells has been 
concurrent with alleviated clinical symptoms and skin prick test reactivity, 
suggesting a functional role for these cells in SIT-induced suppression of 
allergic symptoms 98;84. Local production of IL-10 has also been observed in 
the skin at the site of SIT injections three month after venom SIT 99, and in 
nasal mucosa two years after grass pollen SIT 100 suggesting an involvement 
of a local tolerogenic mechanism through induction of IL-10. In the studies 
mentioned above it is not clear, however, whether the observed CD4+ CD25+ 
IL-10 producing cells are FOXP3- Tr-1 cells or FOXP3+ IL-10 producing 
cells, since FOXP3 has not been measured in the studies. Although it has been 
shown that both FOXP3 positive and negative IL-10 producing subsets have 
similar tolerogenic capacities 80;81, the two subsets are induced by different 
mechanisms.
Evidence for a potential role of IL-10+FOXP3+ Treg cells in therapeutic 
effects of SIT comes from three recent clinical studies. In the first study, the 
investigators observed that house dust mite (HDM) SIT increased the number 
of circulating CD4+CD25+FOXP3+IL-10+ Treg cells one year after the SIT 
treatment in house dust mite sensitized asthmatic children 88. HDM-SIT in 
these children was reported to also increase soluble IL-10 in plasma, which 
was significantly and positively correlated with the Forced Expiratory Volume 
in 1 second (FEV1), an index of lung function, indicating an association of IL-
10 production with clinical improvement. Similarly, the second study found 
that 1.5 to 2 years after HDM-SIT in HDM sensitized allergic children, the 
number of CD4+CD25+FOXP3+IL-10+ Treg cells were increased in ex vivo 
HDM-stimulated peripheral blood mononuclear cells (PBMCs) in comparison 
to SIT-untreated asthmatic children 83. One final study reported that SIT to 
Japanese cedar pollinosis induces CD4+CD25+FOXP3+IL-10+ Treg cells in 
ex vivo stimulated PBMCs, which was accompanied by attenuated IL-4 and 
IL-15 responses and improved clinical symptoms 92. 
All together, clinical studies suggest a role for IL-10 producing Treg cells 
in SIT-induced allergen tolerance. Although these studies have observed a 




IL-10 producing T cells, it has yet to be elucidated whether the observed 
induction of IL-10 producing Treg cells is critically important for the 
therapeutic effects of SIT.   
TGF-β  producing Th-3 regulatory T cells in SIT
Transforming Growth Factor-b plays important roles in immune regulation 
and homeostasis 101. TGF-β has been implicated in SIT and can contribute 
to SIT-mediated tolerance induction through different mechanisms. The first 
mechanism of action for TGF-β is facilitating the induction of FOXP3+ Treg 
cells. TGF-β can induce FOXP3+ iTreg cells from naïve T cells upon antigen 
stimulation in the absence of IL-6 102;103 or presence of all-trans retinoic acid 
104. TGF-β producing Th3 cells are a subtype of iTreg cells that were first 
identified during the induction of oral tolerance 105. The second mechanism of 
action for TGF-β is instructing B cells to produce antigen specific IgA which 
can bind to allergen preventing its binding to IgE 106. Several clinical studies 
have observed increased TGF-β production after different SIT treatments. 
The first study showed that HDM-SIT reduces the ex vivo allergen specific 
proliferation of T cells from the pool of PBMCs during the first 70 days of 
the treatment 89. Neutralization of TGF-β in these cultures using soluble 
TGF-β receptor II increased the specific proliferation of T cells in this study, 
suggesting that SIT-induced suppression of T cell proliferation is mediated 
by TGF-β. Likewise, O’Hehir and colleagues have observed that sublingual 
HDM-SIT resulted in suppressed ex vivo allergen-specific proliferation of T 
cells 6 month after starting the treatment 107. Again, neutralization of TGF-β in 
the cultures using TGF-βRII-Ig augmented the allergen-specific proliferation 
of T cells of SIT-treated patients. In a different study, it was shown that grass 
pollen SIT increased the expression level of mRNA of TGFb in nasal mucosa 
and specific IgA2 in serum of the treated patients 2 years after the treatment 
100. 
The authors observed that the TGF-β expression level positively correlated 
with the level of specific IgA2 in serum indicating a potential contribution 
of TGF-β to the immunoglobulin class switching of B cells.  A similar 
observation was reported 2 years after pollen SLIT 45. Increased levels of 
TGF-β were observed in the serum of treated patients, and these correlated 
with the increased level of serum IgA two years after the treatment. Another 
study reported that HDM-SIT increased the level of TGF-β in the serum of 
treated patients which significantly correlated with the improved FEV1 in 
these patients one year after the treatment 88. All together, data from clinical 
studies suggest a role for TGF-β in SIT-induced allergen tolerance. TGF-β 
can be produced by a variety of immune cells including dendritic cells, B 
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cells and T cells 75;108;109; however, the source of production of TGF-β in SIT 
and its detailed mechanism of action is currently incompletely understood. 
Improvement of SIT
There is an unmet medical need for improving the clinical efficacy of SIT 35. 
One approach towards improving the efficacy of SIT is modifying the immune 
response to the administered allergen by triggering pathogen associated 
pattern recognition receptors (PPRs) such as toll-like receptors and NOD-
like receptors on dendritic cells during SIT treatment 110. Alum, the classical 
adjuvant of SIT, triggers NALP3 on dendritic cells and has shown a good 
safety profile while its efficacy in improving SIT is not optimal 110;111 so there 
is a need for a better adjuvant. It has been shown that lipopolysaccharide, 
polyinosinic-polycytidylic acid (polyIC), CpG-containing DNA sequences 
are able to inhibit Th2 cell activation and could potentially be used as 
adjuvant for SIT 112. However, safety of such compounds should be addressed 
cautiously since ligands of PPRs are potent immunostimulators and they can 
lead to undesirable immune reactions 112. 
Another approach to improve the efficacy of SIT is by facilitating the 
generation of iTreg cells for instance by inhibiting DC maturation through 
administration of vitamin D3 or tryptophan deprivation, blocking CD28-
mediated T cell co-stimulation, and administration of TGF-β with SIT. We 
have previously shown that co-administration of vitamin D3, an inhibitor of 
nuclear factor kappa B pathway which prevents DCs maturation, enhances 
the efficacy of SIT in suppressing the manifestation of allergic asthma in a 
mouse model of SIT 113. The efficacy of blocking CD28-mediated T cell co-
stimulation and administration of TGF-β during SIT has to be yet elucidated. 
Mouse model of SIT
Since the functional role of individual cell subsets and molecules involved 
in SIT-induced allergen tolerance could not be addressed in clinical studies 
we used a well-established mouse model of ovalbumin-driven SIT to unravel 
the mechanisms of SIT-induced allergen tolerance. In our model mice are 
sensitized by two intraperitoneal injections of ovalbumin (OVA) precipitated 
on alum. After a period of at least ten days mice receive three subcutaneous 
injections of either OVA-SIT (sub-optimal: 100 µg/injection, optimal: 1 
mg/injection) or saline-placebo as control. Two weeks later, mice will be 
three times exposed to aerosolized OVA to evaluate whether develop the 
manifestation of allergic asthma 114. 




First, performing SIT in the mouse model leads to a long-term suppression 
of three cardinal parameters of experimental allergic asthma: AHR, airway 
eosinophilia and specific IgE in the serum, mirroring observations in human 
studies on SIT 114. Second, SIT suppresses the manifestations of experimental 
allergic asthma in an IL-10-dependent manner 115. Alike clinical SIT, the level 
of specific serum IgE in this model is initially increased by SIT followed by 
a gradual decline 114. Taken together, the provided evidence indicates that the 
used mouse model of SIT is a relevant model to study the mechanisms of 
action of allergen immunotherapy for allergic asthma.   
Aim of the this thesis
The prevalence of allergic diseases has been increased during the past five 
decades while a casual explanation for this increase is still lacking today 
2. The hygiene hypothesis has been postulated to explain this increase but 
it is under debate and has not been experimentally proven yet 116. Besides 
improved hygiene status, increased prevalence of allergic diseases has been 
associated with increased iron intake by infants in industrialized countries 
117;118. In Chapter 2 of this thesis with the aim of finding an explanation for the 
increased prevalence of allergic diseases we address the effects of high iron 
intake on the manifestation of allergic asthma. 
SIT is the only treatment for allergic diseases that modifies the allergen-
specific immunological responses underlying the disease, leading to long 
term relief of symptoms. However, there is an unmet medical need for further 
improvement of SIT to overcome drawbacks such as the requirement of 
application of high doses of allergen, the risk of severe side-effects including 
anaphylaxis, the long duration of treatment and the controversial efficacy in 
allergic asthma 35. Rational improvement of SIT requires a detailed knowledge 
of the mechanism of its action. 
The blocking IgG hypothesis has been suggested as a mechanism of action 
of SIT since increased level of IgG in serum of SIT-treated patients has been 
associated with the alleviation of allergic symptoms 52;54;55. However, blocking 
IgG hypothesis has not been tested in functional studies yet. Moreover, 
regulatory B cells might play a role in SIT-induced allergen tolerance 50;119. To 
address the role of regulatory B cells and functional importance of blocking 
IgG antibodies for the therapeutic effects of SIT, we compared the efficiency 
of SIT in FcγR and B cell deficient with wild type mice as described in 
chapter 3 of this dissertation. 
There is evidence indicating that plasmacytoid dendritic cells play tolerogenic 
roles in the lungs 73. It has been shown that pDCs express inducible indoleamine 
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2,3 dioxygenase enzyme (IDO) which shows anti-inflammatory activities 120. 
The contribution of IDO to the suppressive effects of SIT in our model has 
been shown previously 121. In the Chapter 4 of this thesis we address the role 
of pDCs in the induction of SIT-mediated allergen tolerance in our model. 
There is evidence suggesting that CD4+FOXP3+ Treg cells contribute to 
the therapeutic effects of SIT 90, however, exact details of their contribution 
has yet to be elucidated. In Chapter 5 of this thesis we address the role of 
CD4+FOXP3+ Treg cells in SIT-mediated suppression of the manifestation of 
experimental allergic asthma at two time points: 1- during the SIT treatment 
2- during inhalation challenges where SIT-induced tolerance suppresses the 
manifestation of experimental allergic asthma.
IL-10 production has been associated with successful SIT in human patients 
and plays indispensible role for the suppressive effects of SIT in our model 
52;115. The source of IL-10 production, however, remains to be indentified to 
date. In chapter 6 of this manuscript we address the identity of the IL-10 
producing cell that is critically required for the suppressive effects of SIT. 
Traditionally alum has been used as an adjuvant for SIT, however, its 
efficacy is not optimal 35. Cytotoxic T Lymphocyte Antigen 4 is an anti T 
cell activation molecule expressed by nTreg cells and activated T cells 122. 
CTLA4-Ig is a fusion molecule, consist of the extracellular domain of CTLA4 
fused to heavy chain of human or mouse IgG 123;124. CTLA4-Ig is a proven 
compound to be clinically used in the treatment of rheumatoid arthritis and 
prevention of allograft rejection. Using our mouse, we test whether CTLA4-
Ig could be used as an efficient and clinically applicable adjuvant for SIT in 
Chapter 7 of this thesis.
Increased levels of TGF-β have been observed in SIT-treated patients that 
correlate with the therapeutic effects of SIT 100. It has been shown that TGF-β 
can induce iTreg cells in the presence of retinoic acid 125. In chapter 8 we 
examine whether administration of TGF-β at the time of SIT-treatment can 
enhance the beneficial effects of SIT presumably by induction of Treg cells. 
Immune complexes can pass through the milk and induce allergen tolerance 
in a mouse model of allergic asthma 126. In chapter 9 of this manuscript we 
address the interesting question whether SIT-induced allergen tolerance can 
be transferred to the offspring through the milk. Chapter 10 of this thesis 
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Abstract 
The prevalence of allergic diseases has increased dramatically during the last 
four decades and is paralleled by a striking increase in iron intake by infants 
in affluent societies. Several studies have suggested a link between increased 
iron intake and the marked increase in prevalence of allergic diseases. We 
hypothesized that the increased iron intake by infants offers an explanation 
for the increased prevalence of allergic disease in industrialized societies 
during the past four decades.
A well-established mouse model of OVA-driven allergic asthma was used to 
test the effects of differences in iron intake and systemic iron levels on the 
manifestations of allergic asthma.
Surprisingly, iron supplementation resulted in a significant decrease in airway 
eosinophilia, while systemic iron injections lead to a significant suppression 
of both allergen induced airway eosinophilia and hyperreactivity as compared 
to placebo. In contrast, mice fed on iron-deprived diet did not show any 
difference in developing experimentally induced allergic asthma when 
compared to those fed on iron-sufficient control diet.
In contrast to our hypothesis, airway manifestations of allergic asthma 
are suppressed by both increased levels of iron intake and systemic iron 
administrations in the mouse model. 
Introduction 
The prevalence of allergic diseases, such as allergic asthma, hay fever, and 
atopic dermatitis has increased markedly in children over the past four decades 
1. Many explanations for this increase have been postulated, of which the 
hygiene hypothesis 2 has gained considerable attention in the last two decades. 
However, an undisputed causal explanation is still lacking 3. Associated with 
the increased prevalence of allergic diseases, there is a steady increase in 
iron intake by infants in affluent societies during the last decades 4;5. The 
reasons for the increased iron intake by infants are: (i) reduced frequency 
and duration of exclusive breastfeeding, (ii) increased use of iron-fortified 
formula milk and (iii) increasing concentrations of iron in the formula milk 
to about 20 times the level in human breast milk 6. In addition, efforts have 
been made to enhance the uptake of the iron from the formula by switching 
to the use of highly bioavailable forms of iron, like ferrous sulfate, and by 
adding vitamin C. The latter agent stimulates iron uptake by keeping it in 
its reduced and more bioavailable form 7. Furthermore, since 1972 there has 
been a widespread introduction of iron-fortified food in the weaning diet 4;5. 
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We hypothesized that the marked increase in iron intake by infants offers an 
explanation for the increased prevalence of allergic diseases during the last 
decades.
Although an epidemiologic study addressing the association between increased 
levels of dietary iron and the increased prevalence of allergic diseases is still 
lacking, there is evidence suggesting a link between increased iron intake 
and the marked increase in prevalence of allergic diseases. The prevalence 
of asthma is higher in patients with disorders such as thalassemia minor and 
sickle cell anemia which cause elevated systemic iron levels compared to 
patients without hemoglobinopathies 8. Furthermore, it has been observed 
that asthmatic patients show increased plasma levels of iron compared to 
healthy controls 9. Moreover, data from animal models also point to a role 
for iron in allergic manifestations. It has been shown that administration of 
an iron chelator significantly decreases the serum levels of IgE in a rat model 
of Th2-mediated autoimmunity 10. Additionally, lactoferrin -a natural iron 
chelator- plays a protective role against symptoms of experimental allergy in 
a mouse model 11. Furthermore, it has been shown that iron overload strikingly 
increases serum levels of antigen-specific IgE in experimental candidiasis in 
mice 12. 
Altogether, these data suggest a causal relationship between iron metabolism 
and the development of allergic diseases. Nevertheless the effects of dietary 
iron supplementation on allergic manifestations have not been experimentally 
tested in detail yet. In the present study, we use a well-established mouse 
model of allergic asthma to investigate whether increased iron intake augments 
the manifestations of experimental allergic asthma. We further addressed the 
impact of elevated level of systemic iron on the symptoms of experimental 
allergic asthma. Finally, we tested the effects of dietary iron deprivation on 
the manifestations of experimental allergic asthma. Remarkably, we found 
that increased serum iron levels significantly reduce allergen-induced airway 
hyperreactivity (AHR) to methacholine and airway eosinophilia but do not 
affect allergen-specific IgE levels. 
Materials and Methods
Animals
Specified pathogen free (according to the Federation of European Laboratory 
Animal Science Associations (FELASA) guidelines) 3-week-old male 
BALB/c mice were purchased from Charles River laboratories (L’Arbresle, 
France) and were kept under SPF condition. All animal experiments were 
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performed in accordance with the guidelines of the institutional animal care 
and use committee of the University of Groningen.
Iron administration
In the first experiment, mice were maintained on drinking water containing 
either 250 mg Fe/L as FeSO4 +1 % ascorbic acid (Sigma-aldrich, Dordrecht, 
The Netherlands) or only 1% ascorbic acid starting two weeks before 
sensitization until the end of the experiment. Since the concentration of iron 
in the formula milk is increased to about 20 times the level in human breast 
milk 6, the dose of supplemented iron in this experiment has been adjusted to 
20 times the concentration of iron in mouse milk which is 12-15 mg/L 13.  
For the second experiment, injectable iron dextran (Cosmofer®, 
Pharmacosmos A/S, Holbaek, Denmark, 60 mg/Kg for treatment group) or an 
equivalent amount of low density dextran (Mw ≈ 6000 for the control group, 
Sigma-aldrich) was injected intraperitoneally on alternate days starting two 
weeks prior to sensitization until the end of the experiment. The dose of 
injectable iron is determined based on non-toxic dose of iron previously used 
by Mencacci et al. 12. In the last experiment mice were fed on casein-based 
semi-synthetic chow (Research Diet Services B.V. Utrecht, The Netherlands) 
containing either 7 or 35 ppm iron. Mice maintained on the diet from two 
weeks prior to sensitization until the end of the experiment.
Protocol for the induction of experimental allergic asthma
Experimental allergic asthma was induced as described elsewhere 14. Briefly, 
mice received 2 intraperitoneal injections of 10 µg ovalbumin (Sigma-aldrich) 
+ 2.25 mg alum (Pierce, Rockford, IL, USA) in 100 µL of pyrogen-free saline 
on days 0 and 7. Two weeks later, they were exposed to aerosolized ovalbumin 
solution in saline (1% w/v) for 20 minutes 3 times every third day.
Evaluation of airway responsiveness
Airway responsiveness to inhaled methacholine (Sigma-aldrich) was measured 
twice (before and after aerosolized ovalbumin inhalation challenges) in 
conscious, unrestrained mice using barometric whole-body plethysmography 
by recording respiratory pressure curves (Buxco; EMKA Technologies) as 
described in detail previously 14.
Determination of serum levels of ovalbumin-specific IgE
After measuring airway responsiveness, blood was taken, serum samples 
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were prepared and stored at a temperature of -80°C until further analysis. 
Serum levels of ovalbumin-specific IgE were determined by enzyme-linked 
immunosorbent assay (ELISA) as described previously and results are 
expressed as EU/ml 15.
Analyses of the BAL fluid
Bronchoalveolar lavage (BAL) was performed as explained previously 15. In 
brief, animals were lavaged five times through the tracheal cannula with 1 
ml aliquots of saline containing a cocktail of protease inhibitors (complete 
mini tablet (Roche Diagnostics) and 1% BSA(Sigma-aldrich)). BAL cells 
were counted, cytospins were made and stained using Diff-Quik (IMEB, CA, 
USA).  Cells were identified by standard morphology.
Preparation of lung tissue for cytokine measurement
Cardiac lobe of lung was taken, homogenized and used to measure cytokine 
levels as described previously 16. Concisely, lung tissue was homogenized in 
20% (w/v) luminex buffer (50 mM Tris-HCl, 150 mM NaCl, 0.002% Tween 
20, and protease inhibitor, pH 7.5) on ice. Subsequently, supernatants were 
collected for cytokine measurement after spinning the lung tissue homogenates 
for 10 min at 12,000 x g.
Measurement of cytokines
IL-4, IL-5, and IL-13 in the lung tissue were determined by a commercially 
available ELISA kit according to the manufacturer’s instructions (BD 
Pharmingen, NJ, USA). The detection limits were 32 pg/ml for IL-5 and 15 
pg/ml for IL-4 and IL-13.
Serum iron quantification
Total iron in serum was measured using colorimetric Bathophenanthroline 
(Sigma-aldrich) assay and according to the Ramsay method 17 with minor 
changes. In brief, the optical density (OD) of the reaction resulted from 
protein-precipitated serum with Bathophenanthroline was read in 96-well 
half-area plates (Greiner Bio-One B.V) using ELx808™ microplate reader. 
The concentration of serum iron was calculated using standard curves drawn 
based on measured OD values of known serial dilutions of iron(II) solution. 
To measure total iron-binding capacity (TIBC), serum was first saturated 
using iron chloride solution (Sigma-aldrich) followed by removal of unbound 
iron. Then the concentration of total of iron was measured using the above 




Hemoglobin concentration in serum was measured using a commercially 
available kit (QuantiChromTM Hemoglobin Assay Kit, BioAssay Systems, 
CA, USA) according to the manufacturers instructions.
Statistical analysis
Data are expressed as mean ± SEM. The airway resistance curves to 
methacholine were statistically analyzed using a general linear model of 
repeated measurements. All the other data were compared using student’s 
t-test. A P-value of less than 0.05 was considered significant.
Figure 1 - Experimental layout
A mouse model of OVA-driven allergic asthma was used to test the effects of increased levels of oral or 
systemic iron or decreased levels of dietary iron on the manifestation of experimentally induced allergic 
asthma. Mice were intraperitoneally sensitized twice at day 0 and 7, followed by three inhalation 
provocations with aerosolized OVA solution (1% in PBS) on day 28, 31, 34 and dissected on day 35. In 
experiment 1, mice were maintained on drinking water containing either 250 or 35 mg/L iron as FeSO4 
starting two weeks before i.p ova sensitization till the end of the experiment. In experiment 2, mice 
received iron injections 60 mg/Kg body weight given as iron dextran on alternate days starting at day 
-14 before i.p. ova sensitization till the end of the experiment. In experiment 3, mice were fed on iron-
deprived diet containing 7mg/Kg food or iron-sufficient diet containing 35mg/Kg food from 14 days 
before i.p. sensitization throughout the experiment.
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Figure 1.
Experiment 1:     Water supplementation with iron
Experiment 2:     i.p. injections of iron on alternate days
Experiment 3:     Feeding on special diets




Dietary iron supplementation reduces airway eosinophilia
To address the question whether increased iron intake augments the 
manifestations of experimental allergic asthma, mice were maintained on 
drinking water supplemented with either 250 mg/L iron + 0.1% w/v ascorbic 
acid or 0.1% w/v ascorbic acid as control throughout the experimental 
procedure (Figure 1). According to the protocol, mice were first sensitized 
by two OVA/alum intraperitoneal (i.p) injections followed by three inhalation 
challenges with OVA aerosols 3 weeks later. 











































































Figure 2 - Effects of iron-supplementation on the manifestation of allergic asthma
Manifestations of experimentally induced allergic asthma in mice receiving iron supplemented drinking 
water (black and hatched bars) or control water (open and gray bars): (a) airway responsiveness to 
methacholine before (open- and hatched bars) and after inhalation challenge (gray and black bars), (b) 
numbers of eosinophils, neutrophils and mononuclear cells in BAL, (c) levels of ova-specific serum IgE 
before (open bars) and after (black bars) inhalation challenge, (d) total iron and TIBC concentrations in 
serum. Data are shown as Mean ± SEM, N=8. (*:P<0.05 , ***,$: P<0.005). 
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and after the airway challenges. We did not observe any significant differences 
between experimental groups in AHR (Figure 2a). 
Nevertheless, we did observe a small but significant decrease in allergen-
induced airway eosinophilia in the group receiving increased concentrations 
of dietary iron in the drinking water as compared to the control group (P<0.05, 
1.3x106 ± 3.0x105  cells in BAL in iron-supplemented compared to 1.9x106 
± 2.2x105, Figure 2b). Serum levels of OVA-specific IgE were not different 
between the two experimental groups (Figures 2c). Surprisingly, no difference 
between iron-supplemented and control groups was observed (Figure 2d) in 
total iron concentration in serum or in TIBC, which reflects transferrin levels 
in serum 18. Body weight gain was constantly monitored during the experiment 
and no significant differences between groups were observed.
Figure 3 - Effects of parenteral iron administration on 
the manifestation of allergic asthma
Manifestations of allergic asthma in mice receiving iron 
injections (black and hatched bars) or control injections 
(open and gray bars): (a) airway responsiveness to 
methacholine before (open and hatched columns) and after 
inhalation challenges (gray and black-filled columns), (b) 
numbers of eosinophils, neutrophils and mononuclear 
cells in BAL, (c) levels of ova-specific serum IgE before 
(open bars) and after (black bars) inhalation challenge, (d) 
total iron concentration in serum and TIBC, (e) Cytokines 
levels in the lung tissue. Data are shown as Mean ± SEM, 
N=8. (*:P<0.05 , **:P<0.01, ***,$: P<0.005).iron and 
TIBC concentrations in serum. Data are shown as Mean ± 








































































































Systemic administration of iron decreases allergen-induced airway 
eosinophilia and Th2 cytokine release
Since total iron concentration in serum was not increased by iron-supplemented 
drinking water, we used a more robust strategy to increase the systemic 
iron levels. To this end, mice received intraperitoneal (i.p.) injections of 
iron dextran (Cosmofer®; 60 mg/Kg Fe) on alternate days throughout the 
asthma induction protocol (Figure 1). As expected, total iron concentration in 
serum and TIBC were significantly increased in the iron treatment group as 
compared to control (P<0.05, 169±31 µmol/L compared to 34±2 and 252±38 
µmol/L compared to 97±6, Figure 3d). Increased total iron in serum and TIBC 
indicate that current iron administration method is suitable for dissecting the 
effects of increased serum levels of iron on the manifestations of allergic 
asthma in our mouse model.
We measured AHR to methacholine before and after airway challenges, 
followed by dissecting the mice, counting airway eosinophils, and 
measurement of Th2 cytokines in lung and allergen-specific IgE levels in 
serum. As presented in figure 3b, airway eosinophilia was markedly and 
significantly decreased in iron-treated mice as compared to dextran-treated 
controls (P<0.05, 2.0x106 cells compared to 5.4x106). Surprisingly, parenteral 
iron treatment almost completely inhibited the allergen induced AHR as 
compared to dextran-treated control mice (P<0.05, e.g. at dose 50 mg/ml 
6.8±0.9 Penh compared to 12.6±1.0 Figure 3a). However, iron treatment did 
not affect serum levels of OVA-specific IgE (p=0.12, Figure 3c). Since in this 
experiment total iron concentration in serum and TIBC were clearly increased 
and a significant suppressive effect was observed for iron administration on 
airway manifestation of allergic asthma, we investigated the T-cell response 
in the lung tissue by measuring IL-4, IL-5, IL-13, interferon-γ and IL-10 in 
the lung tissue. Levels of the Th2 cytokines IL-4, IL-5 and IL-13 in lung 
tissue were significantly reduced in iron-treated mice as compared to dextran-
treated controls (P<0.05, 342±36 compared to 534±38, 961±126 compared 
to 1437±127  and 2997±335 compared to 4248±471 respectively, Figure 3e). 
Neither interferon-γ nor IL-10 levels in the lung tissue were affected by iron 
treatment (data not shown). These data show that differences in serum levels 
of iron do have a direct effect on manifestations of allergic asthma in the 
mouse model, with a marked reduction of AHR and airway eosinophilia in 
mice with increased levels of serum iron and TIBC.
Low dietary iron does not affect the development of allergic asthma
In contrast to our initial hypothesis, we found that increased iron intake and high 
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systemic iron administration suppress the manifestations of allergic asthma in 
the mouse model. Therefore, we asked the question whether restricting dietary 
iron causes augmented allergic response. It is recommended that mice are 
maintained on diets containing at least 35 ppm iron to prevent iron deficiency. 
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Figure 4 - Effects of iron-deprivation on the 
manifestation of allergic asthma
Manifestations of experimentally induced 
allergic asthma in mice fed on iron-deprived diet 
(black and hatched bars) or iron-suffiecient diet 
(open and gray bars): (a) airway responsiveness 
to methacholine before (open and hatched 
columns) and after inhalation challenge (gray 
and black columns), (b) numbers of eosinophils, 
mononuclear cells and neutrophils in BAL, (c) 
ova-specific serum IgE before (open columns) 
and after inhalation challenge (black columns), 
(d) total iron concentration in serum and TIBC, 
(e) Hemoglobin concentration in blood. Data 




previously used in other studies without causing deficiencies 20. Therefore, 
we examined the effect of a low-iron diet (7 ppm iron) as compared to iron-
sufficient control diet (35 ppm iron) in our mouse model of allergic asthma. 
As presented in figure 1, mice were fed on diets starting two weeks prior to 
the first i.p sensitization and continued throughout the experiment. Total iron 
concentration in serum at the end of the experiment showed a trend towards 
a decrease (p=0.067, 26.8±3.3 compare to 35.5±2.4 Figure 4d) in the low 
iron diet group as compared to iron-sufficient control group. Nevertheless, 
the mice maintained on a low dietary iron diet did not show any difference in 
allergen-induced airway eosinophilia, AHR and serum levels of OVA-specific 
IgE as compared to mice fed on regular iron diet (Figures 4a-c). Hemoglobin 
concentration was measured in this experiment as an indication of iron body 
status and showed no difference between mice fed on low iron containing 
chow as compared to control treated mice (Figure 4e). 
Discussion 
In the present study we demonstrate that in contrast to our initial hypothesis, 
increased iron intake does not exacerbate the manifestations of experimental 
allergic asthma. Conversely, high iron intake induces a small but significant 
decrease in allergen induced airway eosinophilia, while serum allergen-
specific IgE levels and AHR are not affected. Moreover, we show that elevated 
levels of systemic iron due to parenteral iron administration strongly impacts 
upon the symptoms of experimental allergic asthma by completely inhibiting 
AHR and largely suppressing airway eosinophilia as well as Th2 cytokines 
in lung tissue. 
Remarkably, our data show that supplementation of drinking water with iron 
does not increase the total iron concentration in serum as compared to control 
mice. This is most likely due to a phenomenon known as mucosal blockade 
of iron absorption which leads to a rapid reduction in iron absorption from 
the gut subsequent to a high dose iron intake 21. Interestingly, it has also been 
shown that iron supplementation does not increase iron absorption in infants 
under the age of 6 month while increases iron absorption in older infants 22. 
Despite the absence of increased serum iron levels, we observed a significant 
reduction of BAL eosinophil numbers in mice receiving iron supplementation 
in drinking water. Reduced number of eosinophils in the BAL can be an 
indirect consequence of several iron-induced regulatory mechanisms. It has 
been shown that increased dietary iron enhances the expression of lactoferrin, 
L-ferritin and hepcidin, to reduce iron absorption and increase iron storage 
capacity 23-25. Interestingly, Kruzel and colleagues showed that lactoferrin 
2Iron treatment reduces airway manifestations of allergic asthma
43
decreases pollen-induced airway eosinophilia by decreasing the formation 
of reactive oxygen species in a murine model of asthma 11. Therefore, we 
speculate that enhanced expression of lactoferrin as a result of increased iron 
intake may explain the reduction of BAL eosinophilia in mice receiving iron 
supplemented drinking water.
Since serum iron levels were not increased after iron supplementation, we 
studied the effect of parenteral iron administration in the mouse model of 
allergic asthma. Our data clearly demonstrate that elevated systemic levels of 
iron due to parenteral iron administration completely inhibit allergen induced 
AHR and largely suppress, airway eosinophilia. These suppressive effects are 
associated with reduced levels of Th2 cytokines in lung tissue. The observed 
inhibition in AHR and eosinophilia could be caused by increased expression 
of heme oxygenase-1 (HO-1) as a result of the elevated iron levels in serum. 
HO-1 is an enzyme involved in heme metabolism that has been demonstrated 
to be increased, particularly in lungs, by iron overload 26. Interestingly, Xia 
and colleagues have demonstrated that induction of HO-1 by hemin or Sn-
protoporphyrin was able to suppress allergen induced AHR, eosinophilia and 
antigen-specific serum IgE in a mouse model of allergic asthma 27.  However, 
these data are not completely in line with our observations since we did not 
observe an effect on serum IgE levels. 
Our data also reveal that OVA-specific IgE level in serum was not influenced 
either by high iron intake or by parenteral iron administration. This appears 
to be in sharp contrast to the study of Mencacci, et al. , who showed that 
iron overload as a result of i.p. iron administration induces high levels of 
antigen specific IgE in serum 12. However, it should be noted that they used 
an infection model using c. albicans which is fundamentally different from 
our model of allergic asthma. Candidiasis induces Th1-dominated immune 
responses for protection 28 while in our asthma model is dominated by a 
Th2 response. Moreover, Candida infection is associated with abundant 
production of pathogen recognition pattern molecules triggering innate and 
adaptive immunity through different pattern recognition receptors 29 whereas 
in our model, ovalbumin lacks intrinsic danger signals. 
Considering the suppressive effects on airway manifestation of allergic 
asthma in our model after oral or parenteral iron administration, we were 
interested whether deprivation of dietary iron causes the opposite effect, e.g. 
exaggerated allergic responses. However, we demonstrate that there is no 
difference between mice maintained on a diet containing 7 ppm versus those 
maintained on a diet containing 35 ppm iron in developing the manifestation 
of experimental allergic asthma. 
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We used a well-established mouse model of allergic asthma under the 
situation of oral and systemic iron manipulations to find evidence supporting 
our hypothesis that the marked increase in iron intake by infants offers an 
explanation for the increased prevalence of allergic diseases during the last 
decades. Using inbred animals with a single genetic background we did not 
observe augmented manifestations of allergic diseases due to increased oral 
or systemic iron administrations. Genetic background may be an important 
determinant of the outcome of increased iron intake on allergic diseases. So, 
at this point it can not be excluded that increased consumption of dietary 
iron by infants may lead to an increased prevalence of allergic diseases, 
including asthma in human populations. Hence, examining the effects of high 
iron intake in different mouse strains would be an informative experiment to 
perform along with comprehensive retrospective epidemiological and genetic 
studies on the association between increased dietary iron and the prevalence 
of allergic diseases. Overall, we demonstrate that in contrast to our hypothesis 
antigen-induced airway manifestations of allergic asthma in the mouse can be 
inhibited by parenteral iron administration. 
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Abstract
Allergen-specific immunotherapy (SIT) uniquely renders long-term relief 
from allergic symptoms and is associated with elevated serum levels of 
allergen-specific IgG and IgA. The allergen-specific IgG response induced 
by SIT treatment was shown to be critical for suppression of the immediate 
phase of the allergic response in mice, and this suppression was partially 
dependent on signaling through FcγRIIB. To investigate the relevance of 
the allergen-specific IgG responses for suppression of the Th2-driven late-
phase allergic response, we performed SIT in a mouse model of allergic 
asthma in the absence of FcγRIIB or FcγRI/FcγRIII signaling. We found that 
suppression of Th2 cell activity, allergic inflammation, and allergen-specific 
IgE responses is independent of FcγRIIB and FcγRI/FcγRIII signaling. 
Moreover, we show that the SIT-induced allergen-specific systemic IgG or 
IgA responses and B cell function are dispensable for suppression of the late-
phase allergic response by SIT treatment. Finally, we found that the secretory 
mucosal IgA response also is not required for suppression of the Th2-driven 
allergic inflammation by SIT. These data are in contrast to the suppression of 
the immediate phase of the allergic response, which is critically dependent 
on the induced allergen-specific serum IgG response. Hence, SIT-induced 
suppression of the immediate and late phases of the allergic response is 
governed by divergent and independent mechanisms. Our data show that 
the SIT-induced suppression of the Th2 cell-dependent late-phase allergic 
response is independent of the allergen-specific IgG and IgA responses that 
are associated with SIT treatment.
Introduction
Allergen exposure in sensitized individuals results in cross-linking of IgE 
bound to FcεRI on the mast cell surface and induces the immediate type 
I hypersensitivity response, which is driven by inflammatory mediators 
released from the mast cells 1. This immediate-phase allergic response is 
strictly IgE dependent and is treated by pharmacotherapy aimed at blocking 
mast cell effector molecules, such as histamine. The late response to allergen 
exposure is characterized by an influx of eosinophils, neutrophils, basophils, 
and activated CD4+ T cells and is sensitive to immunosuppressive drugs, 
such as steroids 1. Allergen-specific immunotherapy (SIT) is the only 
disease-modifying treatment for allergic disorders and consists of a series 
of s.c. injections with increasing doses of allergen, which induces long-term 
desensitization and relief of symptoms 2, 3. SIT is commonly used for the 
treatment of allergic rhinitis and insect venom hypersensitivity, yet its efficacy 
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in allergic asthma is controversial. The main drawbacks of SIT are the long-
term treatment protocols and the risk for eliciting anaphylactic reactions 2. 
Improvement of safety and efficacy can only be achieved by characterizing 
the immunological mechanisms that contribute to SIT-induced suppression of 
allergic inflammation in more detail.
Although the critical mechanisms by which SIT suppresses allergic symptoms 
have not been fully identified, several potential mechanisms have been 
postulated to contribute to SIT, converging on the modulation of T and B 
cell responses to the allergen 4. With regard to the T cell responses, SIT was 
postulated to divert the allergen-specific Th2 response into Th1 responses and 
induce regulatory T cell activity 5. With regard to the B cell responses, SIT was 
shown to induce an IgG1 and IgG4-dominated Ab response to the allergen with 
a mild increase in IgA levels, whereas the serum levels of allergen-specific IgE 
showed an early increase followed by a long-term gradual decline 1. However, 
the relationship between the efficacy of SIT and induction of allergen-specific 
IgG remains controversial, with serum concentrations of allergen-specific 
IgG not consistently correlating with clinical improvement1; 6; 7.
The increase in IgG serum levels, and especially IgG4, following SIT 
treatment led to the formulation of the blocking Ab hypothesis, which states 
that the IgG Abs compete with IgE for binding to the allergen 8. As a result, 
the allergen is neutralized, preventing IgE cross-linking by the allergen and 
degranulation of mast cells 9. In addition, signaling through the low-affinity 
IgGR (FcγRIIB) was shown to directly suppress IgE cross-linking–induced 
mast cell activation 10. Cross-linking of FcγRIIB receptors on memory B 
cells by the allergen-specific IgG4 induced by SIT was shown to inhibit 
IgE production 11; 12. In the mouse, allergen–IgG complexes can also induce 
IL-10 production by macrophages 13;14 and induce deviation of the Th cell 
response, resulting in increased IgG1 serum levels 13. Allergen-specific IgA 
responses in serum are also induced by SIT for grass pollen 15 and house dust 
mite 16, although not consistently 17. The possible role for allergen-specific 
IgA responses induced by SIT is thought to encompass the induction of IL-
10 expression in monocytes by FcαRI cross-linking and allergen capture at 
mucosal surfaces 15.
We developed a mouse model for allergen-specific SIT based on the 
OVA-induced mouse model for allergic asthma. In this mouse model, SIT 
treatment by s.c. application of gradually increasing doses of OVA inhibits 
allergen-induced allergic airway inflammation and hyperresponsiveness 
in OVA-sensitized mice and significantly suppresses the OVA-specific IgE 
response in serum 18. Subcutaneous delivery of three high-dose (1 mg) OVA 
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injections was shown to suppress asthma manifestations as efficiently as the 
gradual up-dosing of OVA in the mouse model 18. The suppressive effects 
on asthma manifestations were found to last for ≥5 wk after SIT treatment 
and to be dependent on IL-10 production 19. Moreover, SIT treatment also 
induces increased serum levels of OVA-specific IgG and IgA Abs, mirroring 
the observations in human subjects. It is unknown whether the induction 
of allergen-specific IgG and IgA responses contributes to the SIT-mediated 
suppression of Th2-driven allergic inflammation that is responsible for the 
late-phase allergic response in vivo. Interestingly, very recent data from a 
mouse model ofFelis domesticus allergen 1 (Fel d1)-specific SIT indicate that 
suppression of the immediate allergic reaction is dependent on the allergen-
specific IgG response 20. Our protocol of OVA-SIT specifically allows analysis 
of the SIT-induced suppression of the Th2-mediated late-phase allergic 
response, because the allergen-induced eosinophilic airway inflammation21;22 
and airway hyperresponsiveness (AHR) 23 are independent of allergen-specific 
IgE responses and the immediate phase of the allergic response in the OVA/
alum mouse asthma model.
In this article, we tested whether the SIT-induced suppression of the Th2 
cell-driven late-phase response is also critically dependent on the induction 
of allergen-specific IgG and IgA responses. Surprisingly, we found that 
suppression of allergic inflammation by OVA-SIT was efficiently induced in 
the absence of FcγRIIB signaling and even in the absence of an adaptive IgG or 
systemic IgA response in B cell-deficient mice. Finally, we show that mucosal 
IgA production is dispensable for suppression of allergic inflammation by 
SIT. Our data show that suppression of the Th2-driven late-phase allergic 
response by allergen-specific SIT is independent of B cell function and the 
induction of allergen-specific Ig responses.
Materials and Methods
Animals
Animal housing and experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee at the University 
of Groningen. All mice used in the experiment were 6–8-wk-old males. Mice 
deficient for FcγRI/III and FcγRIIB and polymeric IgR (pIgR)-deficient mice 
were on the BALB/c background. Wild-type BALB/c control mice were 
obtained from Charles River Laboratories (Maastricht, The Netherlands). 
B cell-deficient Igh-6tm1Cgn (μMT) and wild-type littermates (both on a 
C57BL/6 background) were purchased from The Jackson Laboratory (Bar 
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Harbor, ME). All mice were housed in Makrolon cages in a laminar flow 
cabinet and provided with food and water ad libitum.
Sensitization, challenge, and SIT protocol
The short-term protocol (OVA-SIT in OVA-sensitized mice, Fig. 1D) was 
the same as previously described 19. Briefly, mice received two i.p. injections 
of 10 μg OVA (endotoxin-free, <0.5 U/ml; Seikagaku Kogyo, Tokyo, Japan) 
adsorbed onto 2.25 mg alum (ImjectAlum, Pierce, Rockford, IL) in 100 
μl pyrogen-free saline (B. Braun, Melsungen, Germany) on days 0 and 7. 
Two weeks after the second sensitization, mice were treated with three s.c. 
injections of 1 mg OVA in 200 μl pyrogen-free saline (SIT) or 200 μl saline 
(sham) on alternate days. One week after the last OVA or sham treatment, 
mice were challenged three times every third day with OVA aerosols in saline 
(1% w/v) for 20 min in a Plexiglas exposure chamber coupled to a Pari LC 
Star nebulizer (PARI Respiratory Equipment, Richmond, VA; particle size 
2.5–3.1 μm) driven by compressed air at a flow rate of 6 l/min. The long-
term protocol (OVA-SIT in OVA-sensitized and -challenged mice;Fig. 1A) 
was identical to the short-term protocol, except for three additional OVA 
inhalation challenges (or PBS control treatment) given 2 wk prior to sham/
SIT treatments. The effects of possible endotoxin contamination in the OVA 
preparations on the efficiency of SIT was previously tested in our laboratory 
(A.J.M. van Oosterhout and B.C.A.M. van Esch, unpublished data), and 
all OVA preparations used in these experiments were in the lower range 
of endotoxin levels that were shown to efficiently induce SIT-dependent 
suppression of allergic inflammation (0.5–500 endotoxin unit/ml).
Airway responsiveness to methacholine, serum levels of Igs, cellular 
infiltration, and Th2 cytokine levels in bronchoalveolar lavage (BAL) fluid 
were measured 24 h after the last OVA inhalation challenge in each mouse.
Measurement of airway responsiveness
Airway responsiveness was assessed by measuring airway resistance in 
response to i.v. administration of increasing doses of methacholine (acetyl-
b-methylcholine chloride, Sigma-Aldrich, St. Louis, MO), as described 
previously 24. Briefly, anesthetized (ketamine/domitor) mice were attached to a 
computer-controlled small-animal ventilator (Flexivent; SCIREQ, Montreal, 
Quebec, Canada). Mice were ventilated at a breathing frequency of 280 
breaths/min and a tidal volume of 10 ml/kg, which was pressure limited at 300 
mm H2O. Airway resistance in response to increasing doses of methacholine 
was calculated from the pressure response to a 2-s pseudorandom pressure 
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wave, as described previously 24.
Determination of serum levels of OVA-specific Igs
Blood for assessment of serum Igs was collected 7 d before the first OVA 
aerosol challenge (via orbital puncture) and 24 h after the last challenge (via 
cardiac puncture). Serum was collected, and OVA-specific IgE, IgG1, IgG2a, 
and IgA levels in serum were measured by ELISA, as described previously 
18. A reference standard was used with arbitrary units of each isotype of 
1000 experimental unit/ml. The detection levels of the ELISAs were 0.05 
experimental unit/ml for IgG2a, 0.5 experimental unit/ml for IgE and IgA, 
and 0.005 experimental unit/ml for IgG1.
Analysis of the cellular composition in BAL fluid
Immediately after bleeding, the lungs were lavaged through a tracheal cannula 
with 1 ml saline at 37°C containing 5% BSA and 2 mg/ml aprotinin (F. 
Hoffman-La Roche, Basel, Switzerland). Cells were pelleted, and supernatants 
were used for measurement of cytokines by ELISA. Subsequently, lungs 
were lavaged with 4 ml saline, and BAL cells were pooled and counted. For 
differential BAL cell counts, cytospin preparations were stained with Diff-
Quick (Merz & Dade, Dudingen, Switzerland) and evaluated by one observer 
in a blinded fashion. Cells were differentiated into mononuclear cells, 
lymphocytes, neutrophils, and eosinophils by standard morphology. At least 
200 cells were counted per cytospin preparation.
Measurement of cytokines
IL-5 and IL-13 in the BAL fluid were determined by ELISA, according to 
the manufacturer’s instructions (BD Pharmingen, San Diego, CA). The lower 
detection limits of the ELISAs were 32 pg/ml for IL-5 and 15 pg/ml for IL-13.
Statistical analysis
All data are expressed as mean ± SEM. The Mann–Whitney U test was used 
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OVA-specific SIT suppresses 
airway inflammation and 
hyperresponsiveness in asthmatic 
mice
We previously developed and used a 
mouse model for OVA-specific SIT 
in the classical OVA/alum mouse 
asthma model 18. In this model, 
gradual up-dosing or application 
of three high doses of OVA by s.c. 
injections in OVA/alum-sensitized 
mice renders these mice protected 
against clinically relevant asthma 
manifestations, such as eosinophilic 
airway inflammation and AHR 
upon subsequent OVA inhalation 
challenge. In this model, the mice 
have not experienced an asthmatic 
response prior to the SIT treatment, 
which is in contrast to the routine 
clinical situation in which a patient 
is treated with allergen-specific SIT 
only upon presenting with clinical 
manifestations of an atopic disease, 
such as rhinitis or allergic asthma. 
Hence, we first tested whether OVA-
specific SIT would also be protective 
in mice that had experienced a prior 
OVA-induced asthmatic response. 
To address this question, we 
designed the experimental layout 
depicted in Fig. 1A. Before SIT 
treatment, mice were given an OVA/
alum sensitization followed by OVA 
inhalation challenges (asthmatic 
mice) or PBS control treatment 
(sensitized-only mice). 
Figure 1 - Allergen-specific SIT protocol in a murine 
model of allergic asthma. A, Long-term protocol of 
OVA-SIT in the mouse model: OVA/alum i.p.-sensitized 
mice received a series of three PBS- (referred to as 
sensitized-only mice) or OVA- (referred to as asthmatic 
mice) inhalation challenges at week 3. Two weeks later, 
mice were treated with three s.c. injections of saline 
(sham treatment) or OVA (OVA-SIT treatment). After an 
additional 2 wk, all mice received a series of three OVA-
inhalation challenges to induce an asthma phenotype. 
AHR was measured, and BAL was collected 24 h after the 
last challenge. B, Airway responsiveness to methacholine 
by sham- (solid symbols) or OVA-SIT– (open symbols) 
treated sensitized-only mice (● and ○) or asthmatic mice 
(▲ or Δ) in comparison with PBS-challenged control 
mice (-◊-) and eosinophil counts in BAL fluid of sham- 
and OVA-SIT–treated mice (C). Values are expressed as 
mean ± SEM of six mice per group. *p < 0.05; **p < 0.01. 
D, Short-term protocol of OVA-SIT in the mouse model.
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Two weeks after the last OVA/PBS inhalation challenge, both groups 
(sensitized only and asthmatic) were sham (saline) or SIT (OVA) treated. 
After an additional 2 wk, all groups received a series of three OVA inhalation 
challenges to induce the asthma phenotype, and AHR to methacholine was 
assessed by direct measurement of airway resistance, followed by section as 
described in Materials and Methods.
As shown in Fig. 1B, OVA-inhalation challenges in sham-treated mice that 
had not received prior OVA-inhalation challenges (sensitized only) induced 
a dose-dependent increase in AHR to methacholine, which was increased 
compared with PBS-challenged control mice. In concordance with the data 
from our previous studies, OVA-inhalation challenges in OVA-SIT–treated 
sensitized-only mice induced a significant reduction in airway responsiveness, 
almost to the level of PBS-challenged control mice (Fig. 1B). These data are 
in agreement with our previous studies 18; 24 in which we showed that OVA-
specific SIT efficiently repressed the induction of an asthmatic phenotype by 
OVA-inhalation challenges in OVA/alum-sensitized mice.
Importantly, OVA challenges in sham-treated mice that had received prior 
OVA-inhalation challenges (asthmatic mice) induced a similar level of AHR 
compared with sham-treated sensitized-only mice, indicating that the AHR 
to methacholine was similar between the first and second series of OVA-
inhalation challenges. Remarkably, OVA-SIT also strongly suppressed the 
AHR to methacholine in the asthmatic mice (Fig. 1B), supporting the notion 
that OVA-SIT in our mouse model suppresses AHR, irrespective of the 
presence of a pre-existing asthmatic phenotype in the treatment group.
Analysis of the eosinophilic airway inflammation yielded similar results 
(Fig. 1C). OVA-SIT treatment in sensitized-only mice reduced the BAL 
numbers of eosinophils compared with sham treatment, as we reported in 
several previous studies 18; 19; 24–26, although the effect was not statistically 
significantly (p = 0.161) in this specific experiment. Importantly, however, 
OVA-SIT in asthmatic mice strongly and significantly suppressed the 
levels of BAL eosinophils (Fig. 1C), indicating that OVA-SIT also renders 
protection against the induction of eosinophilic airway inflammation in 
mice that received prior OVA-inhalation challenges. Taken together, these 
data indicate that OVA-SIT in the mouse model of OVA-induced asthma 
efficiently suppresses the induction of clinically relevant asthma phenotypes 
upon OVA-inhalation challenges, irrespective of the presence or absence of 
a prior asthma phenotype at the time of OVA-SIT treatment. Therefore, the 
remaining experiments were performed using the short protocol as our model 




OVA-specific SIT suppresses the late-phase allergic response in FcγRIIB-
deficient mice
SIT treatment in human subjects, as well as in mouse models, induces strong 
allergen-specific IgG responses 1; 18, which were shown to be critically required 
for suppression of the immediate response in a mouse model of Fel d1 SIT 20. 
We hypothesized that induction of an allergen-specific IgG response by SIT is 
critical for suppression of the Th2-dependent late-phase allergic response in 
an FcγRIIB-dependent fashion. To test our hypothesis, we assessed whether 
SIT treatment was able to suppress Th2 cell-driven allergic inflammation in 
the absence of FcγRIIB signaling. To this end, we performed our experimental 
mouse model of allergen SIT (schematically depicted in Fig. 1D) using 
FcγRIIB-deficient mice.
In OVA-sensitized and sham-treated wild-type or FcγRIIB−/− mice, OVA 
aerosol challenges induced a significant OVA-specific IgE response (Fig. 2A, 
pre- versus postchallenge). In addition, the OVA challenges induced moderate 
IgG1, IgG2a, and IgA responses in sensitized and sham-treated wild-type 
and FcγRIIB−/− mice (Fig. 2B–D). OVA-SIT treatment in sensitized wild-
type mice induced a strong IgG1 and IgG2a response, which was not further 
upregulated by subsequent OVA challenges as we showed previously 18. In 
Figure 2 -OVA-specific Ig responses to SIT treatment in FcγRI/FcγRIII−/−, FcγRIIB−/−, and wild-
type mice. Levels of OVA-specific IgE (A), IgG1 (B), IgG2a (C), and IgA (D) in serum were measured 
before (prechallenge) and after (postchallenge) OVA aerosol challenges in sensitized and SIT/sham-
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FcγRIIB−/− mice, OVA-SIT also induced strong IgG1 and IgG2a responses 
(Fig. 2B, 2C), in agreement with the recent observations in the mouse model 
of Fel d1 SIT 20. Finally, OVA-SIT strongly suppressed the OVA-specific IgE 
response in wild-type mice (Fig. 2A). Surprisingly, FcγRIIB−/− mice also 
displayed a strong reduction in the OVA-specific IgE response upon OVA-
SIT, indicating that the SIT treatment efficiently suppressed allergen-specific 
IgE, independent of FcγRIIB signaling. Remarkably, the OVA-specific IgA 
response induced in wild-type mice by OVA-SIT was not observed in FcγRIIB 
mutant mice (Fig. 2D).
Because OVA-SIT efficiently suppressed the allergen-specific IgE response in 
mice deficient for FcγRIIB, we next analyzed Th2-driven eosinophilic airway 
inflammation. In line with the observed loss of the OVA-specific IgE response 
after OVA-SIT treatment, wild-type mice displayed an aborted eosinophilic 
airway inflammation upon OVA-SIT, accompanied by strongly decreased 
local Th2 cell activity, as measured by IL-5 and IL-13 levels in BAL fluid 
(Fig. 3). Intriguingly, FcγRIIB mutant mice showed an identical suppression 
of eosinophil cell counts, as well as IL-5 and IL-13 levels, in BAL fluid after 
OVA-SIT. Taken together, these data indicate that OVA-specific SIT is fully 

































































































































































Figure 3 -SIT-induced suppression of allergic 
inflammation in FcγRI/FcγRIII−/−, FcγRIIB−/−, 
and wild-type mice. BAL fluid was obtained 
from OVA-sensitized and SIT/sham-treated mice 
24 h after the last inhalation challenge. Cytospin 
slides were prepared for differential cell counts, 
and cytokines were measured by ELISA. Num-
ber of eosinophils (A) and levels of IL-5 (B) and 
IL-13 (C) in BAL fluid. Values are expressed as 
mean ± SEM (n = 6). *p < 0.05; **p < 0.01.
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eosinophilic airway inflammation, in the absence of FcγRIIB-dependent 
signaling.
OVA-specific SIT suppresses IgE responses and Th2-driven inflammation 
in FcγRI/FcγRIII−/− mice
Although the suppressive activities of FcγRIIB signaling on mast cell 
activation and APC function are well established 10, cross-linking of FcγR by 
OVA–IgG immune complexes was also shown to induce IL-10 expression in 
macrophages through FcγRI 14, resulting in deviation of the T cell phenotype 
and induction of an OVA-specific IgG response 13. 
Hence, we next aimed to assess whether signaling of IgG–allergen immune 
complexes through FcγRI or FcγRIII contributed to the SIT-induced IgG and 
IgA responses or the suppression of the late-phase allergic response. To this 
end, we performed OVA-SIT in double-mutant FcγRI−/−/FcγRIII−/− mice. 
As observed in wild-type mice, the OVA-specific IgE response was strongly 
suppressed by OVA-SIT treatment in FcγRI/FcγRIII−/− mice and was 
accompanied by strongly increased OVA-specific IgG1 and IgG2a responses 
(Fig. 2A–C). These data indicate that neither the increased IgG responses 
induced by SIT nor the suppression of IgE responses are dependent on 
FcγRI or FcγRIII signaling. Interestingly, we found that although OVA-SIT 
induced significantly increased OVA-specific IgA levels in wild-type mice, 
decreased levels of OVA-specific IgA were detected in serum from FcγRI/
FcγRIII−/− mice after OVA-SIT.
To evaluate the suppression of allergic airway inflammation by OVA-SIT in 
FcγRI/FcγRIII−/−mice, we also analyzed eosinophil counts and Th2 cytokine 
levels in BAL after sham or OVA-SIT treatment followed by OVA challenge. 
Similar to wild-type mice, BAL eosinophil counts in FcγRI/FcγRIII−/− mice 
were significantly decreased after OVA-SIT compared with sham-treated mice 
(Fig. 3A). In addition, OVA-SIT significantly reduced levels of IL-5 and IL-
13 in BAL fluid compared with those of sham-treated FcγRI/FcγRIII−/− mice 
(Fig. 3B,3C). Taken together, these data indicate that FcγRI/FcγRII-mediated 
signaling is not required for the suppression of the late-phase allergic response 
by SIT. Hence, we next asked whether the allergen-specific Ig responses 
were required for the suppression of the Th2-driven allergic inflammation by 
allergen SIT.
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SIT suppresses allergic airway inflammation in B cell-deficient mice
Because we showed that SIT efficiently suppresses Th2 cell activity and 
eosinophilic airway inflammation in mice deficient for FcγRI and FcγRIII, 
as well as in mice deficient for FcγRIIB, FcγR-mediated signaling seems to 
be redundant for the suppression of the late-phase allergic response by SIT. 
Nevertheless, SIT treatment induces a strong OVA-specific IgG response in 
FcγRIIB−/− mice and FcγRI−/−/FcγRIII−/− mice (Fig. 2B, 2C). Therefore, 
we aimed to test whether the IgG serum responses contribute to SIT by a non–
FcγR-dependent mechanism. Moreover, we wanted to assess the putative role 
of IL-10–producing B cells 27 in the SIT-dependent suppression of Th2 cell 
activity. Therefore, we subjected B cell-deficient μMT mice to our mouse 
model of SIT in allergic asthma (Fig. 1D).
As a result of the functional inactivation of the H chain of IgM in μMT mice, 
B cell differentiation is arrested at the pro-B cell stage, and these mice lack 
most mature B cells capable of producing Ig 28. Except for some residual 




































































































































































































Sham OVA-IT Sham OVA-IT
A
Figure 4 -OVA-SIT suppresses allergic in-
flammation in B cell-deficient mice. OVA-
sensitized C57BL/6 μMT mice and wild-type 
controls were SIT/sham treated and challenged 
with OVA aerosols. A, OVA-specific IgE was 
measured before (prechallenge) and 24 h after 
(postchallenge) the last inhalation challenge in 
wild-type control mice. BAL fluid was collect-
ed 24 h after the last inhalation challenge. IL-5 
levels (B) and number of eosinophils (C) in 
BAL were determined. Values are expressed as 
mean ± SEM (n = 6–8). *p < 0.05; **p < 0.01.
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mice. Interestingly, in the OVA/alum mouse model of allergic asthma, μMT 
mice were shown to display Th2 cytokine production and airway eosinophilia 
and hyperresponsiveness, despite the absence of OVA-specific IgE responses 
30. Therefore, the μMT mouse model allows analysis of the regulation of the 
allergen-specific Th2 cell-driven late-phase allergic response by SIT in the 
absence of allergen-specific IgE and IgG and systemic IgA responses and the 
immediate phase of the allergic response.
To confirm that our SIT protocol was successful, we first evaluated serum 
levels of OVA-specific IgE in wild-type controls. As expected, OVA-SIT 
significantly inhibited the OVA-specific IgE response induced by OVA 
inhalation in sham-treated mice (Fig. 4A). Furthermore, the SIT treatment 
Figure 5 - OVA-specific Ig responses after SIT treatment in pIgR−/− mice. 
OVA-sensitized mice received SIT/sham treatments. Levels of OVA-spe-
cific IgE (A), IgG1 (B), IgG2a (C), and IgA (D) in serum were measured 
before (prechallenge) and 24 h after (postchallenge) the last OVA aerosol 
challenge. Values are expressed as mean ± SEM of six mice per group. *p 
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itself induced a strong upregulation of OVA-specific IgG1 levels, in agreement 
with our typical SIT-induced Ig responses.
To evaluate the suppression of Th2-driven airway inflammation after OVA-
SIT in μMT mice, we measured eosinophil cell counts and Th2 cytokine 
levels in BAL fluid. After sham treatment, OVA challenge resulted in high 
IL-5 levels in BAL fluid and the infiltration of a high number of eosinophils 
into the airways in wild-type and μMT mice (Fig. 4B, 4C). As expected, BAL 
levels of IL-5 and airway eosinophilia were strongly suppressed by OVA-SIT 
in wild-type mice. Interestingly, the same level of suppression of BAL IL-5 
and airway eosinophilia was observed in SIT-treated μMT mice (Fig. 4B, 4C), 
indicating that the suppression of Th2 cell activity and allergic inflammation 
by allergen-specific SIT is exerted independently of the allergen-specific IgG 
and systemic IgA responses induced by SIT.
Suppression of allergic inflammation by SIT in pIgR-deficient mice
Our data in the μMT mouse model indicate that the IgG and systemic IgA 
responses induced by OVA-SIT are dispensable for the suppression of Th2-
driven allergic inflammation. Nevertheless, μMT mice were shown to retain 
a functional mucosal B cell population that is capable of producing luminal 
IgA 29. Because airway delivery of allergen-specific IgA to sensitized mice 
was shown to suppress airway responses upon subsequent allergen challenge 
and to induce a systemic allergen-specific IgG2a response 31 resembling some 
SIT-induced phenotypes, we wanted to test whether modulation of the airway 
Figure 6 - SIT suppresses allergic inflammation in pIgR−/− mice. OVA-sensi-
tized and SIT/sham-treated pIgR-deficient and wild-type mice were challenged 
with OVA aerosols. At 24 h after the last OVA challenge, BAL fluid was recov-
ered and the total number of cells and eosinophils (A) and the levels of IL-5 



























































































luminal IgA response by SIT could contribute to the suppression of allergic 
inflammation. To this end, we performed our mouse model of OVA-SIT in 
pIgR-deficient mice, which are incapable of transporting polymeric IgA across 
the airway epithelium and, therefore, lack luminal IgA 32. As shown in Fig. 
5, pIgR-deficient mice displayed a strong IgG1 response upon OVA-SIT 
treatment (Fig. 5B). In contrast, the OVA-specific IgG2a response induced by 
OVA-SIT in wild-type mice was not observed in pIgR−/− mice, even though 
these mice have a higher basal level of OVA-specific IgG2a after sensitization 
(Fig. 5C). Nevertheless, OVA-specific IgE responses are suppressed by OVA-
SIT in pIgR−/− and wild-type mice to a similar degree (Fig. 5A). Finally, the 
OVA-specific serum IgA responses were strongly increased in pIgR−/− mice, 
in agreement with previous observations 32; 33, but no differential effect of 
SIT treatment on serum IgA was seen between wild-type and pIgR−/− mice 
(Fig. 5D). 
Surprisingly, measurement of OVA-specific IgA levels in BAL of the 
nontransgenic littermates indicated that, in our model, OVA inhalations in 
SIT-treated mice resulted in a reduced level of BAL IgA compared with OVA 
inhalations in sham-treated control mice, although the differences were not 
statistically significant (1504.5 ± 673.49 experimental unit/ml in SIT versus 
5978 ± 1545.4 experimental unit/ml in sham-treated controls; p = 0.157).
To extend our findings to the effects of SIT on the suppression of Th2-
driven airway inflammation in pIgR−/− mice, we also analyzed BAL Th2 
cytokine levels and eosinophil cell counts (Fig. 6). IL-5 levels and eosinophil 
cell counts in BAL were equally suppressed by OVA-SIT in wild-type and 
pIgR−/− mice, indicating that the suppression of allergic inflammation by SIT 
is independent of airway luminal IgA levels.
Discussion
We present a comprehensive set of data assessing the relevance of allergen 
SIT-induced Ig responses for the suppression of the Th2-driven allergic 
inflammation that underlies the late-phase allergic response. We show evidence 
that cardinal features of the late-phase allergic response in the OVA-driven 
mouse model of allergic asthma are suppressed by SIT via a mechanism that 
does not depend on the induction of IgG or IgA responses, FcγRIIB signaling, 
or B cell function. The use of s.c. injections of high-dose OVA in the classical 
OVA-driven mouse model of asthma was previously established as a mouse 
model that phenocopies the human response to SIT treatment in considerable 
detail 18; 19. Nevertheless, OVA as a model allergen lacks several aspects of 
natural allergens and consequently requires i.p. immunization adsorbed to 
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alum to achieve sensitization. Moreover, repeated airway administrations 
with OVA were shown to induce a gradual loss of the asthmatic phenotype 
in sensitized mice 34–36, although this effect is not Ag specific. We observed 
a limited reduction in eosinophilic airway inflammation in mice receiving 
two series of three OVA inhalations compared with mice that received only 
a single series of three OVA-inhalation challenges (Fig. 1C; compare sham-
treated asthmatic mice with sham-treated sensitized-only mice, which might 
be attributed to the repeated OVA inhalations in this extended SIT protocol. 
This observation underscores the notion that the data from these mouse 
studies can only be extrapolated to the human situation with great care. 
Nevertheless, the suppressive effect of repeated airway administrations with 
OVA was not observed on the AHR to methacholine, and, importantly, OVA-
SIT still suppressed AHR and airway eosinophilia in the asthmatic group very 
efficiently, indicating that despite the side effects of repeated OVA exposure, 
SIT is still fully operational. Importantly, the three high doses of OVA used in 
our model were previously shown to be as efficacious as a gradual up-dosing of 
OVA in the mouse model 18, and suppression of clinically relevant parameters 
of the asthmatic phenotype, such as AHR and airway eosinophilia, are as 
efficiently suppressed by the SIT treatment in mice that were only sensitized 
to OVA as in mice that had experienced a prior asthmatic phenotype at the 
time of SIT treatment, the latter reflecting the clinical practice more closely.
In human allergic individuals, allergen SIT was shown to efficiently suppress 
the late phase of the allergic response 37–39, associated with reduced numbers 
of infiltrating T cells, basophils, neutrophils, and eosinophils. Intriguingly, 
the effects of SIT on the immediate phase of the allergic response are modest, 
although a reduction in the magnitude of the immediate-phase allergic 
response was reported 39; 40. The most prominent response to allergen SIT 
treatment in allergic individuals is the induction of allergen-specific IgG1 and 
IgG4 responses, yet the relevance of the SIT-induced IgG Ab response has 
remained controversial 1. Although some studies reported observations that 
indicate a contribution of blocking Abs to SIT 41, several groups failed to show 
a correlation between the presence of neutralizing IgG Abs and improved 
clinical outcome6; 42. The allergen-specific IgG Abs might contribute to SIT by 
blocking access of the allergen to IgE on mast cells or basophils or by preventing 
FcεRI-dependent mast cell activation by binding to FcγRIIB (reviewed in 
Ref. 1). Upon cross-linking of the FcεRI–IgE complex on the mast cell surface 
with the FcγRIIB–IgG complex by the same multivalent ligand, FcγRIIB ITIM 
phosphorylation by FcεRI-associated kinases can directly suppress FcεRI 
signaling and mast cell activation 43; 44. In the mouse model of Fel d1-specific 
SIT, both mechanisms have been postulated to contribute to the suppression 
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of the immediate phase of the allergic response 20. Although suppression of 
systemic anaphylaxis by SIT was critically dependent on FcγRIIB signaling, 
suppression of tissue mast cell degranulation was maintained in FcγRIIB-
deficient mice. Remarkably, the suppression of the systemic and the local 
immediate-phase allergic response could be passively transferred by serum 
or the serum IgG fraction, indicating the requirement for allergen-specific 
IgG 20. The allergen-induced Th2 cell-driven airway inflammation 21; 22 and 
AHR 23 in the OVA/alum mouse model of experimental allergic asthma were 
previously shown to be independent of allergen-specific IgE responses and 
the immediate-phase allergic response induced by cross-linking of IgE on 
mast cells and basophils. This is in marked contrast to the human situation, 
in which allergic asthma is characterized by a clear immediate and late-
phase allergic response, depending on allergen-specific IgE and Th2 cells, 
respectively 45. Our mouse model of OVA-SIT exclusively allows the analysis 
of the mechanism by which the treatment suppresses the late-phase allergic 
response. We found that the allergen-specific IgG response induced by SIT is 
not critically required for suppression of the Th2 cell-dependent late-phase 
allergic response or the allergen-specific IgE responses.
The FcγRIIB-independent suppression of allergen-specific IgE responses was 
also observed in the Fel d1 virus-like particle vaccination study 20. Although 
the investigators hypothesized a contribution of the ssRNA within the virus-
like particles to suppression of the IgE response through TLR3/7 signaling, 
our data replicate their findings on the FcγRIIB-independent suppression of 
the IgE response by SIT, even in the absence of TLR signaling. Therefore, 
the mechanism by which allergen SIT represses the IgE response seems to be 
independent of direct suppression of IgE-producing B cells via FcγRIIB 46;47. 
In fact, the SIT-induced suppression of the Th2-driven allergic inflammation 
and the allergen-specific IgE responses seem to correlate, indicating that 
inhibition of Th2 cell activity might be critical for the reduced IgE levels 
after SIT.
In serum, OVA-SIT induces a specific IgA response in our mouse model (Fig. 
2D), in agreement with human studies 15; 16. Nevertheless, the use of a reference 
serum containing an arbitrary level of OVA-specific IgA as a standard in these 
assays precludes the absolute quantification of the OVA-specific IgA levels 
induced by OVA-SIT or a direct comparison with the magnitude of the OVA-
specific IgG response. Consequently, the biological relevance of this response 
remains to be determined. Moreover, the secreted form, rather than the serum 
levels, of IgA is critical for mucosal protective activity of this Ig isotype. For 
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instance, direct nasal installation of allergen-specific IgA was shown to have 
systemic effects, reflected in an altered allergen-specific CD4+ T cell response 
and increased serum IgG2a levels 31, indicating that increased luminal IgA 
levels can contribute to suppression of allergic manifestations. We did not 
directly measure OVA-specific IgA levels in BAL after OVA-SIT but prior to 
inhalation challenge. However, after OVA challenge, specific IgA levels were 
not significantly reduced in the serum (Fig. 5D) and BAL fluid of OVA-SIT–
treated mice compared with sham-treated mice. These data seem to indicate 
that in our mouse model, the luminal IgA levels might not be critical for 
the suppression of the late-phase response by SIT treatment. Our data in the 
pIgR−/− mice lend further support to the notion that mucosal IgA responses 
are dispensable in SIT-induced suppression of local allergic inflammation. 
In addition, our data from the μMT mice strongly indicate that the systemic 
IgA responses induced by SIT are also dispensable for suppression of the late 
phase of the allergic response.
Remarkably, we found that pIgR deficiency selectively abrogates the SIT-
induced OVA-specific IgG2a response, whereas other Ig responses and 
suppression of allergic inflammation remain unaffected, in line with the 
observations of Schwarze et al. 31. These data seem to indicate the presence 
of a feedback mechanism by which luminal IgA levels regulate the systemic 
Ag-specific IgG2a response. Given the Ag specificity of this process, we 
would assume the involvement of a Th1 cell population, as was previously 
postulated 31. Nevertheless, we find that this mechanism does not contribute 
to the SIT-induced suppression of the late-phase allergic response or allergen-
specific IgE.
Our experiments in μMT mice also indicated that allergen-specific SIT can 
efficiently suppress Th2-driven eosinophilic airway inflammation in sensitized 
mice in the absence of B cells. This is in contrast to the critical role for B cells 
in tolerance induction in naive mice by mucosal application of allergen 48; 49, 
but is in agreement with earlier observations that T cells can efficiently be 
tolerized in vivo in the absence of B cells 50. Because FcγRIIB-dependent 
signaling was shown to be required for the induction of mucosal tolerance 
in naive mice by intranasal installation of OVA 51, oral-tolerance induction in 
naive mice seems to be at least partially dependent on the Ig response. Because 
we found that suppression of Th2 cell activity can be induced independently 
of B cells, it remains of interest to determine which APC is required for the 
observed suppression of Th2 cell activity by SIT. We recently showed that 
SIT treatment is partially dependent on IDO 24, the rate-limiting enzyme in 
tryptophan metabolism that contributes to the induction of adaptive regulatory 
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T cells by plasmacytoid dendritic cells 52. Because we and other investigators 
showed a dependency of the suppression of allergic inflammation by SIT 
on IL-10 19; 53, it is tempting to speculate that IDO-competent dendritic cells 
induce adaptive regulatory T cells during SIT treatments that then suppress 
Th2 activity upon allergen exposure. Alternatively, the high-dose OVA 
treatment might induce Th2 cell anergy, although the IL-10 dependence of 
the SIT-induced suppression of allergic inflammation would not seem to 
support anergy induction as a major mechanism for SIT in our mouse model. 
In this article, we show that, irrespective of the involvement of regulatory 
or anergic T cell populations, the SIT-induced suppression of the late-phase 
allergic response is induced independently of allergen-specific IgG and IgA 
responses and FcγR signaling.
In summary, to our knowledge, we demonstrate for the first time that the 
allergen-specific IgG and IgA responses induced by allergen-specific SIT in 
a sensitized host are not critically required for the suppression of allergen-
specific IgE responses and the Th2 cell-driven late-phase allergic response 
upon allergen provocation. This is in marked contrast to recent data showing 
that allergic desensitization by an Fel d1 vaccination strategy caused 
suppression of the immediate phase of the allergic response that could be 
passively transferred by serum or the serum IgG fraction and which was, in 
part, dependent on FcγRIIB signaling 20. We postulate that allergen-specific 
SIT suppresses the immediate and late-phase allergic response by divergent 
and independent mechanisms. Other mechanisms that could contribute to 
the SIT-induced suppression of allergic inflammation, such as local IL-10 
production, induction of regulatory T cells, or immune deviation to Th1 or 
Tr-1 cells, need to be addressed in future studies.
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Abstract
Allergen-specific immunotherapy (SIT) is the only treatment for allergic 
diseases that leads to long-lasting alleviation of the allergic symptoms by 
targeting the root cause of the disease. There is an urgent requirement for 
improving the efficacy of SIT which needs a detailed understanding of 
the mechanism of action of SIT. Antigen presentation during SIT is a less-
known key step of the mechanism of action of SIT. Plasmacytoid dendritic 
cells (pDCs) have been shown to play tolerogenic effects by expressing 
indoleamine 2,3 dioxygenase (IDO), however, it remains to be determined 
whether pDCs play a critical tolerogenic role during SIT treatment. In this 
study, we examined whether pDCs contribute to antigen presentation during 
SIT and whether they are critically important for SIT-induced tolerance in our 
model. 
Performing subcutaneous SIT using fluorochrome-labeled ovalbumin (OVA) 
revealed that most of the APCs that captured OVA are located in head and 
forelimb draining lymph nodes. Proliferation of CFSE-labeled OVA-specific 
T cells at these locations demonstrates that the captured OVA is presented to T 
cells. Detailed analysis of cell surface markers revealed that pDCs constitute a 
high proportion of APCs that capture OVA during SIT in our model. To assess 
whether pDCs are required for the induction of SIT-induced tolerance, we 
performed SIT in pDC depleted mice. Remarkably, we found that depletion 
of pDCs during SIT does not abrogate the therapeutic effects of SIT. We 
conclude that although pDCs significantly contribute to antigen presentation 
during SIT, these cells are dispensable for SIT-mediated tolerance induction 
to the model allergen OVA.
Introduction 
Allergen specific immunotherapy (SIT) is the only treatment for allergic 
diseases that results in long-lasting relief of the symptoms by targeting the 
root cause of the disease 1. Currently, SIT has been effectively used to cure 
allergic rhinitis and venom allergy in which the efficacy of the treatment 
varies between patients 1;2. Moreover, the efficacy of SIT in allergic asthma 
and patients with multiple allergies is controversial 3. Improving the efficacy 
of SIT in a way that it can be used in a wider range of allergic diseases and 
patients is desirable, however, this requires a detailed knowledge of the 
mechanism of SIT-induced allergen tolerance. Classically, allergen is applied 
to the hypodermis layer of the skin where it can be captured by antigen 
presenting cells (APCs) and presented to CD4+ T cells in secondary lymphoid 
organs 4. To the best of our knowledge it has not been yet addressed, which 
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type of APCs contributes to allergen presentation during SIT and what their 
contribution is to SIT-induced allergen tolerance.
Dendritic cells (DCs) are the most professional antigen presenting cells, 
playing critical roles in the induction of T cell mediated immune response 
and peripheral tolerance 5. DCs can be divided into two main subsets, 
conventional DCs (cDC) and plasmacytoid DCs (pDC) with distinct roles in 
immune regulations 6. Conventional DCs express high level of CD11c and 
varying levels of CD11b. These cells are involved in the induction of Th2 and 
Th1 responses in the lungs 7.
pDCs can induce tolerance by expression of indoleamine 2,3 dioxygenase 
(IDO) and inducible costimulatory ligand (ICOSL)  and through the induction 
of CD4+FOXP3+ and CD4+IL-10 producing regulatory T cells (Tregs) 8-10. 
Clinical data have shown that SIT increases mRNA level of IDO in peripheral 
blood mono nuclear cells at very early stages of venom SIT 11. Furthermore, 
we previously showed that SIT-induced suppression of the manifestation of 
experimental asthma is partially mediated by IDO 12. These data suggest that 
pDCs may play an important role in SIT-induced allergen tolerance.
Therefore, we were interested in evaluating the role of pDCs in the generation 
of SIT-induced allergen tolerance using our mouse model of ovalbumin 
(OVA)-driven asthma and SIT 13. To this aim we tested which draining lymph 
nodes are the major sites of antigen presentation after s.c. OVA-SIT treatment 
and if pDCs contribute to antigen presentation in these lymph nodes. 
Furthermore, using antibody-mediated depletion, we determined if pDCs are 
critically required for the generation of SIT-induced allergen tolerance. We 
show that pDCs contribute to antigen presentation during SIT by capturing 




We purchased 6-8 week specific pathogen free BALB/cByJ mice from Charles 
River laboratories (L’Arbresle, France) and kept them under SPF conditions 
in individually ventilated cages. OVA-TCR transgenic mice (DO11.10) on a 
BALB/c background were bred at University Medical Center Ghent (Ghent, 
Belgium). The guidelines of the institutional animal care and use committee 
of the University of Groningen were followed when performing animal 
experiments.  
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Induction of allergic asthma and SIT
The protocol of the induction of experimental allergic asthma is described 
in detail elsewhere 14. In brief, mice were sensitized by intraperitoneal 
(i.p.) injection of 10 µg LPS-free OVA (Seikagaku Kogyo, Tokyo, 
Japan, LPS<5 EU/mg) and 2.25 mg alum (Pierce, IL, USA) in 100 µl of 
pyrogen-free saline. SIT consisted of three subcutaneous (s.c.) injections of 
100 µg OVA / 200 µl sterile saline on alternate days two weeks later. Saline 
was injected as placebo. Fourteen days after the last s.c. injection mice were 
challenged by aerosolized OVA 1% in phosphate-buffered-saline (PBS) 3 
times every third day. As described in detail below, airway responsiveness to 
increasing doses of methacholine was measured 24 h after the last challenge, 
thereafter mice were dissected, bronchoalveolar lavage was performed and 
blood and lung samples were taken. 
OVA-tracking and cell transfer 
To test whether pDCs contribute to antigen uptake, 100 µg/mouse Alexa 
Fluor® 555 ovalbumin (4›,6-diamidino-2-phenylindole, dilactate; invitrogen, 
Merelbeke, Belgium) was s.c. injected to previously OVA/alum sensitized 
mice. 24 h after the last injection mice were dissected and mandibular, 
accessory mandibular and superficial parotid lymph nodes were pooled and 
referred to as ‘head draining’ LNs; Forelimb draining (proper axillary and 
accessory axillary) and thoracic (bronchial and mediastinal lymph nodes) 
and spleen were collected and analyzed for traces of AF555-labeled OVA by 
flow cytometry. To evaluate whether pDCs present OVA to T cells, 10x106 
splenocytes of DO11.10 mice were isolated, stained with Carboxyfluorescein 
succinimidyl ester (CFSE; invitrogen, Merelbeke, Belgium) as described 
elsewhere 15 and were injected intravenously to OVA/alum sensitized mice. 
24 h after cell transfer, 100 µg/mouse OVA was s.c. injected. 48h after OVA 
injection mice were dissected and the above mentioned lymph nodes were 
collected and analyzed for T cells proliferation by flow cytometry.
pDC depletion protocol 
Two days before SIT, 120G8 (750 µg/injection) or rat IgG (750 µg/injection) 
was s.c. injected two times on consecutive days. This treatment resulted in 
99 ± 0.1% depletion of pDCs (MHC-IIintCD11cintmPDCA-1+) in the head 
and forelimb draining lymph nodes in 120G8 receiving as compared to rat 
IgG receiving mice (Figure 7). SIT was performed one day after the second 
antibody injection. Antibodies were injected again (500 µg/injection) before 
2nd and 3rd SIT injections. 
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Measurement of airway reactivity
The resistance of airways in response to increasing doses of methacholine 
was directly measured using invasive measurements as previously described 
12. Briefly, mice were anesthetized by i.p. injection of ketamine (100 mg/kg; 
Pfizer, NY, USA) and medetomidine (1 mg/kg; Pfizer) then tracheotomized 
(20-gauge intravenous: i.v. cannula; Becton Dickinson, Alphen a/d Rijn, The 
Netherlands) and attached to a computer-controlled small-animal ventilator 
(Flexivent; SCIREQ, Quebec, Canada). After paralyzing the mice with i.v. 
injection of Pancuronium bromide (Pavulon, 50 µg/kg Merck Sharp & Dohme, 
NJ, USA), ventilation was adjusted at a breeding frequency of 300 breaths/
minutes and a tidal volume of 10 ml/kg. Tidal volume was pressure limited 
at 300 mm H2O. An i.v. cannula was inserted through the jugular vein for 
the administration of methacholine. Methacholine (acetyl-b-methylcholine 
chloride, Sigma-Aldrich, Dordrecht, the Netherlands) was administered 
intravenously. Airway resistance was calculated from the pressure response 
to a 2-second pseudorandom pressure wave. 
Measurement of the levels of specific IgE in serum
Serum levels of OVA-specific IgE were determined by sandwich enzyme-
linked immunosorbent assay (ELISA) as described previously 16. In brief, 96-
well microplates (Greiner Bio-One, Hannover, Germany) were coated with 
2 µg/ml anti-mouse IgE antibody (BD bioscience, Breda, the Netherlands) 
over night. Then, plates were washed using wash buffer consist of 0.005% 
Tween20Ò (Sigma-Aldrich) in PBS. After blocking the plates with 3% bovine 
serum albumin (Sigma-Aldrich) in PBS for 2 h, serial dilutions of reference 
serum as well as sample serums were added and incubated for 1.5 h at room 
temperature (RT). Then, plates were washed again and digoxigenin-labeled 
(Roche Diagnostics, Almere, the Netherlands) OVA was added and incubated 
for 1 h at RT. Anti-digoxigenin-POD (Roche Diagnostics) was added 
after washing the plate and incubated for 1 h at RT. O-Phenylenediamine 
(Thermo-scientific, IL, USA) was used for chromogenic reaction. Optical 
density of individual wells was read at 490 nm using ELx808™ microplate 
reader (BioTek, Friedrichshall, Germany).  Concentrations were calculated 
according to the standard curve drawn based on serial dilutions of reference 
serum and results are expressed as experimental units (EU)/ml. 
Performing BAL
We lavaged the mice five times through the tracheal cannula with 1-ml aliquots 
of saline. The cells of bronchoalveolar lavage were pooled, counted, and cells 
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types were indentified using flow cytometry as described elsewhere 17.  
Flow cytometry
The following were used: PerCP-Cy5.5-anti-CD11b, FITC-anti-I-A/I-E and 
PE-Cy™7-CD11c (BD Pharmingen™, Erembodegem, Belgium), APC-
mPDCA-1 (eBioscience, Vienna, Austria). For flow cytometry, single cells 
were washed with FACS buffer (PBS + 1% BSA + 0.1% NaN3) then incubated 
with antibody mixtures for 30 minutes on ice. Thereafter, cells were washed 
3 times with FACS buffer. Flow cytometry data were analyzed using FlowJo 
(Treestar, RO, USA). Flow cytometry was performed using LSR-II and 
FACSAria-II (BD bioscience, Erembodegem, Belgium).












Experiment 2: T-cells proliferation
Figure 1 - Time line of experiments addressing antigen presentation during SIT.  Experiment 1, mice 
were sensitized by OVA / alum on day 0 and 7. On day 21 fluorochrome-labeled OVA (100 µg/ 200 µl) 
was injected s.c. On day 21 mice were dissected and lymph nodes and spleen were checked for OVA+ 
cells by flow cytometry. In experiment 2, CFSE-labeled DO11.10 cells were injected i.v. to OVA/alum 
sensitized mice on day 20 followed by OVA-SIT 24 h later. Mice were dissected on day 23 and lymph 
nodes and spleen were checked for cell divisions using flow cytometry.
Statistical analysis
Data are expressed as mean ± SEM. The airway resistance curves to 
methacholine were statistically analyzed using a general linear model of 
repeated measurements. All the other data were compared using Mann–
Whitney U test corrected for multiple comparisons. A P-value of less than 




pDCs highly contribute to antigen presentation during experimental SIT
First, we aimed to test whether pDCs take up OVA during SIT. To this aim we 
injected fluorochrome-labeled OVA s.c. to OVA/alum sensitized mice (Figure 
1). Draining lymph nodes of the head, forelimb, and thoracic cavity as well 
as the spleen were analyzed for cells that captured the labeled OVA using 


































Live Live Live Live
Figure 2 - Analysis of lymph nodes and spleen for 
the presence of OVA+ cells. A, dot-plot graphs dis-
playing fluorchrome-labeled-OVA on the y-axis and 
side scatter on the x-axis. Graphs are gated on live 
cells and representative of 5 mice. B, bar-graph dis-
playing the percentage of OVA+ cells of total live 
cells in different lymph nodes and spleen as indicat-














































Figure 3 - Proliferation of 
DO11.10 CD4+ T cells in A, head 
and B, forelimb draining lymph 
nodes 48 h after OVA injection in 
vivo. Left panels, dot-plot graphs 
displaying live DO11.10 CD4+ T 
cells gated based on the expres-
sion of CD4 on the y-axis and 
DO11.10 T cell receptor on the x-
axis. Right panels, dot-plot graphs 
displaying CD69 on the y-axis 
and CFSE on the x-axis. Graphs 
are representative of 5 mice. 
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of mandibular, accessory mandibular and superficial parotid lymph nodes. 
Forelimb draining lymph nodes include proper axillary and accessory axillary 
lymph nodes. Bronchial and mediastinal lymph nodes were pooled together 
as thoracic lymph nodes. Analysis of cells obtained from head draining lymph 
nodes shows that 0.36 ± 0.12% (n=5) of total live cells were positive for 
OVA (Figure 2A-B). In forelimb draining lymph nodes 0.42 ± 0.17% (n=5) 
of total live cells were positive for OVA while OVA+ cells were absent in 
thoracic lymph nodes or spleen (Figure 2A-B). These data demonstrate that 
s.c. injected OVA has been up taken up by DCs that have migrated to head and 
forelimb draining lymph nodes. 
To determine if pDCs contribute to the APCs in head and forelimb draining 
lymph nodes during SIT treatment, OVA+ cells were further analyzed for 
the expression of MHC-II, CD11c and PDCA-1. Live OVA+ cells were first 
divided into MHC-II intermediate and MHC-II high populations followed 
by analyzing the levels of CD11c and mPDCA-1expression for each. As 
presented in figure 4A,C in head draining lymph nodes 53.0 ± 2.8% (n=5) of 
live OVA+ cells express intermediate MHC-II and 35.5 ± 6.7% (n=5) express 
high MHC-II. In forelimb draining lymph nodes 42.9± 8.4% (n=5) are MHC-
IIint and 50.5 ± 9.4% (n=5) are MHC-IIhi cells (Figure 5A,C). 
Figure 4
A. B. 




































































Figure 4 - Analysis of sub-types of OVA+ cells in head draining lymph nodes 
based on the expression of MHC-II, CD11c and mPDCA-1. A, representative 
histogram of 5 mice of live OVA+ cells divided into MHC-II intermediate and 
high cells. B, expression of CD11c and mPDCA-1 of left panel, live MHC-II 
intermediate, and right panel, MHC-II high cells. Representative of 5 mice C, 
the percentage of MHC-II intermediate and high of total live OVA+ cells. D, 
the percentage of different sub-types of OVA+ cells based/ total OVA+ cells 











































































Figure 5 - Analysis of sub-types of OVA+ cells in forelimb draining lymph 
nodes based on the expression of MHC-II, CD11c and mPDCA-1. A, repre-
sentative histogram of 5 mice of live OVA+ cells divided into MHC-II inter-
mediate and high cells. B, expression of CD11c and mPDCA-1 of left panel, 
live MHC-II intermediate, and right panel, MHC-II high cells. Representative 
of 5 mice C, the percentage of MHC-II intermediate and high of total live 
OVA+ cells. D, the percentage of different sub-types of OVA+ cells based/ 
total OVA+ cells on the expression of MHC-II, CD11c and mPDCA-1. Data 
are shown as mean ± SEM, N=5.
A significant sub-population of live OVA+ cells in head (32.0 ± 1.2%, Figure 
4B,D) and forelimb (28.3 ± 5.7%, Figure 5B,D) draining lymph nodes show 
the profile of pDCs by expressing intermediate level of MHC-II, CD11c 
and high level of mPDCA-1. Besides pDCs, the other main APC population 
that captures OVA is, MHC-IIhi CD11chi mPDCA-1+ cDC population, in 
head (14.0 ± 3.6%, Figure 4B,D)  and forelimb (26.4 ± 6.5%, Figure 5B,D) 
draining lymph nodes. These data indicate that pDCs are major APCs during 
SIT treatment in our mouse model.
To determine whether the captured OVA by APCs was presented to T cells in 
the head and forelimb draining lymph nodes CFSE-labeled splenocytes from 
DO11.10 mice were intravenously injected to OVA/alum sensitized mice 
followed by s.c. OVA-SIT treatment 24 h later. After 48 h, the lymph nodes 
were taken and intensity of CFSE and expression of CD69 (a lymphocyte 
activation marker) were analyzed in live CD4+DO11.10 T cells by flow 
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cytometry. As shown in figure 3A-B, OVA-specific T cells in head and 
forelimb draining lymph nodes, but not in other secondary lymphoid organs, 
showed multiple cell divisions within 48 h after s.c. OVA injection. OVA-
specific T cells in placebo-treated mice show no divisions (Figure 8). T/
hese data show that the captured OVA by APCs after migration to head and 
forelimb draining lymph nodes is readily presented to T cells in a stimulatory 
fashion. Expression of CD69 is decreasing by each cell division indicating 
that the activation state of T cells declines progressively during cell division. 
pDCs are dispensable for therapeutic effects of experimental SIT
Next, we depleted pDCs during SIT treatment to investigate whether antigen 
presentation by pDCs is critically required for the therapeutic effects of 
SIT. As demonstrated in figure 6A, mice were sensitized by OVA/alum 
followed by pDC depletion and SIT. Thereafter mice were challenged 
and dissected. SIT treatment in control IgG receiving mice significantly 
suppressed AHR (P<0.05, 27.8 ± 12.9%, Figure 6B), OVA-specific 
IgE in serum (P<0.01, 85.6 ± 3.2, Figure 6C) and airway eosinophilia 
Figure 6 - The efficacy of SIT in pDC depleted versus control mice. A, timeline of experiment. Mice 
were sensitized using OVA absorbed to alum on day 0 and 7. pDC depleting antibody, 120G8 or rat IgG 
were injected on day 19 and 20 (750 µg/injection) and on day 22 and 24 (500 µg/injection). OVA-SIT 
was performed on day 21,23 and 25 followed by inhalation challenges on day 39, 42 and 45. Mice were 
dissected on day 46. B, airway resistance measured in response to injection of saline and increasing 
doses of methacholine. C, the levels of OVA-specific IgE in the serum 24 h after the last inhalation 
challenge. D, total number of eosinophils in the BAL fluid 24 h after the last inhalation challenge. Data 
are shown as mean ± SEM, N=5. 
Figure 6









































































































(P<0.05, 42.7 ± 10.4, Figure 6D) compared to placebo treatment. The 120G8-
mediated pDC depletion resulted in 99 ±0.1% depletion of pDCs in head and 
forelimb draining lymph nodes (Figure 7). Performing SIT in pDC depleted 
mice leads to a significant suppression of AHR (P<0.05, 31.9 ± 8.5%, 
Figure 6B), OVA-specific IgE in serum (P<0.01, 85.2 ± 2.7, Figure 6C) 
and airway eosinophilia (P<0.05, 44.9 ± 11.8, Figure 6D) as compared with 
placebo treated 120G8 receiving mice. There was no significant difference 
in the level of SIT-induced suppression of AHR, airway eosinophilia and 
specific-IgE between pDC-depleted and pDC competent groups. 
These results demonstrate that the role of pDCs in antigen presentation 
during SIT is dispensable for SIT-induced suppression of the manifestations 
































A. B. C. 
Figure 7 - The percentage of pDCs of total live CD11c cells in forelimb 
draining lymph nodes of mice receiving two injection of 750 µg/injection 
A, rat-IgG, B, pDC depleting 120G8 antibody on two consecutive days. C, 
Analysis of percentage of pDCs of total live CD11c cells forelimb draining 
lymph nodes of rat-IgG receiving mice versus 120G8 treated mice. Data are 
shown as mean ± SEM, N=3.
Figure 8 - Proliferation of 
DO11.10 CD4+ T cells in A, 
head draining and B, forelimb 
draining lymph nodes. Left 
panels, selection of DO11.10 
CD4+ T cells out of total live 
cells. Right panels, dot-plot 
graphs displaying the expres-
sion of CD69 y-axis and CFSE 
x-axis. Graphs are representa-
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Discussion
In this study we found that head and forelimb draining lymph nodes are the 
major sites of antigen presentation after s.c. IT as evident by the presence of 
OVA+ APCs and proliferation of OVA-specific CD4+ T cells in our mouse 
model of allergic asthma. We show that pDCs significantly but not exclusively 
contribute to antigen presentation during SIT in this model. However, despite 
their significant contribution to antigen presentation, pDCs are dispensable 
for the generation of SIT-induced suppression of AHR, airway eosinophilia 
and OVA-specific IgE in serum.
Several APCs are present in the normal skin including, langerhans cells, 
dermal DCs (dDCs), skin macrophages and pDCs that can be rapidly recruited 
from the blood upon stimulation 18;19. Here, we show that a high proportion of 
OVA+ APC in the draining lymph nodes express mPDCA-1 and intermediate 
levels of CD11c and MHC-II, a typical profile for pDCs 20. 
pDCs play crucial roles in the induction of tolerance particularly because 
of their unique capacity to express large amounts of inducible IDO upon 
stimulation in addition to its constitutive expression 21. These cells are found 
in large numbers in sentinel lymph nodes of melanoma patients 22 and it has 
been shown that activity of IDO is critically important for pDC-induced 
tolerance to tumor cells in a mouse model 23. More importantly, in the lungs, 
it has been shown that pDCs play a crucial role in the induction of tolerance to 
harmless airborne antigen 24. Interestingly, an early induction of IDO has been 
observed after venom SIT in human patients indicating an important role for 
IDO in human SIT 11. We previously showed that pharmacological inhibition 
of IDO partially abrogated SIT-induced suppression of airway eosinophilia in 
our model, also pointing to a role for IDO in tolerance induction 12. 
Mechanistically, pDCs contribute to tolerance induction by inducing 
CD4+CD25+FOXP3+ as well as IL-10 producing Treg cells through expression 
of IDO 10. Increased numbers of IL-10 producing CD4+ T cells in peripheral 
blood have been reported after human SIT 25;26. We have also shown that SIT-
induced suppression of the manifestation of experimental allergic asthma is 
critically dependent of IL-10 in our model 27. Moreover, we recently found that 
SIT results in a transient increase in the percentage of CD4+CD25+FOXP3+ 
Treg cells in the blood and spleen (unpublished data). Taken together, these 
data suggest that pDCs may play an important tolerogenic role in SIT-induced 
allergen tolerance. However, here we show that efficient depletion of pDCs 
during SIT does not abrogate SIT-induced suppression of AHR, specific IgE 
in serum and airway eosinophilia, indicating that pDCs play a dispensable 
role in this model. Thus, it appears likely that other APCs play a critical 
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tolerogenic role in SIT-induced tolerance.
Dermal DCs are located in the dermis layer of the skin where they can 
efficiently take up the subcutaneously administered antigens and present it to 
T cells. Here we found that besides pDCs the second major population that 
captures OVA after SIT shows a profile similar to dermal migratory DCs by 
expressing high levels of CD11c and MHC-II 28. It has been shown that dDCs 
have high migratory capacity in vivo 29 and have the capacity to generate 
inducible Tregs in vitro 30 and in vivo 31. It remains to be elucidated whether 
dDCs play a role in tolerance induction by SIT. 
Langerhans cells have also been suggested to be involved in tolerance 
induction by sublingual immunotherapy 32 and could potentially be involved 
in tolerance induction in our model. However, langerhans cells mainly 
reside in the epidermis layer of the skin 33 while we administer OVA-SIT 
to hypodermis layer of skin where langerhans cell are rare. Thus, although 
we cannot completely exclude a role for LCs in our SIT model, it is rather 
unlikely that they play a critical role. 
Macrophages are also present in the skin and can play tolerogenic roles 
during antigen presentation 18. We have previously shown that OVA-pulsed 
macrophages injected as cell-based immunotherapy induces tolerance to 
subsequent allergen challenges in a mouse model of asthma 34. Furthermore, 
it has recently been shown that macrophage-like cells play a critical role 
in antigen presentation and tolerance induction during sublingual SIT in a 
mouse model 35. However, the route of antigen administration and potentially 
the mechanism of tolerance induction in sublingual SIT are different from 
subcutaneous SIT. The importance of skin macrophages for SIT-induced 
allergen tolerance has yet to be elucidated.    
We show that a high proportion of the cells that capture the s.c. injected 
fluorochrome-labeled OVA are located in head and forelimb draining lymph 
nodes where OVA-specific T cells show multiple cell-divisions after OVA-
SIT. Similarly, we have previously shown that s.c. injection of OVA to 
naïve mice after active transfer of DO11.10 OVA-specific T cells resulted in 
vigorous proliferation of the transferred cells in brachial lymph nodes 36. Here 
we found that the expression of CD69, an early lymphocyte activation marker 
is decreased by each proliferation step of T cell cells demonstrating that 
CD69 is rapidly induced upon stimulation followed by its gradually decline. 
It has been shown that induction of oral tolerance is accompanied with initial 
activation of CD4+ T cells and rapid up-regulation of CD69 followed by 
subsequent down-regulation of CD69 and hypo-responsiveness of T cells 
underscoring the importance of T cell activation for tolerance induction 37;38. 
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In summary, we demonstrate that the major sites of antigen presentation 
during SIT in our mouse model of allergic asthma are head and forelimb 
draining lymph nodes. We show that pDCs highly contribute to OVA capture 
and antigen presentation in our model; however, these cells are not critically 
required for SIT-driven tolerance induction in this model. Further studies are 
needed to unravel the details of antigen presentation during SIT treatment and 
cellular mechanism of SIT-induced allergen tolerance.
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Abstract
Background: Allergen specific immunotherapy (SIT) has been used since 
1911, yet its mechanism of action remains to be elucidated. There is evidence 
indicating that CD4+FOXP3+ regulatory T cells (Tregs) are induced during 
SIT in allergic patients. However, the contribution of these cells to SIT has 
not been evaluated in vivo. 
Objective: To evaluate the in vivo contribution of (i) naturally occurring 
FOXP3+ Tregs during SIT and of (ii) SIT-generated inducible FOXP3+ 
Tregs during allergen exposure to SIT-mediated suppression of asthmatic 
manifestations.
Methods: We used a mouse model of SIT based on the classical OVA-driven 
experimental asthma. Tregs were quantified by flowcytometry 24 and 96 
hours post SIT treatment. CD4+FOXP3+ Treg were depleted either during SIT 
treatment or prior to allergen challenges to study their contribution to the 
suppression of allergic manifestations by SIT treatment. 
Results: Our data show that depletion of Tregs at the time of SIT treatment 
reverses the suppression of AHR but not of airway eosinophilia and specific 
IgE levels in serum. Interestingly, the number of CD4+CD25+FOXP3+ T 
cells is transiently increased after SIT in the spleen and blood, suggesting 
the generation of inducible and presumably allergen-specific Tregs during 
treatment. Depletion of CD4+FOXP3+ Tregs after SIT treatment partially 
reverses the SIT-induced suppression of airway eosinophilia but not of AHR 
and serum levels of specific IgE. 
Conclusion and clinical relevance: We conclude that SIT-mediated tolerance 
induction towards AHR requires CD4+CD25+FOXP3+ T cells at the time of 
allergen injections. In addition, SIT generates CD4+CD25+FOXP3+ T cells that 
contribute to the suppression of airway eosinophilia upon allergen challenges. 
Therefore, enhancing FOXP3+ T cell number or their activity during and after 
SIT could be of clinical relevance to improve the therapeutic effects of SIT.   
Introduction
Allergen specific immunotherapy (SIT) is a unique treatment for IgE mediated 
allergic diseases. SIT fundamentally alters the adaptive immune response to 
the allergen and results in long-lasting relief of the disease symptoms and 
induction of immune tolerance to the allergen 1. The clinical application of 
SIT was first documented by Noon and Freeman in 1911 2. Although SIT is 
efficacious in allergic rhinitis, allergic conjunctivitis, venom allergy, and in 
monosensitized patients 1;3, its efficacy in patients with allergic asthma or with 
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multiple sensitizations is controversial and symptomatic pharmacotherapeutic 
strategies are often preferred in these patients 4. Currently, SIT is accompanied 
by several major drawbacks including the need for long-term treatment, high 
risk of anaphylactic reactions and variable efficacy in the treatment outcome. 
Improving SIT by overcoming these disadvantages is of particular importance 
to encourage children to participate in SIT, since it can prevent the progression 
of respiratory allergies to allergic asthma as well as reducing the chance of 
developing multiple allergies 5. Rational improvement of SIT is dependent 
on an exact and detailed understanding of the yet incompletely characterized 
mechanisms by which SIT induces tolerance to the allergen.
There is ample evidence suggesting that CD4+FOXP3+ Tregs may play a 
role in the therapeutic effects of SIT. In clinical studies it has been observed 
that the number of CD4+FOXP3+ Tregs is increased locally in nasal mucosa 
after grass pollen SIT 6 and in blood during venom SIT 7. Using MHC-II 
tetramers, Aslam and colleagues have shown that there is a sustained 
induction of circulating FOXP3+ antigen specific T cells within 3-5 weeks 
of venom immunotherapy8. Similarly, in asthmatic children, house dust mite 
immunotherapy increases the number of circulating CD4+CD25+FOXP3+ 
Tregs 1.5-2 years after the treatment 9. All together this evidence suggests 
that inducible Tregs may contribute to the therapeutic effects of SIT. 
Regulatory T cells are indispensible components of the immune system 
and are required for the prevention of exaggerated immune response 
against pathogens and immunological tolerance to self-antigens as well as 
environmental allergens 10. Natural regulatory T cells (nTregs) arise as a 
distinct lineage in the thymus and express the transcription factor FOXP3 
and high levels of interleukin-2 receptor α-chain (CD25) 11. Tregs can 
also be derived from naïve T cells in the periphery by the acquisition of 
regulatory properties, inducing the outgrowth of so-called inducible Tregs 
(iTregs) under certain conditions 11. Both naturally occurring and inducible 
FOXP3+Tregs are capable of suppressing allergic asthma manifestations in 
the mouse model 12. Interestingly, nTregs can facilitate the conversion of 
naïve CD4+ T cells to different types of iTregs, in experimental conditions in 
vitro 13;14 and may therefore play a role in the induction of tolerance by SIT. 
However, the functional role for either nTregs in maintaining a tolerogenic 
microenvironment during SIT injections, or for iTregs in actively suppressing 
the allergic manifestations upon allergen challenge after SIT treatment remain 
unknown and are difficult to address in human studies. 
We hypothesize that Tregs are critically required for the suppression of 
allergic manifestations by SIT.  Here, we aim to test the role of FOXP3+ 
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Tregs at two time points: (i) during SIT injections where FOXP3+ nTregs 
could facilitate the generation of allergen-specific tolerance, and at the time 
of allergen challenges after the completion of SIT treatment where indicible 
FOXP3+ Tregs could contribute to suppression of the manifestations of 
asthma. We show that depletion of nTregs during SIT partially reverses the 
SIT-associated suppression of AHR but does not affect the suppression of 
airway eosinophilia and OVA-specific IgE in serum. We demonstrate that the 
number of FOXP3+ Tregs is transiently increased in spleen and blood but 
not in the regional draining lymph nodes upon SIT. Importantly, depletion of 
CD4+FOXP3+ T cells prior to inhalation challenges partially abrogated SIT-
associated suppression of airway eosinophilia.  
Methods
Animals
6-8-week-old female BALB/c mice were purchased from Charles River 
laboratories (L’Arbresle, France) and were kept under SPF condition. All 
animal experiments were performed in accordance with the guidelines of the 
institutional animal care and use committee of the University of Groningen. 
Depletion of regulatory T cells (DEREG) mice on Balb/c and C57BL/6 
background were used to specifically deplete FOXP3+ Tregs in vivo 15. Non-
transgenic littermates of DEREG mice were used as controls. 
Experimental allergic asthma, SIT
The protocol to induce experimental allergic asthma and to perform SIT 
is described elsewhere 16. In brief, as shown in figure 1, mice received 2 
intraperitoneal (i.p.) injections of 10 µg ovalbumin (OVA; Seikagaku Kogyo, 
Tokyo, Japan, endotoxin levels 5> U/mg) and 2.25 mg alum (Pierce, Rockford, 
IL, USA) in 100 µL of pyrogen-free saline on days 0 and 7. Two weeks after 
the last i.p. injection, they received three subcutaneous (s.c.) injections at 
the base of the neck of either 1 mg OVA in 200 µl pyrogen free saline (SIT-
treated groups) or 200 µl pyrogen free saline (placebo groups) on alternate 
days. At least ten days after the 3rd s.c. injection mice were exposed to 3 
times OVA inhalation challenges. Airway responsiveness to increasing doses 
of methacholine was measured 24 hours after the last challenge, thereafter 
mice were dissected, bronchoalveolar lavage was performed and blood and 




As shown in figure 1, in experiment A, nTregs were depleted before SIT using 
anti-CD25 (500 µg/mouse) 17 administered i.p. one day before every s.c. OVA 
SIT injections. Control mice received rat IgG (500 µg/mouse).
In experiment B, CD4+FOXP3+ Tregs were depleted by administration of 
unnicked diphtheria toxin (DT, 1 µg/mouse, Merck, Darmstadt, Germany) to 
transgenic DEREG mice and to their wild type littermates (as control for DT 
treatment) on two consecutive days, two days prior to the first OVA inhalation 
challenge. This approach leads to removal of more than 90% of CD4+FOXP3+ 
Tregs for at least 3 days 15. 
Evaluation of airway responsiveness
Airway responsiveness to inhaled methacholine (Sigma-aldrich, Zwijndrecht, 
Netherlands ) was measured twice (before and after ovalbumin inhalation 
challenges) in conscious, unrestrained mice using barometric whole-
body plethysmography by recording respiratory pressure curves (Buxco; 
EMKA Technologies, Paris, France) in experiment A as described in detail 
previously18. 
In the experiment B airway responsiveness to increasing doses of methacholine 
was evaluated by directly measuring airway resistance by invasive methods 
as explained in detail elsewhere 19. For details see supplementary methods in 
repository materials.  
Determination of serum levels of ovalbumin-specific IgE
After measuring airway responsiveness, blood was drawn; sera were collected 
and stored at -80°C until further analysis. Serum levels of ovalbumin-specific 
IgE were determined by enzyme-linked immunosorbent assay (ELISA) as 
described previously 16 and results are expressed as EU/ml. 
Analyses of the BAL fluid
Bronchoalveolar lavage (BAL) was performed as explained previously 
19. In brief, animals were lavaged five times through the tracheal cannula 
with 1-ml aliquots of saline. The first ml of saline contained a cocktail of 
protease inhibitors (complete mini tablet (Roche Diagnostics, Woerden, 
the Netherlands) and 1% bovine serum albumin (BSA: Sigma-aldrich, 
Zwijndrecht, Netherlands). BAL cells from all 5 ml were pooled, counted, and 
cells types were indentified using flow cytometry as described elsewhere20. 
Flow cytometry data were analyzed using FlowJo (Treestar, RO, USA) and 
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CD3e-,CD19-,CD11c-,CCR3+ cells were considered as eosinophils.  
Preparation of lung tissue for cytokine measurement
Cardiac lobe of lung was taken, homogenized and used to measure cytokine 
levels as described previously 19. Concisely, lung tissue was homogenized in 
20% (w/v) luminex buffer (50 mM Tris-HCl, 150 mM NaCl, 0.002% Tween 
20, and protease inhibitor, pH 7.5) on ice. Subsequently, supernatants were 
collected for cytokine measurement after spinning the lung tissue homogenates 
for 10 min at 12,000 x g and stored at -80°C until later analysis by ELISA. 
Measurement of cytokines
IL-4, IL-5, and IL-13 in the lung tissue were determined by a commercially 
available ELISA kit according to the manufacturer’s instructions (BD 
Pharmingen, NJ, USA). The detection limits were 32 pg/ml for IL-5 and 15 
pg/ml for IL-4 and IL-13.
Isolation of LNs
To analyze the expression of FOXP3+ regulatory T cells after SIT, lymph 
nodes were isolated after dissecting the mice. Head draining (mandibular, 
accessory mandibular and superficial parotid) lymph nodes and forelimb 
draining (proper axillary and accessory axillary) lymph nodes were collected 
and pooled for analysis. A sample size of 6-8 animals was used in each group. 
For details about preparation of single cell suspension see supplementary 
methods in repository materials. 
Flow cytometry and antibodies
PerCp labeled anti-CD4 (clone RM4-5) was purchased from BD Bioscience 
(NJ, USA). PE-labeled anti-mouse FOXP3 (clone FJK-16s), eFluor450-
labeled anti mouse CD25 (clone eBio3C7) were purchased from eBioscience 
(CA, USA). For flow cytometry see supplementary methods in repository 
materials. 
Statistical analysis
Data are expressed as mean ± SEM. The airway resistance curves to 
methacholine were statistically analyzed using a general linear model of 
repeated measurements. All the other data were compared using student’s 




Depleting nTregs during SIT treatment partially reverses SIT-mediated 
suppression of AHR
Naturally occurring Tregs might contribute to SIT treatment by facilitating 
a tolerogenic microenvironment at the time of allergen injections in the 
sensitized host. To examine whether nTregs are required for the induction 
of a suppressive allergen-specific immune response during the induction 
phase of SIT, mice received nTreg-depleting anti-CD25 (PC61) or rat IgG 
control antibody, 24 hours before each SIT/placebo injection (Figure 1: 
Experiment A). Fourteen days after the completion of SIT treatment, mice 
were challenged by the relevant allergen to evaluate the suppression of 
allergic manifestations by SIT. In placebo-treated control antibody receiving 
mice, OVA inhalation challenges increased airway hyperresponsiveness 
(AHR) (Figure 2A). Inhalation challenges in these mice also elevated the 
level of OVA-specific IgE in serum (Figure 2B), and recruited eosinophils to 
the airways (Figure 2C). As expected, SIT-treatment in the rat IgG control-
treated group significantly suppressed AHR to methacholine (63 ± 2.4% at 
the peak response, P<0.005, Figure 2A), OVA-specific IgE in serum (79 ± 











Experiment A (depleting Tregs before IT):
Experiment B (tracking dynamic of Tregs):
DT administration to
DEREG mice and wild typeExperiment C (depleting Tregs in DEREG mice after IT):
dissection-measure
the frequency of Tregs
Figure 1
Figure 1 - Experimental setup in evaluating the role of naturally occurring and inducible Tregs in 
the mouse model of SIT. Mice were sensitized by OVA (10 µg) combined with alum (2.25 mg) on day 
0 and 7. SIT was performed by three s.c. injections of 1 mg OVA in SIT-treated or saline in placebo-
treated mice on alternate days two weeks after the last sensitization. Airway hyperreactivity, airway 
eosinophilia and increased OVA-specific IgE in serum, the basic manifestations of allergic asthma 
were induced by three inhalation challenges with aerosolized OVA every third day. One day after the 
last challenge lung function was measured, and then mice were dissected. In experiment A, nTregs 
were depleted using anti-CD25 (PC61) antibody i.p. injected one day before every SIT injection. In 
experiment B, a group of SIT-treated and placebo-treated mice were dissected one day after the last 
SIT injection and another group of SIT-treated and placebo-treated mice were dissected four days after 
the last SIT injection. In experiment C, all CD4+FOXP3+Tregs were selectively depleted in DEREG 
transgenic mice by administration of 1 µg/mouse diphtheria toxin on two consecutive days, two days 
prior to inhalation challenges.
5Role of FOXP3+ Tregs in allergen immunotherapy
101
Figure 2
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5.6%, P<0.005, Figure 2B) and airway eosinophilia (83 ± 3.4%, P<0.001, 
Figure 2C). These results demonstrate that allergen-specific IgE and AHR 
were elevated and eosinophils were efficiently recruited to the airways in 
our mouse model of experimental allergic asthma. Importantly, all three 
mentioned basic manifestation of allergic asthma were efficiently suppressed 
by SIT treatment in this model.
To evaluate whether during SIT treatment CD4+FOXP3+ Tregs contributed 
to the induction of allergen tolerance, we depleted these cells using CD25-
specific antibodies at the time of SIT treatment 17. Administration of anti-
CD25 antibody efficiently depleted more than 90% of CD4+FOXP3+CD25+ 
Tregs in the spleen and blood of mice 24 hours after antibody injection and 
Figure 2 - The effects of depleting nTregs 
during SIT injections on A) airway hyper-
reactivity, B) OVA-specific IgE in serum, C) 
airway eosinophilia. A: Inhalation challenges 
lead to an increased airway reactivity to meth-
acholine in placebo-treated control antibody 
receiving (gray-filled squares with gray solid 
line, P<0.05) and placebo-treated anti-CD25 
receiving mice (black-filled circles with black 
solid line, P<0.05) as compared to pre-chal-
lenge values (triangles with black dotted line). 
SIT treatment suppressed allergen-induced 
AHR in control antibody receiving mice (unfilled squares with gray solid line, P<0.05 compared 
to placebo-treated control antibody receiving mice). Depletion of nTregs partially abrogated SIT-
mediated suppression on AHR (unfilled circles with black solid line, P<0.05 as compared to SIT-
treated control antibody receiving mice). B: Inhalation challenges significantly (P<0.005) increased 
OVA-specific IgE in serum in placebo-treated mice (filled bars) as compared to pre-challenge values 
(open bars). SIT treatment in both control antibody receiving and anti-CD25 antibody receiving 
mice significantly (P<0.05) suppressed OVA-specific IgE in serum. C: Eosinophils were recruited 
to the airways after inhalation challenges. SIT treatment in both control antibody receiving and anti-
CD25 antibody receiving mice significantly (P<0.005) suppressed airway eosinophilia
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that effect lasted for at least 48 hours (Figure S1). Compared to control-
antibody treated mice, anti-CD25 treatment in the placebo-treated group 
did not affect antigen-induced manifestation of allergic asthma (Figures 2A-
2C). In the SIT-treated group, however, we observed a significantly reduced 
suppression of AHR by SIT treatment as compared to the suppression in 
control rat IgG receiving SIT-treated mice (63 ± 2.4% at the peak response). 
Notwithstanding, SIT still induced a significant 33% suppression of AHR in 
the anti-CD25-treated group (Figure 2A). Anti-CD25 treatment did not affect 
the suppression of airway eosinophilia (79 versus 83% in control) and OVA-
specific IgE levels in serum (82 versus 79% in control) compared to control 
antibody receiving SIT-treated mice (Figures 2B-C). Thus, depletion of Tregs 
cells by CD25 antibody treatment prior to SIT injections partially reverses 
suppression of AHR but not airway eosinophilia and OVA-specific IgE levels 
in serum in this model. 
CD4+CD25+FOXP3+ regulatory T cells are transiently 
increased after SIT
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Figure 3 - Frequency of CD4+CD25+FOXP3+ 
Tregs in head and forelimb draining lymph 
nodes, spleen and blood 24 and 96 hours af-
ter the last SIT injection. The number of 
CD4+CD25+FOXP3+ Tregs in the spleen and 
blood were significantly increased in SIT-treat-
ed mice as compared to placebo-treated group 
(P<0.005 and P<0.05 respectively).
CD4+CD25+FOXP3+ Tregs as has been observed in human studies 6. To this 
aim, the frequency of CD4+CD25+FOXP3+ Tregs was measured in spleen, 
blood and pooled head and forelimb draining lymph nodes one and four days 
after the last SIT injection. Interestingly, we found that SIT significantly 
increases the number of CD4+CD25+FOXP3+ Tregs in the spleen by 98% and 
in the blood by 39% of placebo the first day after the last SIT injection (Figure 
3). This difference in the number of CD4+CD25+FOXP3+ Tregs between 
SIT-treated and placebo-treated control mice was no longer evident 4 days 
after the last SIT injection. Analyzing the number of CD4+CD25+FOXP3+ 
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Tregs reveals no difference at either time point between SIT-treated and 
placebo in the lymph nodes draining the injection site of the allergen during 
treatment. These data indicate that SIT treatment induced a transient increase 
in peripheral FOXP3+ T cells shortly after the allergen injections, indicating 
a potential induction of inducible allergen-specific CD4+CD25+ Tregs by the 
treatment.
Selective depletion of FOXP3+ regulatory T cells partially 
reverses the effects of SIT
To test the hypothesis that SIT induces CD4+FOXP3+ inducible Tregs 
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Figure 4 - The effects of selective deple-
tion of CD4+FOXP3+Tregs in DEREG mice 
after SIT on, A) airway hyperreactivity, B) 
OVA-specific IgE in serum, C) airway eosino-
philia. A: Inhalation challenges resulted in an 
increased airway reactivity to methacholine 
in placebo-treated non-transgenic (gray-filled 
squares with gray solid line, P<0.05) and pla-
cebo-treated DEREG mice (black-filled circles 
with black solid line, P<0.05) as compared to 
pre-challenge values (triangles with black dot-
ted line). AHR was significantly reduced in 
SIT-treated non-transgenic as well as DEREG 
mice (unfilled squares with gray solid line and unfilled circles with black solid line, P<0.05 com-
pared to placebo-treated control antibody receiving mice). B: Inhalation challenges significantly 
(P<0.005) increased OVA-specific IgE in serum in placebo-treated mice (filled bars) as compared 
to pre-challenge values (open bars). SIT treatment in non-transgenic mice significantly (P<0.05) 
reduced OVA-specific IgE in serum. SIT treatment in CD4+FOXP3+Treg depleted DEREG mice 
did not significantly reduce OVA-specific IgE in serum. C: Number of bronchoalveolar eosinophils 
was significantly reduced in SIT treated non-transgenic mice as compared to placebo treated non-
transgenic mice (P<0.05). Bronchoalveolar eosinophilia in CD4+FOXP3+Treg depleted DEREG 
mice was not suppressed by SIT as compared to placebo-treated mice and it is significantly higher 
as compared to SIT-treated non-transgenic  mice (P<0.01).
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DEREG mice to selectively deplete CD4+FOXP3+ Tregs 24 hours prior to 
allergen challenges in SIT- or control- treated mice (Figure 1: experiment 
C). DT administration in transgenic DEREG mice resulted in more than 90% 
depletion of CD4+FOXP3+ regulatory T cells as compared to their wild type 
littermates (Figure S2). As expected, OVA inhalation challenges induced the 
manifestations of experimental asthma in OVA sensitized placebo-treated 
mice by induction of AHR, recruitment of eosinophils to the airways and 
increasing the level of OVA-specific serum IgE in both DEREG transgenic 
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Figure S1 - Depletion efficacy of anti-CD25 antibody in wild type mice. Dot plot figures show 











Figure S2 - Depletion efficacy by diphtheria toxin administration to DEREG mice, histogram 
figures show the frequency of CD4+FOXP3+ T cells in the spleen of DT treated, A) wild type mice, 
versus B) DEREG mice.
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SIT resulted in a significant level of suppression of AHR that was similar 
between wild type (59%) and DEREG mice (48%) (Figure 4A, P<0.05). 
Interestingly, depletion of CD4+FOXP3+ Treg cells in DEREG mice resulted in 
slightly increased levels of OVA-specific IgE in serum compared to wild-type 
mice, while the level of suppression achieved by SIT treatment was similar 
between the two groups (Figure 4A and 4B). In contrast, SIT caused only a 
mild reduction of airway eosinophilia in DEREG mice (57.23%, P=0.12), 
whereas the suppression in wild-type mice was much more pronounced 
(81%, P<0.05) (Figure 4C). Moreover, the number of airway eosinophilia in 
DEREG mice was significantly higher compared to their wild-type littermates 
(7.8x105 versus 1.9x105, P<0.01). Thus, specific depletion of CD4+FOXP3+ 
Tregs partially abrogates SIT-associated suppression of airway eosinophilia 




This study addresses the functional relevance of nTregs for generating 
allergen-specific tolerance during SIT injections as well as the role of SIT-
generated CD4+FOXP3+ inducible Tregs in the suppression of allergic 
manifestations upon allergen exposure. Using a mouse model of allergic 
asthma, we show that during SIT injections CD4+CD25+ Tregs are partially 
required for developing the SIT-induced suppression of AHR. Furthermore, 
we show that SIT transiently increases CD4+CD25+FOXP3+ Tregs in spleen 
and blood, indicating that SIT generates inducible allergen-specific Tregs. 
Finally, we demonstrate that CD4+FOXP3+ Tregs partially mediate SIT-
induced suppression of airway eosinophilia but not of AHR and specific IgE 
upon allergen provocation.
Considering that nTregs can facilitate the generation of iTregs 21;22, we 
evaluated the role of nTregs in tolerance induction during SIT injections. 
Tolerance induction in our model was evaluated based on the suppression 
of AHR, airway eosinophilia and specific IgE in serum 23. Interestingly, 
when nTregs are depleted during SIT injections, SIT-induced suppression of 
AHR was partially reversed while suppression of specific IgE and airway 
eosinophilia remained unchanged. Confirming our previous findings 16, 
these data clearly demonstrate that suppression of different manifestations 
of allergic asthma in mice including AHR, eosinophilia and specific IgE 
are differentially regulated by SIT. Nevertheless, the mechanism by which 
nTregs specifically induce tolerance towards antigen-induced AHR remains 
to be elucidated. In contrast to our findings that nTreg cells are not critical for 
SIT-induced suppression of airway eosinophilia, Boudousquie and colleagues 
24 have observed that CD4+CD25+ T cells are critical for suppression of 
eosinophilic airway inflammation in a model of intranasal tolerance induction. 
The differences might be the result of the divergent pathways of tolerance 
induction: Boudousqui et al, administered the antigen intranasally to induce 
tolerance, whereas SIT in our model was performed by s.c. injections. 
Different mechanisms are involved in tolerance induction through different 
routes of antigen administration 25;26. For instance, while plasmacytoid DCs 
are essential for tolerance induction through inhalation 25, conventional DCs 
play a major role in oral tolerance 26. Moreover, Boudousquie and colleagues 
injected anti-CD25 antibody at three different time points, before and after 
intranasal antigen application, and at the time of inhalation challenge, while 
we only used the anti-CD25 only during SIT injections to specifically dissect 
the functional importance of nTregs during SIT-induced tolerance.
Although it has been shown that SIT increases the number of CD4+FOXP3+ 
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Tregs systemically 6 and locally 7 in SIT-treated allergic patients, a functional 
role for these cells in vivo has not been shown. We hypothesized that 
CD4+FOXP3+iTregs are induced by SIT and mediate SIT-induced suppression 
of allergic manifestations during allergen provocation in our mouse model. 
Here, we show that similar to human SIT studies 6;7, SIT transiently induces 
CD4+CD25+ FOXP3+Tregs in the spleen and blood in our mouse model. 
Our results show that in SIT-treated mice the frequency of CD4+CD25+ 
FOXP3+Tregs is increased in the spleen and blood 24 hours after SIT injections 
followed by a subsequent return to the level of placebo-treated mice 96 hours 
after the last SIT injection. In line with this hypothesis, Kerstan et al, have 
shown that venom immunotherapy in human subjects results in the activation 
and migration of blood CD4+CD25+FOXP3+ Tregs to regional lymph nodes27. 
Using DEREG mice we show that selective depletion of CD4+FOXP3+Tregs 
after SIT partially abrogates the suppressive effects of SIT on airway 
eosinophilia, suggesting that induction of CD4+FOXP3+ iTregs is important 
but not the only mechanism by which SIT induces tolerance to OVA in this 
model. Moreover, our results show that AHR and allergen-specific IgE are not 
influenced by depletion of CD4+FOXP3+Tregs again confirming that the three 
different cardinal features of allergic asthma namely, AHR, eosinophilia and 
specific IgE are differentially regulated by SIT. 
Besides CD4+FOXP3+ Tregs, TGF-β producing Th3 cells and IL-10 producing 
Tr1 cells have been also implicated in SIT 28;29. Jutel and colleagues have 
shown that venom SIT induces TGF-β producing as well as IL-10 producing 
venom specific peripheral CD4+ T cells in human patients 30. They found 
that neutralization of these cytokines hampers SIT-induced suppression of 
proliferation of ex vivo venom stimulated T cells. Furthermore, Hansen and 
colleagues showed that CD4+ T cells engineered to express TGF-β effectively 
suppress AHR and allergic inflammation in a mouse model of allergic asthma 
31 demonstrating that TGF-β producing CD4+ T-cells are capable to suppress 
asthma manifestations in vivo. Moreover, TGF-β instructs B-cells to produce 
allergen-specific IgA which competes with IgE to bind to the allergen leading 
to neutralizing the allergen and preventing mast cell degranulation 28. Although 
OVA-IgA is increased after IT in our mouse model, we have previously 
shown that IgA production is dispensable for SIT-induced suppression of 
experimental asthma features 16. It remains to be determined if, in addition to 
FOXP3 Tregs, TGF-β producing Tregs are involved in our mouse model of 
SIT.
Production of IL-10 has been frequently observed during and after SIT in 
clinical studies 29;32-37, suggesting that IL-10 plays important roles in SIT in 
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human patients. The induction of IL-10 producing Tregs was first shown in 
peripheral blood mononuclear cells which were stimulated ex vivo 28 days 
after venom SIT 30;32. Similar results were found after grass pollen SIT in 
patients with systemic anaphylaxis 38 and house dust mite SIT in asthmatic 
children 9. In line with clinical findings, SIT in our mouse model of allergic 
asthma induces a long-term IL-10 dependent tolerance that lasts for at least 20 
weeks (39 and unpublished data). The key role of IL-10 for tolerance induction 
in this model might be an indication for the involvement of IL-10 secreting 
iTregs, presumably Tr-1 cells. Kearly et al, have shown that transfer of OVA-
specific CD4+CD25+ T cells to OVA-sensitized mice suppress OVA-induced 
airway inflammation and AHR in an IL-10-dependent fashion 40. However, 
IL-10 secretion from the transferred Treg cells was not required for the 
observed effects, suggesting that CD4+CD25+ T cells instruct a different cell 
type to secrete the asthma suppressing IL-10. In the present study we show 
that CD4+FOXP3+ iTregs are only partially involved in SIT-induced tolerance 
induction, indicating that another, as yet unknown sub-type of CD4+ FOXP3- 
Tregs is implicated. This unidentified regulatory T cell may be more critical 
for suppression of AHR and IgE than for airway eosinophilia, explaining their 
differential regulation by SIT. 
In summary we show that nTregs are partly required for establishing tolerance 
during SIT injections. Furthermore, we show that SIT transiently increases the 
number of CD4+FOXP3+Tregs in the spleen and blood and provide evidence 
that CD4+FOXP3+Tregs are partially responsible for the beneficial effects of 
SIT. It is suggested that generation of a subtype of FOXP3 negative Tregs is a 
complementary mechanism underlying the induction of full-tolerance by SIT. 
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Abstract 
Background: Allergen-specific immunotherapy (SIT) is a disease-
modifying treatment for allergic diseases, and is associated with 
desensitization of mast cells and basophils, induction of neutralizing 
antibody responses and suppression of Th2 cell activity. A hallmark of SIT 
is the expression of IL-10 by T cell subsets, and IL-10 signaling is critical 
for suppression of allergic inflammation in mouse models of SIT. Here, we 
dissect the mechanism of IL-10 induction for the suppression of allergic 
inflammation. 
Methods: A mouse model for OVA-specific SIT based on the classical 
experimental asthma mouse model was used to assess IL-10 production 
by flowcytometric secretion assays. CD8+ T cells were depleted using 
antibodies. OVA-pulsed dendritic cells (DCs) were adoptively transferred to 
sensitized and SIT-treated mice to assess the relevance of DC derived IL-10 
for suppression of inflammation by SIT.
Results: SIT treatment induces IL-10 producing CD4+ and CD8+ T cells. 
CD8+ T cells are not required for suppression of eosinophilic airway 
inflammation. Allergen challenge of SIT-treated mice does not induce 
IL-10 producing T cell subsets in lung tissue. In contrast, we identify a 
subset of DCs as the major IL-10 producing cell type in SIT-treated mice 
after allergen challenge. Adoptive transfer of IL-10-deficient or wild-type 
OVA-pulsed bone-marrow derived DCs to sensitized and SIT- or sham-
treated acceptor mice demonstrates that the IL-10 production from the 
allergen-presenting DCs is critically required for suppression of Th2-driven 
eosinophilic airway inflammation. 
Conclusions: We conclude that IL-10 production by allergen-presenting 
DCs is required for suppression of the allergic inflammation by allergen-
specific IT.
Introduction
Allergic individuals respond to allergen exposure with an IgE dependent 
immediate type I hypersensitivity response that can be transiently suppressed 
by blocking mast cell effector molecules such as histamine, followed by a Th2 
dependent late allergic exposure that can be suppressed by immunosuppressive 
drugs1. In contrast, allergen-specific immunotherapy (SIT) is a disease-
modifying treatment for allergic disorders, inducing long-term relief of 
symptoms2. SIT treatment entails subcutaneous or sublingual applications of 
allergen with increasing doses. The response to SIT is characterized by early 
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inhibition of mast cell and basophil activity, increase of allergen-specific IgG4 
titers and suppression of allergen-specific Th2 cell activity1,3,4. Induction of 
allergen-specific regulatory T cell responses is thought to be critical for the 
altered allergen-specific B and T cell responses, and is associated with the ex 
vivo expression of IL-10 and TGFβ in PBMC cultures1,5,6. IL-10 production 
in T cells after allergen-specific stimulation of PBMCs isolated from SIT-
treated patients was found to be induced already a few hours after the first 
allergen injection in wasp venom immunotherapy7 and has been observed 
after SIT treatment for a range of allergens, including house dust mite (HDM), 
birch pollen and grass pollen8-11. IL-10 production has also been observed in 
vivo upon allergen challenge in SIT-treated patients10,12. Interestingly, IL-10 
secretion is not limited to CD4+ T cells. For instance, IL-10 was also produced 
by monocytes in the original bee venom SIT study6, and in the nasal mucosa 
after grass pollen SIT10. Finally, HDM-specific SIT was shown to induce IL-
10-producing FOXP3+ CD8+ cells13. Hence, whereas the induction of IL-10 
expression by SIT-treatment is well established, the cellular source of IL-
10 varies between studies, and the mechanism underlying IL-10 induction 
has not been characterized. Therefore, it remains to be established which 
cell is critical for the IL-10 production required for suppression of allergic 
symptoms upon allergen challenge, and thereby for therapeutic efficacy in an 
SIT-treated individual.
In order to dissect the mechanisms underlying the therapeutic effects, we 
employ a mouse model for allergen-specific SIT based on the ovalbumin 
(OVA) induced mouse model for allergic asthma. Experimental SIT treatment 
renders a long-lasting protection from allergic airway inflammation and is 
dependent on IL-10 signaling in vivo16. Here, we aim to characterize the 
mechanism by which SIT treatment suppresses the allergic manifestations 
upon allergen challenge. We observe a strong induction of IL-10 production by 
CD8+ T cells after SIT injections and by inflammatory DCs in the lung tissue 
after allergen challenge. Whilst CD8+ T cells are irrelevant for suppression of 
allergic manifestations, we find that IL-10 expression by DCs is required for 




Male wild-type or IL-10 deficient BALB/c mice 6-8 week old were purchased 
from Charles River (Maastricht, The Netherlands). Animal housing and 
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experiments were performed in accordance with the guidelines of and after 
ethical review by the Institutional Animal Care and Use Committee (IACUC/
DEC) at the University of Groningen. 
Experimental SIT protocol 
The protocol used for OVA (endotoxin-free (<0.5 U/ml) Seikagaku; Tokyo, 
Japan) sensitization, SIT and inhalation challenge was previously described15.
Ovalbumin-specific immunoglobulin in serum and cell counts and 
cytokine ELISAs in BAL
Serum was collected 3-5 days before the first OVA challenge and 24hrs after the 
last challenge. OVA-specific IgE and IgG1 levels were measured by enzyme-
linked immunosorbent assays (ELISA)15. Lungs were lavaged with 5mL of 
saline, and cytokines were measured in cell-free supernatants of the first 
1mL. Cellular composition of the BAL was analyzed with flowcytometry17. 
IL-5 and IL-13 in the BAL were determined by ELISA (Becton Dickinson, 
Franklin Lakes, NJ, USA). The detection limits were 32 pg/ml (IL-5) and 15 
pg/ml (IL-13).
Isolation of lung, thoracic lymph nodes (TLNs) and spleen for 
flowcytometry
Single-cell suspensions were obtained from lung after enzymatic digestion 
and from spleen and lymph nodes by mechanical disruption18. IL-10 was 
quantified using the IL-10-secretion assay (Miltenyi Biotec, Leiden, the 
Netherlands), after erythrocyte (RBC) lysis and culture (2x105) in 96-well 
round bottom plates with 10μg/ml OVA for 18hrs using a FACSCalibur or 
LSRII (Becton Dickinson) for measurement and FlowJo software (Tree star 
inc, OR, USA) for analysis.
Depletion of CD8+ T cells
CD8+ T cells were depleted using two i.p. injections with YTS169 (500µg/
mouse), 24hrs before the first OVA inhalation challenge and after 5 days. 
Generation of bone marrow derived DC (BM-DC)
BM-DC were generated as described19. At day 9 of culture, BM-DCs were 
pulsed with 100μg/ml OVA for 24hrs, and 1x106 mature DCs were injected 




All data are expressed as mean ± SEM. Mann-Whitney U test for non- 
parametric data (SPSS software version 16.0) was applied to analyze the 
results and a p<0.05 was considered significant. Significance is indicated in 
the figures with * for p<0.05 and ** for p<0.01.
Results
SIT does not suppress airway inflammation in IL-10 knockout mice 
To test whether compensatory pathways for the IL-10 mediated suppression of 
allergic inflammation induced by SIT exist in vivo, we first performed OVA-
SIT in IL-10 deficient mice. It is well-established that IL-10-deficient mice 
have an altered asthma phenotype21,22. Therefore, we evaluated the efficacy 
of SIT by comparing control (Sham) to OVA-SIT-treatment within IL-10-/- 
mice only (figure 1). OVA inhalation challenges induced strong OVA-specific 
IgE responses in both Sham- and SIT-treated IL-10-/- mice (figure 1B). OVA-
SIT also induced strong OVA-specific IgG1 responses that were not further 
increased by OVA inhalation challenges in IL-10-/- mice. These results are 
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Figure 1Figure 1 -(A) The experimental protocol for OVA-IT in IL-10 knockout mice. (B) OVA-specific 
immunoglobulin responses induced by OVA-IT or sham treatment (pre-challenge) and subsequent 
OVA inhalation challenges (post-challenge) in IL-10 deficient mice. (C) Total cell counts and num-
bers of eosinophils in bronchoalveolar lavage (BAL) of OVA-IT (black bars) or sham (grey bars) 
treated and OVA-challenged IL-10 deficient mice. (D) Th2 cytokine levels in lung tissue of OVA-IT 
(black bars) or sham (grey bars) treated and OVA-challenged IL-10 deficient mice.
6DC-derived IL-10 is critical for allergen-SIT
119
In sham treated IL-10-/- mice, OVA inhalation challenge induced infiltration 
of eosinophils and other inflammatory cells into the airways, which was even 
more pronounced in SIT-treated IL-10-/- mice (figure 1C). In addition, Th2 
cytokines in lung tissue were not reduced by SIT treatment (figure 1D). These 
results are in contrast to the SIT-induced suppression of airway eosinophilia 
and Th2 cytokine production observed in wild-type mice14-16, demonstrating 
that IL-10 is critically required for suppression of the Th2 mediated 
eosinophilic airway inflammation by OVA-SIT.  
IL-10 production is induced in T cells by OVA-SIT treatment.
Next, we aimed to identify the cellular source of IL-10 in SIT. IL-10 can in 
fact be produced by a plethora of different cell types, including regulatory B 
and T-cells, macrophages and dendritic cells23. We first analyzed the IL-10 
producing cells 24 hrs after the last SIT injection (figure 2). 
A
Figure 2
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Figure 2 -(A) Schematic representation of the experimental protocol for detection of IL-10-se-
creting cells after IT treatment. (B) Fraction of IL-10 secreting cells within the CD4+ and CD8+ T 
cell population in sham (grey bars) or OVA-IT (black bars) treated mice. (C) Fraction of T1/ST2 or 
FoxP3-expressing cells within the CD4+ T cell population in sham (grey bars) or OVA-IT (black 
bars) treated mice. (D) Fraction of IL-10 secreting cells within the T1/ST2 or FoxP3-expressing 
CD4+ T cell subpopulation in sham (grey bars) or OVA-IT (black bars) treated mice.
In spleen, percentages of CD4+, CD8+ T-cells or FOXP3+ CD4+ regulatory T 
cell subsets were not changed by SIT treatment, while the T1/ST2+ fraction of 
CD4+ T-cells was increased only after OVA-SIT, indicating a rapid expansion 
of Th2 cells (figure 2C and data not shown). In the SIT treated group, an 
increased fraction of IL-10+ cells was observed within CD4+ and CD8+ T-cells 
compared to Sham treated controls (figure 2B). Interestingly, the fraction of 
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IL-10 producing cells present in CD8+ T-cells was much higher than in CD4+ 
T-cells. We did not observe increased numbers (figure 2C) or IL-10 production 
of FOXP3+ CD4+ regulatory T-cells (figure 2D). 
B
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Figure 3 -(A) The experimental protocol for CD8+ T cell depletion during OVA inhalation chal-
lenges in OVA-IT or sham-treated mice. (B) Efficiency of CD8+ T cell depletion in spleen. (C) Total 
cell counts and numbers of eosinophils in BAL of OVA-IT (black bars) or sham (grey bars) treated 
and OVA-challenged mice treated with control antibody or CD8-depleting antibody as indicated. 
(D) OVA-specific immunoglobulin responses induced by OVA-IT or sham treatment (pre-challenge) 
and subsequent OVA inhalation challenges (post-challenge) in mice treated with control antibody 
or CD8-depleting antibody as indicated. (E) Th2 cytokine levels in BAL of OVA-IT (black bars) or 
sham (grey bars) treated and OVA-challenged mice treated with control antibody or CD8-depleting 
antibody as indicated.
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CD8+ T cells do not contribute to suppression of eosinophilic airway 
inflammation.
The presence of IL-10-producing CD8+ T cells after SIT treatment might 
mark the induction of regulatory CD8+ T cells, similar to those reported in 
mouse models of low-zone tolerance24. Therefore, we asked whether CD8+ 
T cells contributed to SIT-induced suppression of Th2 driven eosinophilic 
airway inflammation, by performing antibody-mediated depletion of CD8+ 
T cells during allergen challenges (figure 3A), resulting in a depletion of 
more than 95% of CD8+ T cells (figure 3B). Loss of CD8+ T cells, however, 
did not affect the suppression of eosinophilic airway inflammation (figure 
3C), of OVA-specific IgE in serum (figure 3D) and of Th2 cytokines in BAL 
(figure 3E). These data do indicate that CD8+ T cells do not make a substantial 
contribution to the suppression of allergic airway inflammation by SIT.
Lung CD11c+MHC-IIint cells produce IL-10 in lung tissue of SIT treated 
mice after OVA-inhalation challenge
In the mouse model of OVA-SIT, suppression of Th2 driven eosinophilic 
airway inflammation is observed after OVA challenges. The studies using 
IL-10R neutralizing antibodies16,20 or using IL-10 deficient mice (figure 1) 
do not inform whether IL-10 is critically required during SIT treatment or 
during allergen challenges. We therefore also evaluated the presence of IL-10 
producing cells in spleen, lymph nodes and lung tissue after OVA inhalation 
challenges in SIT or Sham-treated mice. We did not observe any changes 
in the fraction of IL-10 producing cells within the major T cell subsets in 
spleen, mediastinal lymph nodes or lung tissue between Sham and SIT-treated 
groups (figure 4B and data not shown). Remarkably, the percentage of T1/
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Figure 4 -(A) The experimental protocol for the identification of IL-10 secreting cells after OVA 
inhalation challenges in OVA-IT or sham treated mice. (B) Fraction of IL-10 secreting cells within 
the CD4+ and CD8+ T cell population in sham (grey bars) or OVA-IT (black bars) treated mice. 
(C) Fraction of T1/ST2 and FoxP3 expressing cells within the CD4+ T cell population in sham 
(grey bars) or OVA-IT (black bars) treated mice. (D) Fraction of IL-10 secreting cells within T1/
ST2+ and FoxP3+ CD4+ T cell population in sham (grey bars) or OVA-IT (black bars) treated 
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the suppression of Th2 cells. The fraction of IL-10 producing cells after OVA 
inhalation challenges, however, was not altered by SIT treatment in either T1/
ST2+ Th2 cells or FOXP3+ CD4+ Tregs in lung tissue or lymph nodes (figure 
4B and data not shown). These data indicate that, surprisingly, T cell subsets 
did no longer produce increased amounts of IL-10 upon inhalation challenge 
in the SIT treated mice. 
Therefore, we also evaluated IL-10 production in CD11c+ APCs in BAL 
and lung tissue. Here, we observed a strongly increased fraction of IL-10 
producing cells in CD11c+CD11bhi cells after OVA inhalation challenges in 
SIT-treated mice (figure 4C, 4D and data not shown). Further characterization 
of the IL-10-producing subset of CD11c+CD11bhi DCs indicated a reduced 
expression of CD86 and MHC-II, as well as Ly6G by this DC subset (figure 
4E), reflecting a reduced maturation of the IL-10 producing DCs in lung 
tissue of SIT-treated mice. 
mice. (E) Identification of IL-10 secreting cells with the CD11c+ dendritic cell population in lung 
tissue, gated for CD11blo versus CD11bhi expression, performed in either sham or OVA-IT treated 
mice as indicated. (E) Fraction of IL-10 secreting cells within the CD11c+CD11bhi inflammatory 
DC cell subset in sham (grey bars) or OVA-IT (black bars) treated mice upon OVA inhalation chal-
lenges. (F) Characterization of MHC-II, Ly6G and CD86 expression levels on CD11c+CD11bhi 
inflammatory DC cells from lung tissue of sham (grey lines) or OVA-IT (red lines) treated mice 
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Figure 5 -(A) The experimental protocol for allergen challenge using OVA-treated bone-marrow 
derived DCs of OVA-IT treated mice. (B) Total cell counts in BAL of OVA-IT (black bars) or 
sham (grey bars) treated mice challenged with OVA-loaded IL-10-proficient (wild-type) or IL-
10-deficient (IL-10 KO) bone-marrow derived dendritic cells as indicated. (C) Total numbers of 
eosinophils in BAL of OVA-IT (black bars) or sham (grey bars) treated mice challenged with OVA-




IL-10 production by DCs is required for suppression of eosinophilic 
inflammation.
Next, we aimed to assess whether IL-10 production by the allergen-presenting 
DCs was required for suppression of eosinophilic airway inflammation in 
SIT-treated mice. To this end, we employed a previously established model 
of allergen challenge using adoptive transfer of bone-marrow derived 
DCs19. Groups of OVA-sensitized and either sham- or SIT-treated mice were 
challenged by intratracheal transfer with OVA-pulsed DCs derived from wild-
type or IL-10-/- bone marrow (figure 5A). Mice that had not received OVA-
A
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Figure S1 -(A) The experimental protocol for the identification of IL-10 secreting cells after 
OVA inhalation challenges in OVA-IT or sham treated mice. (B) Identification of IL-10 secreting 
cells with the CD11c+ dendritic cell population in lung tissue or BAL, performed in either sham or 
OVA-IT treated mice as indicated.
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SIT treatment displayed marked infiltration of eosinophils into the airways 
48 hours after instillation of OVA-pulsed wild-type DCs. This infiltration 
of inflammatory cells (figure 5B; left panel) and the numbers of eosinophils 
(figure 5C; left panel) were significantly reduced in SIT-treated mice challenged 
with OVA-pulsed wild-type DCs. These data demonstrate that the transfer of 
OVA-pulsed DCs induces an eosinophilic airway inflammation that remained 
sensitive to SIT treatment of the recipient mouse. Remarkably, upon challenge 
of the OVA-SIT treated mice with OVA pulsed IL-10-deficient DCs, neither 
the total cell count of the BAL nor the number of eosinophils were decreased 
compared to sham-treated mice, which was in marked contrast to the situation 
after challenge using IL-10-proficient DCs. Taken together, these data show 
that the production of IL-10 by the antigen presenting DCs is required for 
suppression of eosinophilic airway inflammation by OVA-SIT.
Discussion
Here, we show for the first time the critical role for DC-derived IL-10 in 
suppression of eosinophilic inflammation upon allergen challenge in SIT-
treated mice. We find that IL-10 is indispensable for SIT-induced suppression 
of allergic inflammation (Figure 1). Although CD4+ and CD8+ T cells produce 
significant amounts of IL-10 shortly after the SIT treatments (Figure 2), 
most of the CD4+ T cells are T1/ST2+ Th2 cells25 while the CD8+ T cells are 
dispensable for suppression of allergic inflammation by SIT (Figure 3).
Upon allergen challenge of SIT-treated mice, we no longer observe an 
increased IL-10 production by CD4+ or CD8+ T cells or CD4+ FOXP3+ Tregs 
(Figure 4). This transient increase in IL-10 expression in T cells after SIT 
injections mirrors observations from patient studies, where IL-10 production 
in CD3+ T cells can be detected already on the day of the first SIT injections7, 
but tends to decrease again during maintenance phase of SIT8,9, indicating 
that IL-10 production by T cells is in fact an early event.
The major IL-10 producing cell in lung tissue upon allergen challenge was the 
CD11c+ CD11b+ inflammatory DC26. Intratracheal delivery of BM-derived 
DCs from wild-type donors into OVA sensitized mice that had received either 
OVA-SIT or Sham treatment induced eosinophilic airway inflammation 
that was suppressed by prior OVA-SIT treatment of the recipient mice. In 
contrast, adoptive transfer of IL-10 deficient DCs failed to induce suppression 
of eosinophilic airway inflammation. These data also strongly indicate 
that OVA-SIT treatment induces the presence of an as of yet unidentified 
allergen-specific regulatory T cell population that induces IL-10 production 
by the adoptively transferred DCs, culminating in suppression of Th2 cells 
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and eosinophilic inflammation. Since we ruled out a role for CD8+ T cells, 
we hypothesize the presence of a CD4+ Treg cell subset to be critical for 
suppression of allergic inflammation in our mouse model of SIT.
Antigen-presenting cells have previously been shown to contribute to the 
suppression of allergen-specific pulmonary responses through the production 
of IL-10. For instance, induction of inhalation tolerance in naïve mice 
was associated with a transient IL-10 production by pulmonary DCs27. 
Moreover, it has been shown that IL-10 treated OVA-pulsed DCs are capable 
of suppressing airway inflammation in OVA-sensitized mice in an IL-10 
dependent fashion28. In human studies, the majority of the IL-10 producing 
cells in biopsies from the nasal mucosa of grass pollen SIT-treated patients 
were APCs of myeloid origin10. Taken together, these data indicate that the 
APCs might very well mediate suppression of local allergic inflammation 
after SIT treatment by producing IL-10. The identity of the putative allergen-
specific regulatory T cell subset licensing the APCs for IL-10 production, 
however, remains to be established.
In our experiments, we did not detect an increased number of IL-10 producing 
FOXP3+ CD4+ (or CD8+) T cells. This might be due to the low frequency 
of allergen-specific Tregs, precluding efficient identification of these cells. 
Alternatively, the putative Tregs that induce IL-10 production by the OVA-
presenting DCs might not express IL-10 themselves. For instance, in mice 
with a T cell-specific IL-10 deficiency, OVA-SIT reportedly retains the 
ability to suppress eosinophilic airway inflammation29,30. Moreover, it has 
been shown that adoptive transfer of OVA-specific CD4+CD25+ regulatory 
T cells to OVA-sensitized mice reduced airway inflammation after allergen 
challenge in an IL-10-dependent manner, even when IL-10 deficient Tregs 
were used for the transfer31. We hypothesize a similar allergen-specific Treg-
DC interaction in SIT, leading to IL10 production by the allergen-presenting 
DCs. 
In summary, our data for the first time show that IL-10 production by the 
antigen-presenting DCs is critically required for SIT-induced suppression of 
allergic inflammation upon allergen provocation in sensitized and SIT treated 
mice. We propose that allergen-SIT induces a regulatory T cell subset that is 
able to instruct the allergen-presenting DC to induce IL-10 production through 
cognate interactions. The identification of the critical cellular mechanisms 
driving the differentiation of this putative allergen-specific regulatory T cell 
subset might allow for the rational design of improved allergen preparations 
for SIT treatment with enhanced efficacy through the use of specific adjuvants.
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Abstract
Background: Allergen specific immunotherapy (SIT) is the only treatment 
for allergic diseases that targets allergen-specific Th2 cells which are the cause 
of the disease. There is an unmet requirement for adjuvants that increase the 
clinical efficacy of SIT allowing application of lower doses of the allergen and 
thereby reducing the risk of anaphylactic reactions. Cytotoxic T-Lymphocyte 
Antigen 4-Ig (CTLA4-Ig) has been shown to induce immunological tolerance 
in autoimmunity and allograft transplantation by blocking T cell co-
stimulation and induction of the immunoregulatory enzyme indoleamine 2,3 
dioxygenase (IDO). Previously, we showed that CTLA4-Ig treatment at the 
time of allergen inhalation induced tolerance to subsequent allergen exposure 
in a mouse model of asthma. In this study, we test whether CTLA4-Ig acts as 
an adjuvant for experimental SIT. 
Objective: To determine if CTLA4-Ig can act as an adjuvant for SIT.
Methods: We performed a mouse model of SIT in the ovalbumin (OVA)-
driven experimental allergic asthma model. Mice were sensitized by OVA/
alum and two weeks later OVA-SIT was performed by three s.c. injections 
with CTLA4-Ig as adjuvant or control IgG. Two weeks after OVA-SIT, mice 
were challenged three times by OVA inhalation. We used wild-type mice as 
well as IDO-deficient mice to assess the role of IDO in the adjuvant effect of 
CTLA4-Ig. 
Results: Co-administration of CTLA4-Ig strongly increased SIT-induced 
suppression of AHR, specific IgE in serum, airway eosinophilia and Th2 
cytokine levels. Moreover, we find that CTLA4-Ig, as an adjuvant for SIT, is 
equally effective in IDO-deficient and wild type mice, demonstrating that the 
effect of CTLA4-Ig is independent of IDO expression. 
Conclusions & Clinical Relevance: We show that CTLA4-Ig acts as a potent 
adjuvant to augment the therapeutic effects of SIT. Since the adjuvant activity 
of CTLA4-Ig is independent of IDO, we conclude that it acts by blocking 
CD28 mediated T cell co-stimulation.
Introduction
Atopic Th2 immune responses against innocuous environmental antigens are 
the cause of allergic diseases that impair the quality of life of a significant portion 
of the world’s population 1;2. Currently, allergen specific immunotherapy 
(SIT) is the only remedy for allergic diseases that modifies the dominant Th2 
response and causes long-lasting relief of symptoms 3. Classically, SIT is 
performed by repeated administration of high doses of the sensitizing allergen 
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for a period of 3-5 years, after an initial gradual increase of administered 
allergen to avoid anaphylaxis 3. SIT not only induces a sustained relief of 
allergic symptoms but it can also prevent the development of new allergen 
sensitizations 4;5 and the progression of allergic rhinitis to allergic asthma 6. 
Currently, there are concerns about the safety of using high doses of allergen 
and the required long-term duration of treatment 7;8. Therefore, improvement 
of SIT by using clinically applicable adjuvants that achieve optimal efficacy 
at lower doses of allergen and leads to a safer therapy in possibly a shorter 
time-frame, is highly required 9. 
Cytotoxic T Lymphocyte Antigen 4 (CTLA4) is an inhibitory co-stimulatory 
molecule expressed by naturally occurring regulatory and activated T cells10;11. 
T cell receptor signaling upon antigen presentation results in T cell activation 
or inhibition when accompanied by CD28 or CTLA4 co-stimulation, 
respectively 11;12. 
CTLA4-Ig is a fusion molecule of the extracellular domain of CTLA4 and 
the heavy chain of human or mouse IgG 13;14. This molecule has been shown 
to exhibit tolerogenic properties towards self and allograft antigens in human 
patients and in animal models 15-17. CTLA4-Ig is an FDA-approved compound 
that has been used in the treatment of rheumatoid arthritis and prevention of 
allograft rejection 18;19. Interestingly, we have previously shown that CTLA4-
Ig treatment at the time of allergen inhalation in sensitized mice induced long-
term tolerance to subsequent allergen-induced airway eosinophilia, but not 
AHR in a mouse model of experimental asthma 20. 
CTLA4-Ig shows tolerogenic properties through two mechanisms: (i) 
sequestration of B7 and thereby inhibition of CD28 signaling 11;21 and (ii) 
reverse signaling into dendritic cells through B7 and subsequent activation of 
the alternative NFkB pathway leading to expression of the immunoregulatory 
enzyme indoleamine 2,3 dioxygenase (IDO) 22. Interestingly, we have 
previously shown that IDO contributes to SIT-induced tolerance induction 
in our model 23. Recently, an early induction of IDO has been observed after 
venom SIT suggesting a role for IDO in SIT-induced allergen tolerance in 
human patients 24.
In this study, we tested whether CTLA4-Ig can act as an adjuvant for 
experimental SIT. To this aim we administered CTLA4-Ig with SIT in 
an ovalbumin (OVA)-driven mouse model of asthma. We show that co-
administration of CTLA4-Ig with SIT highly enhances the SIT-induced 
suppression of airway hyperreactivity (AHR), airway eosinophilia and OVA-
specific IgE levels in serum. Furthermore, we show that the effect of CTLA4-
Ig is independent of IDO indicating that CTLA4-Ig in our model acts by 
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blocking the CD28-mediated T cell co-stimulatory signal.
Methods
Animals
Specific pathogen free 6-8 week BALB/cByJ mice (Charles River laboratories, 
L’Arbresle, France) and IDO-knockout (IDO-KO; C.129X1(B6)-Ido1tm1Alm) 
on BALB/c background (kindly provided by Dr. A.L. Mellor, GA, USA), 
were used according to the guidelines of the institutional animal care and use 
committee of the University of Groningen. 
Experimental allergic asthma, SIT
Experimental allergic asthma was induced and SIT was performed according 
to the previously described protocol 25. Concisely, as shown in figure 1, mice 
were sensitized by intraperitoneal (i.p.) injection of 10 µg endotoxin-free/
low (<5 EU/mg) OVA (Seikagaku Kogyo, Tokyo, Japan) and 2.25 mg alum 
(Pierce, IL, USA) in 100 µL of pyrogen-free saline. Two weeks later, they 
either received 100 µg OVA in 200 µl saline per injection as OVA-SIT or 
200 µl saline as placebo through three subcutaneous (s.c.) injections on 
alternate days. At least ten days after the 3rd s.c. injection mice were challenged 
by aerosolized OVA 1% in phosphate-buffered-saline 3 times every third day. 
Airway responsiveness to increasing doses of methacholine was measured 24 
hours after the last challenge, thereafter mice were dissected, bronchoalveolar 
lavage was performed and blood and lung samples were taken. 
Administration of CTLA4-Ig as adjuvant for SIT
In the experiment using IDO-KO mice clinical grade CTLA4-Ig (abatacept, 
Bristol-Myers, Woerden, the Netherlands) was used. In other experiments 
CTLA4-Ig was obtained as described previously 26;27. CTLA-Ig (280 µg/ 
injection) or control IgG (280 µg/injection) were mixed with OVA-SIT 
(100 µg/injection) and s.c. injected. 
Measurement of lung function
Airway reactivity to methacholine was evaluated by direct measurement of 
airway resistance in response to increasing doses of methacholine as explained 
previously 23. In brief, anesthetized mice (by i.p. injection of ketamine 100 
mg/kg; Pfizer, New York, NY and medetomidine 1 mg/kg; Pfizer) were 
tracheotomized (20-gauge intravenous: i.v. cannula; Becton Dickinson, 
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Alphen a/d Rijn, The Netherlands), attached to a computer-controlled small-
animal ventilator (Flexivent; SCIREQ, Montreal, Quebec, Canada), then 
paralyzed (i.v. injection of Pancuronium bromide: Pavulon, 50 µg/Kg Merck 
Sharp & Dohme, NJ, USA).Ventilation was adjusted at a breeding frequency 
of 300 breaths/min and a tidal volume of 10 mL/kg. Tidal volume was pressure 
limited at 300 mm H2O. An i.v. cannula was inserted through the jugular 
vein for the administration of methacholine. Airway resistance in response to 
intravenous methacholine (acetyl-b-methylcholine chloride, Sigma-Aldrich, 
Dordrecht, the Netherlands) was calculated from the pressure response to a 
2-second pseudorandom pressure wave.
Determination of serum levels of specific IgE
Serum levels of OVA-specific IgE were determined by enzyme-linked 
immunosorbent assay (ELISA) as described previously 28 and results are 
expressed as experimental unit/ml. 
Analyses of bronchoalveolar lavage fluid
Animals were lavaged five times through the tracheal cannulae with 1-ml 
aliquots of saline. BAL cells were pooled, counted, and cell types were 
indentified using flow cytometry as described elsewhere 29.  
Cytokines measurement in the lung tiusse
Homogenates were made from the cardiac lobe of lung as described elsewhere30. 
The levels of IL-4, IL-5, IL-10, IFN-g and TGF-β in the lung homogenates 
were determined by commercially available ELISA kits according to the 
manufacturer’s instructions (BD Pharmingen, NJ, USA). 
Flow cytometry and antibodies
PerCP-anti-CD4 (BD, NJ, USA), FITC-anti-T1ST2 (MD-Biosciences, Zurich, 
Switzerland), PE-anti-FOXP3 and eFluor450-anti-CD25 (eBioscience, CA, 
USA) were used for FACS. 
Statistical analysis
Data are expressed as mean ± SEM. The airway response curves to methacholine 
were analyzed by repeated measurements. All the other data were compared 
using Mann–Whitney U-test corrected for multiple comparisons. A P-value 
of less than 0.05 was considered significant.
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Results
CTLA4-Ig strongly augments the therapeutic effects of SIT
CTLA4-Ig was combined with SIT to examine whether it augments the 
suppressive effects of SIT in a mouse model of allergic asthma (Figure 1). 
OVA-sensitized placebo-treated mice exhibit a strong OVA-specific IgE 
response, airway eosinophilia and AHR upon OVA inhalation challenges 
(Figure 2A-C). OVA-SIT treatment significantly reduced the level of these 
three basic manifestations of allergic asthma (P<0.05, Figure 2A-C) but did 
not significantly affect the levels of IL-4 and IL-5 in lung tissue (Figure 2 
D, E). Co-administration of CTLA4-Ig with SIT highly augmented the SIT-
induced suppression of AHR (P<0.05), OVA-specific IgE (P<0.005) and 
airway eosinophilia (P<0.005) as compared to SIT alone. Combination of 
CTLA4-Ig with SIT also induced a reduction in the levels of IL-4 (P<0.05) 
and IL-5 (P<0.05) in lung tissue, which was not observed with SIT treatment 
alone (Figure 2D, E). 
CTLA4-Ig-mediated augmentation of SIT is independent of IDO
Since CTLA4-Ig has been shown to increase the expression of indoleamine 2,3 
dioxygenase and thereby induce tolerogenic effects (31), we tested whether 
the augmenting effect of CTLA4-Ig on SIT in our model is dependent on IDO 
activity. To this aim we compared the effects of co-administration of CTLA4-
Ig with SIT between IDO-KO and wild-type BALB/c mice. OVA-SIT alone 




















Experiment 1: Evaluate the adjuvant effect
                        Balb/c mice
CTLA4-Ig or control IgG
Experiment 2: Mechanism: role of IDO
                        IDO-/- mice
Experiment 3: Mechanism: FOXP3/Cytokines
                        Balb/c mice
CTLA4-Ig or control IgG
CTLA4-Ig or control IgG
Co-administration:
 
Figure 1 - Experimental layout: in experiment 1, to evaluate that whether CTLA4-Ig can enhance 
the suppressive effects of SIT, it was combined with OVA-SIT (100 µg/mouse) in Balb/c mice. In 
experiment 2, CTLA4-Ig is combined with OVA-SIT in IDO-/- mice to examine whether the effect of 
CTLA4-Ig is mediated by IDO. In experiment 3, to analyse the effects of CTLA4-Ig on regulatory T 
cells the frequency of CD4+CD25+FOXP3+ Treg cells and CD4+T1ST2+ Th2 cells were analyzed 24h 
after the last SIT injection and 24h after inhalation challenges.
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significantly suppressed AHR (P<0.05), specific IgE in serum (P<0.05) 
and airway eosinophilia (P<0.05) in wild-type mice (Figure 3A,C-D). Co-
administration of CTLA4-Ig with OVA-SIT significantly increased the 
suppression level of AHR (P<0.05), OVA-specific IgE in serum (P<0.05) 
Figure 2



































































































































Figure 2 - The effects of co-adminis-
tration of CTLA4-Ig with OVA-SIT. A)
Airway reactivity to methacholine, B) 
OVA-specific IgE in serum, C) Number of 
Eosinophils in bronchoalveolar lavage, D) 
Level of IL-4 in lung tissue, E) Level of 
IL-5 in lung tissue
and airway eosinophilia (P<0.05) compared to OVA-SIT alone in wild type 
mice (Figure 3A,C-D). In IDO-KO mice, OVA-SIT significantly suppressed 
airway eosinophilia (P<0.05) but neither AHR nor specific OVA-specific 
IgE levels were suppressed (Figure 3B-D). Surprisingly, co-administration 
of CTLA4-Ig with OVA-SIT in IDO-KO mice also strongly enhanced SIT-
induced suppression of the manifestation of experimental allergic asthma, 
resulting in significant suppression of OVA-specific IgE and AHR, which was 
not achieved by the OVA-SIT alone, and significantly augmented suppression 
of eosinophils (Figure 3B-D). These data indicate that although SIT treatment 
is less efficient in IDO-KO mice, CTLA4-Ig co-administration remains 
7CTLA4-Ig is a potent adjuvant for experimental SIT
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effective in enhancing the suppressive effects of the OVA-SIT.
Co-administration of CTLA4-Ig with SIT reduces peripheral Treg and 
Th2 cells
To evaluate whether administration of CTLA4-Ig results in the induction 
of Treg cells, that might suppress reactivation of Th2 cells upon allergen 
inhalation challenge, we analyzed the frequency of CD4+CD25+FOXP3+ Treg 
Figure 3 - The effects of co-administration of CTLA4-Ig with OVA-SIT in IDO-/- mice. A) Airway 
reactivity to methacholine in wild type mice , B) Airway reactivity to methacholine in IDO-/- mice , 
C) OVA-specific IgE in serum, D) Number of Eosinophils in bronchoalveolar lavage.
cells and CD4+T1ST2+ Th2 cells in peripheral blood 24h after OVA-SIT. Solo 
treatment of OVA-SIT does neither alter the frequency of CD4+CD25+FOXP3+ 
Treg cells nor the frequency of CD4+T1ST2+ Th2 cells (Figure 4A-B). 
Surprisingly, co-administration of CTLA4-Ig with SIT significantly reduced 
the percentage of both CD4+CD25+FOXP3+ Treg cells and CD4+T1ST2+ Th2 
cells within the CD4+ T cell population (P<0.05, Figure 4A-B) as compared 
to OVA-SIT alone. To test whether these effects of CTLA4-Ig on Treg persist 
after OVA inhalation challenges, the percentage of CD4+CD25+FOXP3+ Treg 
cells were analyzed in the blood 24h after the last inhalation challenge. No 
significant differences in the percentage of CD4+CD25+FOXP3+ Treg cells 































































































































CTLA4-Ig reduces interferon-γ in the lung tissue after inhalation 
challenge
To further dissect the mechanism of the augmenting effects of CTLA4-Ig on 
SIT we tested whether these effects are mediated by enhancing the activity 
of lung-resident Treg cells or Th1 cells which can suppress Th2 and effector 
cells upon allergen inhalation challenge. To this aim we measured the levels 
of IL-10, TGF-β and interferon-γ in the lung tissue 24h after the last OVA 
inhalation challenge. Remarkably, the levels of interferon-γ in lung tissue 
were significantly reduced in the group receiving combined CTLA4-Ig and 
OVA-SIT compared to the group receiving only OVA-SIT (P<0.05, Figure 
5C). No differences were observed in the levels of IL-10 and TGF-β in lung 
tissue between the different experimental groups (Figure 5A-B). 
Discussion
In this study we demonstrate that CTLA4-Ig acts as a potent adjuvant for 
SIT by strongly enhancing SIT-induced suppression of the manifestations 
of experimental allergic asthma, including the suppression of Th2 cytokines 
production, which was not achieved by SIT treatment alone. The adjuvant 
effect of CTLA4-Ig on SIT is independent of IDO activity, indicating that it is 
mediated by blocking the CD28-mediated T cell co-stimulatory signal. 







































































































Figure 4 - The effects of co-administration of 
CTLA4-Ig with OVA-SIT on the frequency of 
CD4+CD25+FOXP3+Treg cells and Th2 cells in the 
blood. A) Frequency of CD4+CD25+FOXP3+Treg 
cells in the blood 24h after the last SIT injection , 
B) Frequency of CD4+CD25+FOXP3+Treg cells 
in the blood 24h after the last inhalation challenge , 
C) Frequency of CD4+T1ST2+ T cells in the blood 
24h after the last SIT injection .
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Signaling into dendritic cells through B7 molecules, leading to activation of 
the non-canonical NF-kB pathway and induction of IDO 32 and (ii) Blocking 
the CD-28-mediated co-stimulatory signal on T cells 12. Here, we show that 
the adjuvant effect of CTLA4-Ig on SIT is independent of IDO. In agreement 
with our observations, David et al showed that CTLA4-Ig inhibits DC-
dependent proliferation of human T cells in vitro, in an IDO independent 
fashion 33. In contrast, it has also been observed that administration of 
CTLA4-Ig is tolerogenic in non-obese diabetic mice in a strictly IDO 
dependent fashion32. However, since NOD mice show impaired expression 
of CTLA4 and spontaneously develop auto-inflammatory disorders 32, these 
latter observation might not be very relevant to our model in which CTLA4-
Ig has been used in mice without such an impaired expression of CTLA4. 
Moreover, IDO can only partially explain the CTLA4-dependent regulation of 
T cell responses, as IDO-KO mice do not show the same lymphoproliferative 
phenotype as CTLA4-KO mice 34. 
In our model, we previously demonstrated that pharmacological inhibition of 
IDO contributes to SIT-induced suppression of the manifestation of allergic 
asthma 23. In the present study, we confirm these observations using IDO-
KO mice and show that the suppression of AHR and specific IgE induced 
by SIT treatment in wild-type mice is absent in IDO-KO mice. Apparently, 
loss of IDO changes the sensitivity to SIT-mediated suppression of asthmatic 
manifestations, but remains sensitive to the adjuvant effect of CTLA4-Ig 






































































Figure 5 - The effects of co-admin-
istration of CTLA4-Ig with OVA-SIT 
on the levels of cytokines in the lung 
tissue 24 h after the last inhalation 




OVA-specific IgE responses in IDO-KO mice to the level observed in wild 
type mice. 
The adjuvant effect of CTLA4-Ig might also indicate point to other tolerogenic 
mechanisms such as activation of members of the forkhead box O (FOXO) 
family of transcription factors, or induction of nitric oxide synthase by so-
called reverse signaling in DCs through B7 molecules. Interestingly, FOXO 
has been implicated in tolerance induction and it has been shown that CTLA4-
Ig induces tolerogenic effects by activating FOXO in DCs 32;35. Moreover, 
it has been observed that induction of allograft tolerance by CTLA4-Ig is 
dependent on both IDO and nitric oxide 36. More studies are needed to unravel 
the role of other pathways induced by reverse signaling in the adjuvant effect 
of CTLA4-Ig towards SIT.
Although we can not yet exclude all reverse signaling pathways, it appears very 
likely that CTLA4-Ig acts by blocking CD28-mediated T cell co-stimulation 
during SIT treatment. Antigen presentation in the absence of proper co-
stimulation leads to T cell anergy or induction of inducible regulatory T cells 
(iTreg cells) 37. Since we found that CTLA4-Ig co-administration suppresses 
the frequency of both CD4+CD25+FOXP3+ Treg and CD4+T1ST2+ Th2 
cells in blood, we speculate that the augmented suppression induced by 
CTLA4-Ig is mediated by a FOXP3 negative Treg cell subset or the direct 
induction of anergy in Th2 cells. Alternatively, the reduced percentage of 
CD4+CD25+FOXP3+ T cells in the blood could be due to migration of these 
cells to the lymph nodes as has been seen in venom SIT in human 38. 
After inhalation challenges when SIT-induced tolerance suppresses the 
manifestation of experimental asthma, we observe no increased production 
of TGF-β or IL-10. In fact, at this time point, we observe suppression of 
both Th1 (IFN-g) and Th2 (IL-4, IL-5) cytokines in the lung tissue. This may 
indicate that co-administration of CTLA4-Ig with SIT leads to increased 
function of Treg cells which are capable of suppressing both Th1 and Th2 
cell activity. Such an enhanced Treg cell function, though, appears to be 
independent of the production of the immunoregulatory cytokines TGF-β 
or IL-10 since their levels were not elevated. An alternative mode of action 
might entail suppression of Th1 and Th2 effector cells mediated by direct 
cell-cell contact39. However, we can not exclude that these immunoregulatory 
cytokines are produced at an earlier time-point or are produced locally in the 
lung and this is not reflected in increased levels in BAL fluid.  
In conclusion, we found that CTLA4-Ig acts as an adjuvant for SIT by highly 
enhancing its suppressive effects on manifestations of experimental allergic 
asthma. Adjuvant effects of CTLA4-Ig appear to be mediated by blocking 
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CD28-mediated T cell co-stimulation since they are independent of IDO 
function. It is tempting to speculate that using CTLA4-Ig might allow a safer 
SIT treatment regimen with lower doses of allergen. 
Interestingly, CTLA4-Ig (Abatacept) has been approved for clinical use 
by United States Food and Drug Administration and European Medicines 
Agency40 and has been safely used in clinical trials as a treatment for 
rheumatoid arthritis 18 and to prevent transplant rejection 19. Therefore, it is 
feasible to design clinical studies using CTLA4-Ig in combination with SIT in 
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Abstract 
Background: Allergen specific immunotherapy (SIT) is a disease modifying 
treatment that has been shown to render long-lasting relief from symptoms in 
variety of allergic disorders such as rhinitis and insect venom allergy. There 
is an unmet medical need to improve SIT, given the long treatment schedule, 
the lack of efficacy in some allergic disorders and the severe side effects 
such as anaphylaxis. Induction of IL-10 and TGF-β producing regulatory 
T cells has been shown to occur during SIT, although their precise role is 
currently unclear. In this study we tested the hypothesis that administration of 
exogenous TGF-β during SIT treatments improves its efficacy, by expanding 
the induction of regulatory T cells (Tregs). In addition, we tested whether 
blocking of IL-6 signaling could enhance the TGF-β dependent induction of 
Tregs.
Methods: TGF-β and a blocking anti-IL6 receptor antibody were co-
administered with suboptimal SIT in a mouse model of ovalbumin (OVA)-
driven asthma.
Results: Co-administration of TGF-β with suboptimal SIT resulted in 
significantly increased serum levels of specific IgA, and improved the 
suppression of eosinophilic inflammation of the airways and Th2 cytokines 
in the BALF as well as OVA-specific IgE responses, but did not enhance 
suppression of AHR. These effects were accompanied with a trend to increased 
numbers of FOXP3+ iTregs. Neutralizing IL-6 signaling during TGF-β/SIT 
treatment did not further improve the TGF-β enhanced suppressive effects of 
SIT, indicating an optimal induction of iTreg activity by SIT treatment in the 
presence of TGF-β.
Conclusion: Here, we show that co-administration of TGF-β with suboptimal 
SIT treatment potentiates the suppressive effects on Th2-driven allergic 
inflammation. Furthermore, the potentiation is associated with a trend 
to increased numbers of FOXP3+ iTreg cells and significant induction of 
specific IgA responses in serum. These data clearly indicate that therapies 
aimed at enhancing iTreg cell function are viable therapeutic strategies for 
improvement of SIT efficacy.
Introduction
Allergen specific immunotherapy (SIT) is the only treatment for allergic 
diseases that leads to long-term relief of symptoms by altering the 
immunological response to the allergen, the underlying cause of the disease 1. 
This treatment is performed by repeated administration of optimal high doses 
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of the sensitizing allergen at least for three years 2. Although high doses of 
allergen are required for optimal effects of SIT, these contribute to the risk of 
anaphylaxis. Therefore, SIT treatment has an induction phase, during which 
low but gradually increasing doses of allergen are given, and a maintenance 
phase during which high doses of allergen are applied 3. Even in such a 
treatment regimen, SIT is accompanied by the risk of anaphylaxis and has 
variable to low efficacy for some allergic disorders, including allergic asthma 
and food allergies, whilst being very efficacious for insect venom allergy and 
allergic rhinitis. Therefore, there is an unmet medical need to improve SIT to 
reduce the risk of anaphylactic reactions and to achieve efficacy of treatment 
for a wider range of allergic disorders. One approach to this end is the use 
of adjuvants to achieve a more pronounced suppressive immune response at 
lower doses of allergen.
Transforming Growth Factor-b (TGF-β) is an immunomodulatory cytokine 
which may play an important role in tolerance induction by SIT. Enhanced 
mucosal expression as well as increased secretion of TGF-β by PBMCs has 
been observed after successful subcutaneous and sublingual SIT 4-6. Moreover, 
a positive correlation has been observed between the levels of TGF-β and 
allergen specific IgA in serum and subsequently in the improvement of clinical 
symptoms after grass pollen immunotherapy 6. 
 It has been demonstrated that TGF-β can contribute to tolerance induction 
by facilitating the generation of two distinct subsets of inducible regulatory T 
cells (Tregs), (i) TGF-β producing Th3 cells and (ii) CD4+FOXP3+ inducible 
Tregs (iTregs) 7;8. For instance, TGF-β has been shown to mediate the induction 
of oral tolerance by generation of de novo iTregs 9. Furthermore it has been 
shown that these, TGF-β induced FOXP3+ iTregs can be generated from naïve 
CD4+ T cells in vivo, express TGF-β and have a potential suppressive function 
that can prevent the HDM-induced allergic pathogenesis in lung10. The role 
for TGF-β  in inducing Treg cell activity, however, is highly dependent on 
the presence or absence of other pro-inflammatory mediators in the local 
microenvironment. For instance, it has been demonstrated that in the presence 
of IL-6, TGF-β  promotes the generation of Th17 cells in mice at the expense 
of Treg induction 11;12. Moreover, IL-6 has been shown to hamper TGF-β-
mediated generation of iTregs in humans 13, suggesting a negative regulatory 
role for IL-6 on TGF-β induced iTregs mediated tolerance.
We have previously found evidence that TGF-β contributes to SIT-induced 
allergen tolerance in a mouse model of OVA-driven asthma 14. However, it is 
currently unknown what the role for TGF-β  is in SIT induction, and whether 
increased TGF-β  levels might enhance the efficacy of SIT in our mouse 
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model. Here, we hypothesize that while endogenous TGF-β contributes to 
SIT-induced allergen tolerance, administration of additional exogenous 
TGF-β might augment the therapeutic effects of SIT by increased induction 
of FOXP3+ iTregs. 
Using a mouse model for SIT based on the classical OVA-driven experimental 
asthma model, we show that administration of TGF-β during SIT treatment 
augments suboptimal SIT-mediated suppression of allergen induced airway 
eosinophilia, serum IgE as well as Th2 cytokines in the bronchoalveolar lavage 
fluid (BALF) but not AHR. Blocking the biological effects of IL-6 concurrent 
to administration of TGF-β and SIT does not enhance the potentiating effects 
of TGF-β suggesting that Th17 cells are likely not induced in this model. 
Materials and Methods
Mice
6-8-week-old female BALB/c mice were purchased from Charles River 
laboratories (L’Arbresle, France) and were kept under SPF (specific pathogen 
free) conditions. All animal experiments were performed in accordance with 
the guidelines of the institutional animal care and use committee (IACUC; 
DEC) of the University of Groningen.
Experimental allergic asthma and OVA-SIT
The OVA-specific immunotherapy for experimental allergic asthma in mice 
was similar as previously described 15, only with minor modification on the dose 
and frequency of SIT injections. Optimal SIT performed by 3 times injection 
of 1 mg OVA results in the maximal suppression of all the manifestations of 
experimental allergic asthma 14. In order to determine the potential enhancing 
effects of co-administration of TGF-β with SIT, a suboptimal SIT treatment 
regime was used in our studies. Sub-optimal SIT could was performed by 
reducing the number of injections (2 injections of 1 mg of OVA instead of 3), 
and in the second experiment also by reducing the dose (2 injections of 0.1 mg 
OVA instead of 1 mg). Briefly, for allergic sensitization mice received 2 i.p. 
injections of 10 μg OVA (endotoxin-free (<0.5 U/ml) Seikagaku Biobusiness 
Corporation; Tokyo, Japan) adsorbed onto 2.25 mg alum (ImjectAlum, Pierce, 
Rockford, IL, USA) in 100 μl pyrogen-free saline (B. Braun, Melsungen, 
Germany) on days 0 and 7. Two weeks after the last sensitization, mice were 
treated with 2 s.c. injections of either 1 mg OVA (suboptimal SIT, regarding 
number of injections) or 100 µg OVA (suboptimal SIT regarding dose and 
number of injections) in 200 μl pyrogen-free saline or 200 μl saline (sham 
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treatment group) on alternate days. After 10 days, mice were challenged 3 
times every third day with OVA aerosols in saline (1% w/v) for 20 min. The 
OVA inhalation challenges were performed in a Plexiglas exposure chamber 
coupled to a Pari LC Star nebulizer (PARI Respiratory Equipment, Richmond, 
VA, USA; particle size 2.5–3.1 μm) driven by compressed air at a flow rate 
of 6 l/min. 
Co-administration of TGF-β with SIT: Recombinant Human Latent TGF-β1 
was purchased from R&D system, the Netherlands. TGF-β was injected 
subcutaneously (1 µg in 100 µl saline) at the time of SIT injections in the same 
region. The dose of TGF-β to be used in these experiments was determined 
based on the utilized dose in previous studies 16;17. Before injection of TGF-β1, 
the latent form was activated as described in detail previously 16. Briefly, 
the latent form of TGF-β1 was activated via acidification in 4 mM HCL 
containing 0.1% BSA for one hour in room temperature, which followed by 
PH neutralization with NaOH (4M) and dissolved in saline before use. 
Blocking IL-6 signaling: mice received one dose (5 mg/mouse, i.p.) of rat 
anti-mouse interleukin-6 receptor monoclonal antibody (MR16-1), was 
kindly provided by Chugai pharmaceutical co., ltd, Tokyo, Japan, just before 
the first suboptimal SIT injection.   
Evaluation of airway responsiveness
Airway responsiveness to inhaled methacholine (acetyl-b-methylcholine 
chloride; Sigma-Aldrich) was measured at 2 time points in each mouse; 
pre-challenge (one week before the first OVA aerosol challenge) and post-
challenge (24 hours after the last challenge) in conscious, unrestrained mice 
using barometric whole-body plethysmography by recording respiratory 
pressure curves (Buxco; EMKA Technologies) as described in detail 
previously 18. In brief, mice were placed in whole-body exposure chambers 
and baseline values were measured and averaged for 3 min. Hereafter, mice 
were exposed to saline aerosols followed by 2-fold increasing concentrations 
of methacholine aerosols (ranging from 1.6 to 50 mg/ml in saline). Aerosols 
were generated by a Pari LC Star nebulizer. In each step mice were exposed 
to the aerosols for 3 min which followed by 3 min of recording to achieve 
average values. As a parameter of airway responsiveness, increases in 
enhanced pause (Penh), an index of airway obstruction were determined, as 
described in details previously 19. Airway responsiveness was expressed as the 
Penh per dose of methacholine. Dose-response curves to methacholine were 
statistically analyzed by a general linear model of repeated measurements 
followed by Bonferroni correction for multiple comparisons. 
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Determination of ovalbumin-specific immunoglobulin in serum
Blood samples for serum analyses were collected 3-5 days before the first 
OVA aerosol challenge (via orbital puncture) and 24 hrs after the last challenge 
(via cardiac puncture). OVA-specific IgE, IgA and IgG1 levels in serum were 
measured by enzyme-linked immunosorbent assays (ELISA) as described 
previously 20. Briefly, 96-well microtiter plates from Nunc A/S (Roskilde, 
Denmark) were coated overnight at 4°C with 1 µg/ml of anti mouse IgE diluted 
in PBS, followed by blocking with ELISA buffer (PBS, 0.5% BSA, 2mM 
EDTA, 136.9 mM NaCL, 50 Mm Tris, 0.05% Tween-20 [Merck, Whitehouse 
Station, NJ USA], PH 7.2) and left for one hour at room temperature. For 
OVA-specific IgA or IgG1 96-well microtiter plates were coated with 100 µl 
of 10 µg/ml OVA (grade V, Sigma-aldrich, Zwijndrecht, the Netherlands) over 
night followed by blocking with ELISA buffer containing 0.5% BSA. After 
multiple washings with PBS containing 0.05% v/v Tween-20, diluted serum 
samples and OVA-specific IgE, IgA or IgG1 reference serums were added 
to the wells and incubated for 2h. The reference serums was obtained by 
immunization of mice with OVA as described above and arbitrarily assigned a 
value of 1000 experimental units/ml (EU/ml). Next after multiple washing the 
wells, plates were incubated with 1µg/ml of DIG-conjugated OVA for 1.5 h 
for IgE. For IgA and IgG1 plates were coated with biotinylated rat anti-mouse 
IgA or biotinylated rat anti-mouse IgG1 for 1.5 h respectively. Thereafter, 
another multiple washing step was performed followed by incubation for 
1 h with anti-DIG Fab coupled to horseradish peroxidase, according to 
manufacturer`s instructions (Roche Diagnostics, Basel, Switzerland) for IgE 
or streptavidin coupled to horseradish peroxidase (R&D systems) for IgA and 
IgG1. For detection, 0.4 mg/ml of O-Phenylenediamine and 4 mM H2O2 in 
PBS were used, and the reaction was stopped by adding 75 µl of 4 M H2SO4. 
O.D. was read at 490 nm, using a Benchmark microplate reader (Bio-Rad, 
Hercules, CA, USA). Results were analyzed using Microplate Manager PC 
software (Bio-Rad). IgE concentration was calculated with reference to the 
standard curve. The lower detection limit of the ELISA was 0.5 EU.ml IgE.   
Cell counts and cytokine ELISAs in BALF 
Mice were sacrificed by collecting blood through the vena cava and opening 
of the thoracic cavity under anesthesia. Lungs were lavaged 5 times through 
a tracheal cannula (23-gauge blunt needle) with aliquots of 1 ml pyrogen-free 
saline at 37°C. The first aliquot contained a cocktail of protease inhibitors 
(complete mini tablet [Roche Diagnostics, Almere, the Netherlands]) and 
5% bovine serum albumin (BSA; Sigma-Aldrich) and was kept separately, 
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whereas the other 4 ml were pooled together after collecting the broncoalevolar 
lavage fluid (BALF). BALF were centrifuged and supernatants of the 
first ml were used to measure cytokines. Total BALF cells were pooled to 
determine the total number of cells using a Burker-Turk counting chamber 
(Karl Hecht Assistant KG, Sondheim/Rohm, Germany).  To determine the 
cellular composition of the BALF, cells were analyzed with flow cytometry as 
described in details before21 .Briefly, A cocktail of antibodies to MHCII-FITC, 
CD11c-APC, CD3and B220-Percp and Siglec F-PE (R&D Systems) were 
used to differentiate the cellular composition of the BALF. All the staining 
procedure was carried on ice and 2.4.G2 was used to prevent nonspecific 
binding. 
Cytokines in the BAL fluid were determined by sandwich ELISA according 
to the manufacturer’s instruction (Becton Dickinson, Franklin, Lakes, NJ, 
USA). 
Flow cytometry of mediastinal lymph nodes (MLNs)
Immediately after sacrificing the mice (24 hours after the last OVA inhalation 
challenges), mediastinal lymph nodes were isolated and kept on the ice. 
Single cell suspension from lymph nodes were prepared by mechanical 
disruption via pressing the organs through a 70 μm nylon cell strainer (Becton 
Dickinson) with the piston of a 1 ml plastic syringe. Cells were stained with 
CD4-FITC, CD3-PE-cy5, CD25-APC and FoxP3-PE for 30 minutes on ice. 
Cells were acquired on a LSRII flow cytometer (BD) and FlowJo software 
(Tree Star, Inc.). 
Statistical analysis
Data are expressed as mean ± SEM and were compared using Mann–Whitney 
U test corrected for multiple comparisons. A P-value of less than 0.05 was 
considered significant. 
Results
Co-administration of TGF-β enhances suppression of airway eosinophilia 
by suboptimal SIT
 To examine whether exogenous administration of TGF-β during suboptimal 
SIT will potentiate the suppression of the asthma  manifestations, we first 
co-administered rhTGF-β (1 µg/ mouse) with suboptimal SIT treatment two 
injectionsof 1 mg OVA) as it depicted in the schematic view in Figure 1.To 
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evaluate the efficacy of the combined treatment, we compared the Penh as 
a substitute measure for AHR 22, as well as airway inflammation and serum 
levels of OVA-specific IgE and IgA between suboptimal SIT treated mice and 
controls.
As expected, the dose-response curve of Penh to methacholine did not vary 
among the different treatment groups prior to allergen challenges (data not 
shown). Hence, the mean value of all treatment groups is depicted as pre-
challenge value in figure 2. OVA inhalation challenges induced a significant 
elevation of Penh in both sham treated control (P < 0.001) and sham/TGF-β 
treated (P < 0.01) mice (Figure 2a). Administration of TGF-β  in sham treated 
mice induced a somewhat lower Penh at higher doses of methacholine, although 
this did not reach statistical significance (Fig 2a). Suboptimal SIT treated mice 
displayed significantly reduced responses to methacholine as compared to the 
sham treated control mice (P < 0.05). In contrast, co-administration of TGF-β 
with suboptimal SIT resulted in a not significantly reduced Penh response 
to methacholine in comparison with either sham treated mice or suboptimal 
SIT alone, indicating that TGF-β  co-administration did not further enhance 
suboptimal SIT-induced suppression of Penh after OVA-challenges (Fig 2a).
A large number of inflammatory cells, especially eosinophils, were observed 
in BAL fluid of sham-treated mice, confirming the efficient induction of 
allergic inflammation in our model (Fig 2b). The total cell count in the BALF 
as well as number of eosinophils was not significantly (31.62% ± 15.66, 
P =0.335 and 41.23% ± 17.68, P = 0.46 respectively) reduced by the 
suboptimal SIT treatment or by TGF-β administration alone in comparison to 
sham treated control mice (Fig 2b). Interestingly co-administration of TGF-β 
with suboptimal SIT significantly reduced the total cell count (66.3%, ± 6.82, 
P < 0.05 compared to sham treatment) as well as the number of eosinophils 
by 78.48% ± 5.32 (P < 0.05) in comparison with sham treated control mice. 
These findings clearly show a potentiating role for exogenous TGF-β on 
suppression of eosinophilic inflammation by suboptimal SIT. As it shown in 
Figure 2c, along with the suppression of airway eosinophilia, a significant 
suppression of IL-5 levels in BALF was observed after co-administration of 
TGF-β with suboptimal SIT (62.74% ± 11.47, P < 0.05 compared with sham 
control), while suboptimal SIT or TGF-β alone failed to suppress the IL-5 
levels in the BALF. Similarly, co-administration of TGF-β with suboptimal 
SIT suppressed level of IL-13 by 56,02% ±14.15, (p=0.061) in comparison 
with sham treatment (supplementary figure 1). No changes on IL-10 levels in 




We further examined whether concurrent administration of TGF-β during 
SIT would enhance the suboptimal SIT mediated suppression of serum IgE 
responses. In sham/control and sham/TGF-β  treated mice, OVA inhalation 
challenges induced a significantly (89.61% ±1.76, P < 0.001 and 83.76%± 
4.68, P < 0.01 respectively) increased level of OVA-specific IgE in serum 
compared with pre-challenge values (Fig 2d). Suboptimal SIT treatment 
strongly suppressed the OVA-specific IgE response in serum (74.88% ± 5.03, 
P < 0.01) in comparison with sham treated control (Fig 2d). A similar level 
of suppression of specific IgE was achieved when TGF-β was combined with 
suboptimal SIT (74.13% ± 6.28, P < 0.01 compared to sham control) as it 
shown in Fig 2d. TGF-β treatment alone did not have any significant effect 
on both, pre and post challenge serum IgE levels when compared with sham 
treated control. 
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Figure 1 - Time line of experimental SIT protocol. Mice were sensitized with 2 i.p. injections of OVA/
alum on days 0 and 7. (Exp A) On days 21 and 23 mice were treated with two s.c injections of either 
suboptimal SIT (1 mg OVA/200 ml saline) or sham treatment (200 ml saline) with and with out TGF-β, 
which then  followed by 3 OVA-aerosols challenges on days 33, 36 and 39. (Exp B) Similar to the exp 
A, sensitized mice received either sham (200 ml saline) or suboptimal SIT (1 or 0.1mg OVA) which 
combined with/with out s.c TGF-β administration. In some groups anti IL-6R antibody was i.p injected 
on day 21 together with the first sham or suboptimal SIT treatment. Thereafter mice were challenged 
with 1% OVA aerosols every three day and 24 hours after the last OVA challenges AHR was measured 
and mice were sacrificed. In both experiments pre-challenge serum was collected 3-4 days after the 
last sham/suboptimal SIT injections and pre-challenge AHR was measured one week before the first 
OVA-aerosol challenges.
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Figure 2 - Co-administration of TGF-β enhances the suppressive effects of suboptimal SIT. OVA-
sensitized and sham or suboptimal (2 x 1mg) treated mice were injected with rhTGF-β or saline and 
challenged with OVA aerosols as depicted in Fig 1 (EXP A). (a) AHR was measured one week before 
the first OVA-challenge (pre-challenge) and 24 hours after the last OVA-challenge (post-challenge). 
(b) Total cell and eosinophils count in the BALF. (c) IL-5 in the BALF. Pre-challenge (white bars) and 
post-challenge (black bars) OVA-specific (d) IgE and (e) IgA in serum. (f) TGF-β levels in pre-chal-




Since TGF-β  can contribute to IgA class switch in B cells, we also analyzed 
the specific IgA responses in serum (Figure 2e; white bars). As expected, a 
remarkable induction of IgA responses was observed after suboptimal SIT 
treatment as compared with sham/control (P < 0.01, Fig 2e). Interestingly 
co-administration of TGF-β enhanced the suboptimal SIT induced specific 
IgA levels by more than 3 fold (326.99% ± 9.01, P < 0.05) as compared to 
suboptimal SIT treatment in the absence of TGF-β. This clearly demonstrates 
that a biologically effective dose of TGF-β was used in our experiments. As 
shown in Fig 2e, no significant changes in the level of IgA were observed after 
OVA inhalation challenges among different experimental groups, although 
the fold induction of specific IgA induced by the inhalation challenges was 
much lower in the suboptimal SIT treated groups.
Measuring the OVA-specific IgG1 in serum revealed that OVA challenges 
induced an increased level of OVA-specific IgG1 in sham treated mice 
(P < 0.01) as well as in sham/TGF-β treated group (P < 0.05) in comparison 
with pre challenge serum levels (table 1). Suboptimal SIT treatment induced 
an enhanced IgG1 responses in serum prior to OVA inhalation challenges 
(P < 0.05 compared to sham-treated control mice), which was not affected 
by concurrent administration of TGF-β. Moreover, in both suboptimal SIT 
and suboptimal SIT/TGF-β treated groups, OVA challenges did not further 
increased the level of IgG1 in serum compared to pre challenge values 
(table 1).  Thus, there appears to be no potentiating effect of TGF-β co-
administration on suboptimal SIT induced IgG1 responses.
Next, we examined whether administration of exogenous TGF-β during 
suboptimal SIT would influence the levels TGF-β either in BALF or in serum. 
Interestingly, analyzing the pre-challenge serum (obtained 4 days after the 
last SIT injection) revealed a robust induction of TGF-β levels by suboptimal 
SIT (P < 0.05, Fig 2f) compared to sham treated controls. Co-administration 
of TGF-β with suboptimal SIT induced a comparable rise in the TGF-β levels 
as in suboptimal SIT treatment alone (P < 0.05 compared with sham control 
and P = 0.093 when compared with sham/TGF-β treated group), indicating 
that local TGF-β  administration did not induce a prolonged systemic increase 
in TGF-β  levels. Moreover, no significant increase in the serum level of 
TGF-β was observed in TGF-β and sham-treated groups compared with their 
respective controls. These data indicate that in our experimental model SIT 
is accompanied with induction of TGF-β in serum and administration of 
exogenous TGF-β had no further effect on TGF-β levels. Remarkably, the rise 
in TGF-β levels induced by suboptimal SIT treatment was no longer observed 
after OVA inhalation challenges. Although the level of TGF-β was comparable 
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Figure 3Figure 3 - Concurrent administration of TGF-β potentiates the efficacy of suboptimal SIT with low-
er dose of OVA. OVA-sensitized mice received sham or suboptimal SIT treatment with high dose 
(2 x 1 mg) or low dose (2 x 0.1 mg) of OVA. TGF-β or saline was co-administered with sham or 
suboptimal SIT treatment which followed by 3 OVA-aerosol challenges according the protocol depicted 
in Fig 1 (EXP B). (a) AHR was measured one week before the first OVA-challenge (pre-challenge) and 
24 hours after the last OVA-challenge (post-challenge). (b) Total cell count and (c) number of eosino-
phils in the BALF. (d) IL-5 and (e) IL-13 in the BALF. (f) Pre-challenge (white bars) and post-challenge 
(black bars) OVA-specific) IgE in serum. Values are expressed as mean ± SEM of 6-7 mice per group. 
*P < 0.05, **P < 0.01 and ***P < 0.001
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between all treatments groups, it dramatically increased compared with pre 
challenge values (supplementary data fig 5d). Measuring TGF-β levels in 
the BALF revealed no significant changes between experimental groups 
(supplementary data, fig 5c). 
Co-administration of TGF-β  allows the use of a low dose allergen for 
suppression of eosinophilic airway inflammation and specific IgE 
Since co-administration of TGF-β with suboptimal SIT treatment using a high 
dose of allergen (1 mg OVA) readily improved suppression of eosinophilic 
inflammation and Th2 cytokines in BALF, we next evaluated whether TGF-β 
co-administration would allow SIT to suppress manifestations of allergic 
inflammation when a suboptimal dose of allergen (100 µg OVA) was used.
As shown in Fig 3a, OVA inhalation challenges induced a strong increase 
in the dose response curve to methacholine in all treated groups compared 
with pre challenge values. Suboptimal SIT treatment at the maximal dose of 
OVA (2 x 1mg) significantly (P < 0.01) suppressed the Penh dose response 
curve to methacholine in comparison to sham treated controls (Fig 3a). SIT 
performed with a 10-fold lower dose of allergen (2 x 0.1mg) only induced 
partial suppression of the Penh dose response curve for methacholine, which 
did not reach statistical significance in comparison with sham treated control. 
Co-administration of TGF-β  with suboptimal SIT treatment at the reduced 
allergen dose did not at all enhance suppression of the Penh curves to the level 






























Figure 4 - Percentage of FOXP3+ 
T cells within CD4+ T cell popula-
tion in mediastinal lymph nodes. 
TGF-β or saline was co-adminis-
tered with sham or suboptimal SIT 
treatment in OVA sensitized mice. 
Thereafter mice were challenged 
with OVA-aerosols and 24 hours af-
ter the last OVA inhalation challeng-
es, mediastinal lymph nodes were 
isolated. CD4+FOXP3+ T cells were 
analyzed with flowcytometry. Values 
are expressed as mean ± SEM of 6-7 
mice per group. *P < 0.05.
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In contrast, at higher doses of methacholine, TGF-β co-administration 
abrogated the suppression of Penh by suboptimal SIT performed with the 
reduced allergen dose. As in the previous experiment, we conclude that TGF-β 
co-administration has no effect on suboptimal SIT-induced suppression of the 
Penh.
In the previous experiment, we observed a remarkably enhanced suppression 
of eosinophilic inflammation and Th2 cytokines in BALF, when TGF-β was 
co-administered with suboptimal SIT at the high allergen dose (2 x 1mg). 
In the second experiment, the same suboptimal SIT (2 x 1mg) treatment did 
effectively suppress the eosinophilic airway inflammation: the total number 
of cells in BALF was reduced by 54.8% ±4.28 and the number of eosinophils 
by 69.8% ± 4.84 (P < 0.01 and P < 0.001 respectively) in comparison to 
sham-treated control mice (Fig 3b and 3c). In contrast, suboptimal SIT using 
the lower dose of allergen (2 x 0.1mg) did not achieve a significant level of 
suppression of airway inflammation. Interestingly, concurrent administration 
of TGF-β with suboptimal SIT at the lower allergen dose (2 x 0.1mg) did 
significantly suppress the total number of cells as well as the number of 
eosinophils in BALF in comparison with sham treated controls (41.72% ± 5.3 
P < 0.01 and 57.26% ± 4.15, P < 0.01 respectively) as well as in comparison 
with suboptimal SIT alone (26.54% ± 7.34, P < 0.05 and 34.94% ± 5.36, 
P < 0.05 respectively), indicating that TGF-β co-administration allowed SIT 
efficacy towards eosinophilic airway inflammation at a 10-fold lower allergen 
dose.  Along with the  suppression of eosinophilic inflammation, suboptimal 
SIT at high allergen dose (2 x 1mg) largely reduced the IL-5 levels by 
59.42%  ± 7.74 and IL-13 by 59.8% ± 4.28 in BALF compared with sham-
treated control (P < 0.01, Fig 3d and 3e). In contrast, suboptimal SIT at the 
low allergen dose (2 x 0.1mg) failed to substantially reduce the levels of either 
IL-5 or IL-13, whereas co-administration of TGF-β with the low-allergen 
dose suboptimal SIT significantly suppressed IL-5 in BALF (50.48% ± 6.78, 
P < 0.05 in comparison with sham control). Although the levels of IL-5 
and IL-13 in suboptimal SIT/TGF-β treated group seems to be lower than 
in suboptimal alone treated group, these differences are not statistically 
significant.
 As it shown in figure 3f, a strong induction of OVA-specific IgE was seen 
after suboptimal SIT treatment at the high allergen dose (2 x 1mg) (P < 0.01, 
Fig 3f), but not after suboptimal SIT with lower dose (2 x 0.1mg), when 
compared to sham-treated controls. Suboptimal SIT at high allergen dose 
(2 x 1mg) also suppressed the challenge-induced OVA-specific IgE response 
in serum compared with sham control (48.46% ± 6.18, P < 0.05), which 
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was not observed with suboptimal SIT treatment at the lower allergen dose. 
However, co-administration of TGF-β with the low allergen-dose suboptimal 
SIT (2 x 0.1mg) significantly suppressed specific IgE after OVA challenges, 
to a level comparable to that observed after suboptimal SIT treatment with the 
full dose of 1mg OVA (56.17% ± 10.03, P < 0.05 in comparison with sham-
treated control), even though the induction of an OVA-specific IgE by the SIT 
treatment - as observed after 1 mg suboptimal SIT - was not observed by the 
































































































OVA-specific IgG1 (x 103 EU/ml, Mean ± SEM)
Pre-challenge Post-challenge
sham/saline 7.371 ± 0.7 12.7 ± 0.49 *
sham/TGF-β 8.665 ± 1.02 11.803 ± 0.34
SIT(2x1mg)/saline 10.965 ± 0.51 11.755 ± 0.69 # 
SIT(2x1mg)/TGF-β 11.045 ± 0.62 10.945 ± 0.36 # 
Figure 5 - Effects of co-administration of TGF-β with suboptimal SIT (2 x 1mg). OVA-sensitized 
and sham or suboptimal (2 x 1mg) treated mice were injected with rhTGF-β or saline and chal-
lenged with OVA aerosols as depicted in Fig 1 (EXP A). (a) IL-10, (b) IL-13 and (c) TGF-β in the 
BALF. (d) level of TGF-β in post challenge serum. (e) OVA-specific IgG1 in serum. Values are 
expressed as mean ± SEM of 6-7 mice per group. *P < 0.01 compared to pre-challenge value of 
sham-treated mice and #P < 0.05 compared to the pre-challenge value of sham-treated mice.
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much lower when TGF-β was co-administered with suboptimal SIT, it did 
not reach the level of significance when compared with suboptimal SIT at the 
low-dose allergen (2 x 0.1mg) alone.
Taken together, these data indicate that co-administration of TGF-β enhanced 
suppression of Th2 cytokines, eosinophilic airway inflammation and serum 
OVA-IgE levels by suboptimal SIT at a 10-fold lower allergen dose, at the 
point where this treatment by itself was no longer efficacious.
CD4+ FOXP3+ Tregs in mediastinal lymph nodes
To study the mechanisms underlying these activities of co-administration 
of exogenous TGF-β, we analyzed the number of FOXP3+ Tregs in MLN 
by flowcytometry. As shown in Fig 4, suboptimal SIT at high-dose allergen 
significantly increased the percentage of CD4+ FoxP3+ iTregs compared to 
sham treated controls (P < 0.05), whilst suboptimal SIT using the low dose of 
allergen failed to induce enhanced levels of CD4+ FoxP3+ T cells in MLN. 
However, co-administration of TGF-β induced a trend (P < 0. 1) towards 
increased numbers of iTregs, both in sham and in suboptimal SIT treated 
mice (Fig 4). These data indicate that co-administration of TGF-β induced 
outgrowth of a FOXP3+ T cell subset independently from the SIT-induced 
effects.  
Neutralizing IL-6 does not further enhance suppression of allergic 
manifestations by suboptimal SIT
Since the effects of TGF-β  on FOXP3+iTreg cell induction (Figure 4) might 
be thwarted by the presence of pro-inflammatory cytokines such as IL-6 at 
the time of allergen presentation during SIT 23, we also assessed whether 
neutralizing IL-6 at the time of allergen injections might further substantiate 
the TGF-β -induced enhancement of suppression of allergic manifestations 
by suboptimal SIT. To this end, we neutralized the IL-6 signaling in vivo by 
injecting the mice with a neutralizing antibody against IL-6R 24, with or with 
out TGF-β co-administration during suboptimal SIT treatment at the low dose 
of allergen.  
As shown in figure 6, blocking IL-6R alone or in combination with TGF-β 
treatment, did not have any effect on the suppression of the Penh dose response 
curve to methacholine after OVA challenges. Moreover, neutralizing the 
IL-6R by antibodies did not enhance the suppression of BALF eosinophils, 
or levels of IL-5 and IL-13 in BALF by suboptimal SIT at low-dose allergen, 
and in fact did even abolished the augmentation observed by TGF-β 












































































































































































































































































































































Figure6 - Neutralization of IL-6R did not enhance the suppressive effects of co-administration of 
TGF-β with suboptimal SIT.  OVA-sensitized mice received sham or suboptimal SIT treatment (high 
dose (2 x 1 mg) or low dose (2 x 0.1 mg)) with or with out TGF-β and anti IL-6R. (a) AHR, (b) total cell 
count and (c) number of eosinophils in the BALF. Level of (d) IL-5 and (e) IL-13 in the BALF. (f) Pre-
challenge (white bars) and post-challenge (black bars) OVA-specific) IgE in serum. (g) Level of IL-17 
in the BALF. (h) Percentage of CD4+FOXP3+ T cells in mediastinal lymph nodes. Values are expressed 
as mean ± SEM of 6-7 mice per group. *P < 0.05, **P < 0.01 and ***P < 0.001
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Remarkably, blocking IL-6R significantly increased the OVA inhalation 
challenge-induced IgE in serum (P < 0.05 compared with sham-control) when 
administered alone or combined with TGF-β in sham treated mice (Fig 6f). 
However, blocking IL-6 signaling during co-administration of TGF-β with 
suboptimal SIT reversed the TGF-β mediated decline of serum IgE after 
challenges. Finally, neutralization of IL-6 signaling during administration of 
TGF-β did not alter the induction of iTregs by suboptimal SIT or by TGF-β 
(supplementary data, Fig 6h). Finally, we assessed whether Th17 cell activity 
was influenced by TGF-β treatment and neutralization of IL-6 signaling, by 
measuring IL-17 in the BALF. To our surprise level of IL-17 was not different 
between any of the treatment groups (supplementary data, Fig 6f). 
Discussion 
In this study, we show that administration of exogenous TGF-β during 
SIT treatments augments suboptimal SIT-induced suppression of airway 
eosinophilia as well as Th2 cytokines in the BALF when suboptimal SIT 
(at high doses of allergen) is given. Furthermore, we observe an enhanced 
suppression of airway eosinophilia, Th2 cytokines in BALF and OVA-
specific IgE when a 10fold lower dose of allergen is applied. We demonstrate 
that the beneficial effect of TGF-β in this model is associated with a trend 
of an enhanced number of FOXP3+ iTregs in the mediastinal lymph nodes 
and significantly increased levels of OVA-specific IgA in serum. Finally, 
neutralization of IL-6 signaling did not increase the induction of iTregs by 
TGF-β and had no effect on improving the TGF-β enhanced suppressive 
function of SIT, indicating that concurrent administration of TGF-β with 
blocking IL-6 signaling aiming at induction of  more iTregs at the expenses 
of Th17 cells is not applicable here in our model. Taken together, these data 
indicate that exogenous TGF-β, used as an adjuvant at the time of allergen 
injection, is able to enhance suppression of allergic manifestations, allowing 
the use of lower doses or reduced frequency of immunotherapy injections to 
achieve these effects. 
Transforming Growth Factor-β (TGF-β) is an important immunomodulatory 
cytokine with a potential capacity to augment the effects of SIT 25. Here 
we show that co-administration of exogenous TGF-β  with suboptimal SIT 
strongly augmented the beneficial effects of SIT. TGF-β can contribute to 
SIT-induced tolerance induction by at least four known mechanisms. The first 
two mechanisms are facilitating the induction of TGF-β producing Th3 cells 
and CD4+FOXP3+ iTregs 26. We observed that sub-optimal SIT increases the 
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levels of TGF-β in the serum, so TGF-β producing Th3 cells may contribute 
to the induction of allergen tolerance by SIT alone. However we have no 
evidence that administration of exogenous TGF-β further potentiates this 
mechanism in our model. Secondly, we observed a trend towards an increase 
in the number of CD4+FOXP3+ iTregs in MLN after TGF-β treatment in both 
sham and SIT treated mice, which indicates that administration of TGF-β 
might promote generation of iTreg cells in vivo in our experimental mouse 
model. Nevertheless, in the absence of the relevant antigen, these FOXP3+ 
iTregs were not able to promote any specific suppression since we did not 
observe any dampening of asthma symptoms on sham/TGF-β treated mice 
despite the increased number of FOXP3+ iTregs. An explanation for this 
observation might lie in the absence of the cognate antigen in the Sham/TGF-β 
treated group. The TGF-β  might induce FOXP3+ iTreg differentiation, but 
these will not be specific for OVA in the absence of the allergen at the time of 
their induction. 
The third mechanism of contribution of TGF-β to SIT-induced allergen 
tolerance is by instructing B cells to produce antigen-specific IgA, which 
can contribute to mucosal protection upon allergen challenge 27;28. Increased 
level of TGF-β after different SIT treatments have been reported in several 
clinical studies 6;29. Moreover it has been demonstrated that SIT treatment is 
associated with elevated IgA responses in serum which positively correlates 
with the enhanced mucosal expression and serum production of TGF-β after 
successful SIT treatments 6;30. In line with these findings, we also observed 
an enhanced TGF-β response in serum, shortly after SIT treatment in our 
study.  Moreover we find that the enhancement of SIT mediated suppression 
of allergic manifestations by TGF-β is accompanied by increased production 
of IgA in serum, indicating that IgA might contribute to the suppression of 
allergic manifestations. Nevertheless, we have previously shown that SIT 
remains effective in polymeric IgR and in B cell deficient mice, precluding a 
critical role for IgA in the tolerance induction by SIT 13. However, these data 
do not exclude the possibility that allergen-specific IgA may contribute to the 
SIT-enhancing effects of TGF-β as observed in the current study. 
The fourth  mechanism of suppressive function of TGF-β is its direct effect on 
dendritic cells (DSs). TGF-β can regulate the maturation and differentiation 
of DCs 31. For example in the study by Mou et al 32, it has been shown that 
TGF-β treated DCs are resistant to maturation and fail to up regulate the 
co-stimulatory molecules upon stimulation with LPS. Additionally, it has 
been shown that autocrine TGF-β is essential in maintaining the tolerogenic 
function of indoleamine 2, 3-dioxygenase (IDO)-competent CD8+ DCs and 
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converting immunogenic CD8-DCs to tolerogenic cells by induction of IDO33. 
Intriguingly we have previously shown that IDO signaling contributes to the 
tolerance induction by SIT in our mouse model of asthma 18. Although in 
the current study, we haven’t investigated the possible effects of TGF-β on 
dendritic cells, but the potential role of TGF-β on promoting tolerogenic DCs 
during SIT should not be disregarded.
In our study, despite the presence of a clear allergen/antigen-induced AHR to 
methacholine, we did not see an effect on AHR by TGF-β co-administration. 
Within contrast to our findings, a regulatory function for TGF-β in directly 
suppressing AHR has been described in literature 34. The major difference with 
our study is the time of administration of TGF-β.  In our experiment, TGF-β 
is administered at the time of SIT injections and is no longer present at the 
time of OVA inhalation challenges. Although, suboptimal SIT significantly 
increases the levels of TGF-β in the serum, there are no additional effects for 
administration of exogenous TGF-β in this regards. Therefore, there may be a 
role for TGF-β producing T cells in suboptimal SIT alone but this mechanism 
is not potentiated by administration of exogenous TGF-β.  Here, we do not 
find evidence for an effect of subcutaneously administered TGF-β on TGF-β 
levels in the BALF, indicating that the peripheral administration of TGF-β 
did not alter local TGF-β  levels in the lungs, and likely did not induce an 
effect on AHR. 
It has been shown that IL-6 can prevent the suppressive function of 
CD4+CD25+ Tregs and induce expansion of Th2 cells thereby inhibiting the 
induction of peripheral tolerance 10. Furthermore it has been demonstrated that 
presence of IL-6 inhibits the induction of Treg cells by TGF-β and drives the 
induction of Th17 cells 13. As the number of FOXP3+ iTregs was increased but 
did not reach the level of statistical significance, by administration of TGF-β, 
we also tested whether blocking the IL-6R concurrent with co-administration 
of TGF-β with SIT would induce a more pronounced outgrowth of 
FOXP3+ iTregs. However, no improvement was achieved on the induction 
of FOXP3+ iTregs by neutralizing the IL-6 signaling. Furthermore the level 
of the prototypic Th17 cytokine IL17 was not changed in the BALF with or 
without blocking IL-6R during administration of TGF-β by SIT. These data 
indicate that deviation of FOXP3+iTregs into Th17 cells does not appear to 
hamper TGF-β induced potentiation of SIT-induced suppressive responses. 
In summary, our findings clearly demonstrate a potential suppressive function 
for TGF-β on the beneficial effects of SIT in our experimental mouse model. 
Co-administration of TGF-β  with suboptimal SIT strongly suppressed the 
eosinophilic inflammation together with Th2 cytokines in the BALF as 
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well as serum IgE responses. These suppressive effects were accompanied 
with an induction of IgA responses in serum and a rise in the number of 
FOXP3+ iTregs in MLN. Overall our data, implicate an immunosuppressive 
function for TGF-β in tolerance induction by SIT in an experimental mouse 
model of asthma. More studies are required to exactly clarify the mechanisms 
underlying its suppressive function to achieve optimal effects and be 
considered as an adjuvant for future immunotherapy strategies in clinic.
8TGF-β potentiates the suppressive effects of OVA-SIT
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Background: Experiments in rodents suggest that prenatal exposure to 
allergens affect the susceptibility of the developing embryo for allergic 
disorders later during life, in part through active immunological protection, 
including materno-fetal transfer of allergens and neutralizing antibodies by 
allergen sensitized mothers. Interestingly, allergen provocation of sensitized 
mice during lactation was recently shown to confer protection to allergic 
sensitization of the offspring by transfer of allergen/IgG immune-complexes 
(IC) through the milk. We hypothesize that allergen-specific immunotherapy 
(SIT), a treatment known to strongly increase the allergen-specific IgG levels 
in allergen sensitized individuals, may induce materno-fetal transfer of 
allergen tolerance.
Objective: In this study we aimed to address whether OVA-SIT treatment 
of allergen sensitized mice prior to pregnancy allows the transfer of allergen 
tolerance to the offspring by either pre-or post-natal maternal transfer. 
Methods: OVA sensitized female mice were sham or SIT-treated before 
mating. Offspring was nursed for 3 weeks either by their own mothers or by 
naïve foster mothers. In a parallel group naive pups were nursed by sham or 
SIT-treated mothers to exclusively determine post-natal transfer of protection. 
At 7 weeks of age, offspring were OVA/Alum sensitized followed by OVA-
inhalation challenges. Eosinophilic inflammation of airways and serum OVA-
specific IgE responses were assessed. 
Results: Despite transfer of OVA-specific IgG and IC via breast milk from 
sensitized and SIT-treated mothers to the offspring, SIT treatment failed to 
convey tolerance to the offspring and protect them from allergic asthma. In 
contrast, offspring from sensitized and sham treated mothers was protected 
from allergic asthma and this protection critically required involvement of 
both pre-and post-natal transfer of tolerance by sensitized and sham-treated 
mothers to the progeny. 
Conclusion: Our data using an experimental mouse model of OVA-SIT show 
that SIT treatment of the mother prior to the pregnancy did not protect the 
offspring from Th2 mediated airway inflammation. However, SIT-treated 
mothers did protect the offspring against allergic sensitization by placental 
transfer which was only apparent if nursed by naïve foster mothers. Moreover 
prenatal sensitization of mothers was sufficient to induce protection against 
allergic asthma in offspring, which required both pre and postnatal maternal 
transfers.
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Introduction
Allergic asthma is a Th2 mediated inflammatory disease of the airways 
and results from an inappropriate immune response to innocuous airborne 
environmental allergens 1-4. Genetic studies have reported that the 
susceptibility to allergic asthma has a strong genetic component, especially 
for childhood asthma 5. The prevalence of allergic asthma is rapidly 
increasing in industrialized countries, which is most likely attributed to 
changes in the environment or life style. These environmental and life style 
factors, especially those present during early life, are thought to contribute to 
the increased prevalence of allergic asthma by inducing epigenetic changes, 
thereby influencing the asthma susceptibility 6. For example it has been 
shown that prenatal exposure to a farming environment conveys protection 
against respiratory allergies, in part through exposure to different species of 
cattle and the consumption of raw, unpasteurized milk 7;8. Epidemiological 
studies assessing the protective effect of other early life exposures, such as 
breastfeeding during the first year of life, have yielded conflicting data 9-11. 
Mechanistic studies using mouse models, however, have clearly indicated 
that allergen-transfer through the breast milk of mothers exposed to an 
airborne allergen during lactation rendered a protective effect in the offspring 
against subsequent induction of allergen-specific IgE and manifestations of 
experimental allergic asthma 12-14. Interestingly, the involvement of allergen-
specific immunoglobulins was only observed in case of allergen sensitized 
mothers exposed to the airborne allergen during lactation 13. The symptoms of 
allergic asthma can be efficiently, but transiently, repressed by a combination 
of bronchodilators and corticosteroids in most patients 15. In contrast to 
these pharmacological treatments for allergic disorders, which provide only 
temporary relief of symptoms, allergen-specific immunotherapy (SIT) is the 
only long-lasting treatment available for allergic disorders, that alters the 
immunological response to allergen exposure and prevents the occurrence 
of new sensitizations 16;17. After the first successful application of SIT by 
Noon et al in 1911 18, SIT has become an efficient therapy for many allergic 
disorders including allergic rhinitis and insect venom allergy 19. Successful 
SIT treatment is associated with a strong increase in allergen-specific IgG 
in serum, the induction of IL-10 expression in allergen-stimulated PBMCs 
and the differentiation of allergen-specific regulatory T cells 20-22. Since the 
protection to manifestations of allergic asthma rendered by allergen exposure of 
lactating mothers was most pronounced in case of allergen sensitized mothers 
and was associated with the presence of allergen-IgG immune complexes in 
the breast milk, we hypothesized that SIT treatment, associated with strongly 
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increased allergen-specific IgG responses, would likewise allow the transfer 
of allergen-specific tolerance upon lactation by SIT-treated mothers.
To test this hypothesis, we employed our previously developed mouse model 
of OVA-SIT in which SIT induces a long-lasting suppression of different 
aspects of OVA induced allergic asthma, including airway eosinophilia, Th2 
cytokines, airway hyperresponsiveness (AHR) and serum immunoglobulins. 
In parallel to clinical observations, SIT injections in our mouse model are 
accompanied by the induction of strong allergen-specific IgG and IgA 
responses in serum 23. Using SIT-treated or naïve mothers, we employed a 
cross-over design (allowing SIT-treated mothers to feed their own pups as 
well as pups from naïve mothers, and vice versa) to assess whether allergen-
specific immunotherapy might in fact induce maternal transfer of allergen-
IgG immune complexes and protection from allergic asthma to the progeny. 
Material and methods
Mice 
BALB/c mice were purchased from The Centre d’Elevage Janvier (France) 
and housed under specific pathogen-free conditions.
Experimental OVA-SIT protocol
The OVA-SIT treatment has been performed as previously described 24 
with elimination of the OVA-inhalation challenges (Fig 1a). Briefly, 
female mice were sensitized with two i.p. injections of 10µg OVA 
(endotoxin-free, < 0.5 U/ml; Seikagaku Kogyo, Tokyo, Japan) adsorbed onto 
2.25 mg alum (ImjectAlum, Pierce, Rockford, IL) in 100µl pyrogen-free 
saline (B.Braun, Melsungen, Germany) on days 0 and 7. Two weeks after 
the last OVA- sensitization, mice received 3 s.c. injections of either 1 mg 
OVA in 200 µl saline (pyrogen-free) as SIT or 200 µl saline as sham control 
treatment every other day. One week after the SIT/sham treatment, mice were 
mated with naïve males. In parallel, naive females were also mated with naïve 
males and used as a control group.  After birth, female pups from SIT/sham 
treated mothers were breastfed by either, their own or by naïve foster mothers 
and vice versa. To evaluate the sensitivity to OVA-induced allergic asthma, 6 
weeks old pups were i.p. sensitized on days 0 and 7 which followed by 3 OVA-
inhalation challenges on days 21, 24 and 27 for 20 minutes. Challenges were 
conducted using an ultrasonic nebulizer (Ultramed, Medicalia) connected to a 
13,000-cm3 box that served as the deposition chamber for the mice. 24 hours 
after the last inhalation challenges mice were sacrificed and BALF and serum 
were obtained to further analyze the asthmatic phenotype (Fig 1a). 
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Determination of level of immunoglobulins (Igs) in serum and milk
Serum levels of OVA-specific IgE and IgG1 were measured by ELISA as 
described previously 25. In brief, 96-well microplates (Greiner Bio-One, 
Hannover, Germany) were coated for 16h with 2 µg/ml anti-mouse IgE 
antibody (BD bioscience, Breda, the Netherlands), washed using 0.005% 
Tween20 (Sigma-Aldrich) in PBS, flowed by a blocking step using 3% 
bovine serum albumin (Sigma-Aldrich) in PBS for 2 h. Serial dilutions of 
reference serum as well as samples were added and incubated for 1.5h at room 
temperature (RT). Then, plates were washed again and digoxigenin-labeled 
(Roche Diagnostics, Almere, the Netherlands) OVA was added and incubated 
for 1h at RT. Anti-digoxigenin-POD (Roche Diagnostics) was added after 
washing the plate and incubated for 1h at RT. O-Phenylenediamine (Thermo-
scientific, IL, USA) was used to detect PO activity by measuring optical 
density at 490 nm using ELx808™ microplate reader (BioTek, Friedrichshall, 
Germany).  Concentrations were calculated according to the standard curve 
drawn based on serial dilutions of reference serum and results are expressed 
as experimental units (EU)/ml.
For IgG1, Maxisorp plates (Nunc) were coated with OVA saturated with 
10% FCS in PBS, and incubated with serial dilution of sera followed by 
biotinylated anti-IgG1 antibody (BD553-441, BD, France).
Immune complexes content in milk and serum
Breast milk was collected from the stomach of 2-week-old pups and diluted 
in 1 volume of PBS. Samples were spun down at 10,000 g for 10 min and the 
supernatant was collected and stored at − 20° C until analysis. Milk and serum 
were analyzed for the presence of OVA-IgG1 immune complexes by ELISA. 
Maxisorp plates were coated with a rabbit anti-OVA polyclonal antibody 
(AB1221, Abcam, U.K), saturated with 3% FCS in PBS-Tween 0.05%, and 
incubated with serial dilutions of milk or serum followed by biotin-conjugated 
anti-IgG1 antibody (BD553-441, BD, France)
Determining the cellular composition of the BAL fluid
After sacrificing the mice, lungs were washed trough a tracheal cannula for 
three times with 1 ml of PBS.  For differential BAL cell counts, cells were 
stained with mAbs to CCR3 (R&DSystems), Gr-1, CD3 and CD19 (Becton 
Dickinson) and analyzed by FACS using a FACSCalibur flow cytometer 
and CellQuest software. Different cells were defined with expression of CD 
markers as defined below; eosinophils  as CCR3+CD3–CD19–, neutrophils as 
180
Chapter 9
Gr-1hiCD3–CD19–, lymphocytes as CD3+CD19+ and alveolar macrophages as 
large autofluorescent cells.
Statistical analysis
All data are expressed as mean ± SEM.  Statistical significance was assessed 
using a two-tailed P value calculated with the Mann-Whitney U test for 
nonparametric data and P < 0.05 was considered significant.
Results
We hypothesized that SIT induced allergen-specific IgG responses allowed 
the transfer of tolerance to OVA-induced airway eosinophilia through the 
formation of allergen-IgG immune complexes in the breast milk. To test our 
hypothesis, female mice were either sham or SIT-treated, and mated to induce 
pregnancy. After birth, the lactating SIT- or sham-treated mothers nursed their 
progeny for three weeks as depicted in Fig 1a.  
OVA-specific IgG1 in mother’s serum and milk 
We have previously shown that SIT injections induce strong antigen-specific 
IgG1 responses in serum 25. Though these increased IgG levels are not 
critically required to the suppression of late-phase allergic responses by SIT, 
they might contribute to maternal transfer of allergen-IgG immune complexes 
through the breast milk, and thereby induce allergen-specific tolerance in the 
offspring.  To confirm the efficient induction of OVA-specific IgG responses 
in the SIT-treated female mice, OVA-specific IgG1 levels were measured in 
serum as well as in breast milk of the lactating mothers. As shown in Fig 1b, 
OVA-sensitized and SIT-treated mothers have significantly increased OVA-
specific IgG1 levels in serum in comparison to OVA-sensitized and sham 
treated mothers (1.4 ± 1 mg/ml versus 0.005 ± 0.002 mg/ml respectively, 
P < 0.05).  Similarly, OVA-specific IgG1 levels in milk were also strongly 
increased in OVA-sensitized and SIT–treated mice, compared to OVA-
sensitized and sham-treated controls (Fig 1c). In line herewith, a strongly 
increased level of allergen-IgG immune-complexes (IC) was present in milk 
from OVA-sensitized and SIT-treated mothers when compared to OVA-
sensitized and sham-treated treated or naïve mothers (Fig 1d).  Overall, these 
data indicate that OVA-specific IgG1 is efficiently induced by SIT treatment 
and was transferred as allergen-IgG immune-complexes to the milk.   
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Maternal transfer of tolerance to OVA-induced airway eosinophilia in 
offspring
Since maternal transfer of allergen-IgG IC via the breast milk was previously 
shown to be associated with a strongly increased protection of the pups to 
manifestations of experimental allergic asthma 13, we OVA-sensitized and 
challenged the pups born to OVA-sensitized and OVA-SIT treated mothers, 
as well as the pups born to OVA-sensitized and sham-treated or  naïve control 
mothers (Fig 1a). As expected, we observed a strong influx of inflammatory 
cells, especially eosinophils, into the airways in the control group which was 
born to and nursed by naïve mothers (Fig 2a, b). Interestingly, and in contrast 
to our hypothesis, offspring from OVA-sensitized and sham treated mothers 















































































Figure 1 - OVA-specific IgG levels in mother’s sera and milk. (a) Schematic overview of 
experimental protocol. Sensitized mothers were sham or SIT-treated before mating. Serum 
samples were obtained from mothers on day 21 and IgG1 levels were measured by ELISA. 
(b) OVA-IgG1 in serum, (c) OVA-IgG1 in milk. Breast milk was collected from pup’s 
stomach on day 14 and analyzed for presence of IgG1 and ICs. (d) IgG-IC in milk. Data 
are expressed as mean ± SEM.
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had a significantly reduced number of eosinophils in BAL compared to mice 
born to naïve mothers (P < 0.05). In addition, mice born to sensitized and OVA-
SIT treated mothers displayed a similar number of eosinophils compared to 
mice born to naïve mothers (Figure 2B). These data are especially intriguing 
given the presence of OVA-IgG immune complexes only in the milk from the 


















































































Figure 2 - Cellular composition of the BAL fluid in the offspring. BAL was collected from 
offspring 24 hours after the last OVA inhalation challenge analyzed by FACS. (a) Total 
number of cells and (b) number of eosinophils in the BAL fluid. Data are expressed as Mean 
± SEM and *P < 0.05.  
In addition to eosinophilic airway inflammation we measured serum levels 
of OVA-specific IgE and IgG1 after the inhalation challenges. Here, the mice 
born to OVA sensitized mothers all had a reduced level of OVA-specific IgE 
in serum, irrespective of OVA-SIT or sham treatment, although the effect was 
slightly more pronounced in the sham-treated group (Fig 2c). Levels of OVA-
specific IgG1 did not show differences between the three groups (Fig 2d). 
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The effect of placental versus breast milk maternal transfer
Since we did not observe an association of allergen-IgG immune complexes 
in the breast milk with protection against eosinophilic airway inflammation 
in the pups, but an effect of sensitization of the mothers could be seen for 
allergen-specific IgE responses, we aimed to ask whether the suppression of 
IgE was transferred through the breast milk. To this end, we also performed an 
experiment in which mice born to sensitized and sham- or OVA-SIT treated 
mothers were weaned by naïve foster mothers, and vice versa. Remarkably, 
the suppression of eosinophilic inflammation observed in the mice born to 
sham-treated sensitized mothers was not observed in any of the groups of 
this cross-over experiment (Fig 3a, b). OVA-specific IgE levels in serum, 
however, were strongly reduced (24.55 ± 12.02 EU/ml) in mice born to 






















































































































Figure 3 - OVA-specific Ig responses in serum from offspring. Progeny was OVA/alum 
sensitized and challenged with OVA aerosols. Serum was collected 24 hours after the last 
OVA inhalation challenge and (a) OVA-IgE and (b) OVA-IgG1 were measured by ELISA. 
Data are expressed as Mean ± SEM and *P < 0.05, **P < 0.01.
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this effect was much stronger than in the mice that were weaned by their 
own SIT-treated mothers (138.08 ± 34.96 EU/ml). For mice born to sham-
treated mothers, weaning by naïve mothers did not enhance suppression of 
IgE responses any further. Remarkably, mice born to naïve mothers that were 
weaned by sensitized mothers only displayed a reduced allergen-specific IgE 
response (by 59.88%, P = 0.095) in case they were weaned by sham, but not 
when weaned by OVA-SIT treated mothers. Again, OVA-specific IgG1 levels 
did not show differences between the different groups (Fig 3d).
Discussion
In the present study we tested whether OVA-SIT treatment of allergen 
sensitized female mice induced an enhanced formation of allergen-immune 
complexes in the breast milk and contributes to protection of the pups from 
manifestations of allergic asthma.   
We show that as expected, SIT treatment induced increased level of OVA-
specific IgG1 in serum. Interestingly, we could confirm that SIT treatment 
also resulted in the presence of high levels of OVA-specific IgG1 as well as 
IgG-ICs in breast milk from sensitized and SIT treated mothers. The levels 
of OVA-specific IgG1 in breast milk, however, only reached about 30% of 
those observed in OVA-sensitized mice that were exposed to OVA aerosols 
during lactation 13. Surprisingly, the presence of OVA-specific IgG1 and ICs 
in breast milk from SIT-treated mothers failed to protect the offspring of 
these mothers against airway eosinophilia and only partially protected against 
OVA-specific IgE responses in serum upon OVA-sensitization and challenge 
of the offspring. Intriguingly, we did observe a protection of the progeny from 
sensitized and sham-control treated mothers to airway eosinophilia upon OVA 
sensitization and challenge. In the original study of Mosconi and colleagues 
using OVA-sensitized mice, the control group lacking the OVA inhalation 
challenges during lactations also did display a slightly reduced level of 
airway eosinophilia and allergen-specific IgE, but these differences were not 
statistically significant, and far less pronounced than the suppression achieved 
in pups from OVA-sensitized mice challenged with OVA during lactation13. 
Taken together, these data seem to indicate that allergic sensitization of female 
mice prior to pregnancy might render a low level of protection against airway 
eosinophilia in the progeny, which is not associated with the presence of 
allergen-IgG immune complexes in the breast milk, and which is abrogated by 
SIT treatment of the sensitized mothers. One reason for this abrogation could 
be an increase in allergen-IgG2a ICs in the breast milk of SIT-treated mothers. 
We have previously shown that SIT treatment induces high levels of allergen-
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specific IgG2a in the serum besides allergen-specific IgG1 25. Although not 
measured in the present study, increased levels of IgG2a in the serum of SIT-
treated mothers could be reflected in the breast milk and thereby abrogate 
the beneficial effects of allergen-IgG1 ICs. In line with this hypothesis, it has 
been shown that maternal transfer of antigen-IgG1 ICs conveys protection to 
antigen immunization in progeny through FCγRIIb 26, while antigen-IgE and 
antigen-IgG2a ICs potentiate T cell responses to the cognate antigen 27. More 
studies are needed to unravel the precise contribution of these different ICs 
in the SIT-induced abrogation of maternal tolerance by allergically sensitized 
mothers. 
Allergen provocation during lactation results in stronger protection of 
offspring from allergic asthma which is mediated by OVA-IgG IC 13. To assess 
the contribution of the OVA-IgG immune complexes in the breast milk, we 
also analyzed the asthma manifestations in mice born to sensitized and sham 
control or OVA-SIT treated mice but weaned by naïve mice, and vice versa. 
Here, we clearly show that the presence of allergen-IgG immune complexes 
in the milk, present in sensitized mother that were SIT-treated, did not confer 
protection to airway eosinophilia or allergen-specific IgE. Mice born to naïve 
mothers displayed in fact a higher level of IgE after weaning by SIT-treated 
mice compared to sham-treated mice, whilst airway eosinophilia was not 
affected at all by weaning by either sham or OVA-SIT treated mothers. In 
contrast, mice born to sensitized and OVA-SIT, but not sham-control, treated 
mothers and weaned by naïve mothers were protected against the induction of 
high OVA-specific IgE levels in. 
Taken together, these findings seem to suggest that sensitization of mothers to 
the model allergen OVA before pregnancy was sufficient to induce a certain 
level of tolerance in the offspring and protect them from OVA-induced airway 
inflammation and allergen-specific IgE responses. However, OVA-SIT 
treatment of the sensitized mother prior to pregnancy abrogated the protection 
against airway eosinophilia, even though this was the sole condition that 
induced significant levels of OVA-immune complexes in the breast milk. 
In a previous study by Mosconi et al, the presence of allergen-immune 
complexes in the breast milk was associated with a strong suppression of 
the parameters of allergic inflammation in the pups in a TGF-β-independent 
manner 13, whereas the presence of free allergen in the breast milk induced 
a TGF-β-dependent repression of allergic inflammation in the pups 12. The 
main difference between these studies and our experiments is the allergen 
challenges of the mother during lactation, which likely strongly increased 
the levels of allergen and allergen-ICs present in the breast milk. In addition, 
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the level of allergen-specific IgG1 in breast milk in our study was only one 
third of that of the previous study, which in the absence of allergen challenges 
during lactation might result in an even lower fraction of immune complexes 
compared to the previous study. In our studies, tolerance was induced prior to 
conception and no further allergen challenges of the mothers were performed 
during pregnancy or lactation. So we tend to interpret the data in our study 
to reflect the level of maternal transfer of allergen-specific tolerance in the 
absence of free allergen in the milk and a relatively low level of allergen-
immune complexes.
It has been clearly shown that maternal IgG, mainly IgG1, has strong inhibitory 
effects on eliciting allergen-specific IgE responses in offspring4;28;29. Maternal 
IgG can be transferred to the offspring either via breastfeeding or via  placenta 
by transfer via Fc receptor (FcRn) 30.
 It has also been shown that oral tolerance induction in female mice 
during pregnancy can induce allergen-specific tolerance towards asthma 
manifestations in the pups, which was exclusively dependent on breastfeeding 
of the tolerized pups, and was associated with the presence of allergen-specific 
IgG in the breast milk 31. Interestingly, in a study using a similar approach 
but inducing oral tolerance prior to conception, tolerance induction was also 
observed, but under these conditions breastfeeding was not critically required 
for the effects, although it remained sufficient in the absence of placental 
IgG transfer in FcRn-deficient mice 30. The main difference between these 
two studies is the timing of tolerance induction relative to pregnancy and 
breastfeeding, where tolerance induction during pregnancy might possibly 
not induce sufficiently high levels of allergen-IgG immune-complexes to 
efficiently allow placental transfer of IgG-allergen ICs and induction of 
tolerance. For tolerance induction by breast feeding, transfer of free allergen 
might contribute in a TGF-β dependent fashion 12. Since in our experiment, SIT 
treatment was performed preconceptionally, and no allergen challenges were 
given to the pregnant or lactating mothers, transfer of tolerance to the progeny 
was anticipated to also include placental transfer of IgG-allergen immune 
complexes. Indeed, mice born to SIT-treated mothers but fostered by naïve 
mice show a strongly reduced allergen-specific IgE upon sensitization and 
challenge, indicating that tolerance towards antigen-specific IgE has indeed 
been induced in these mice. Remarkably, eosinophilic airway inflammation 
was not suppressed under these conditions, in contrast to the other models of 
placental tolerance transfer 13;30. The cause for this discrepancy between the 
individual parameters of our experimental allergic asthma model is unknown, 
although we and others have previously shown the IgE-independence of 
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the eosinophilic airway inflammation in the OVA-driven asthma model 25;32. 
Intriguingly, according to our data on suppression of IgE responses, breast 
milk from SIT-treated mothers, despite containing high level of IgG and IC, 
actually did not confer suppression of IgE responses to the offspring, since 
pups born to naive mothers but nursed by SIT-treated fosters had unaltered 
IgE responses compared to pups born to and nursed by naive mothers. Hence, 
we conclude that either the level of allergen-IgG ICs in the breast milk of the 
SIT-treated mothers was not sufficiently high or the nature of allergen-IgG ICs 
is different in the milk of SIT-treated versus untreated allergically sensitized 
mothers. Therefore tolerance towards the induction of OVA-specific IgE 
responses in the pups is not achieved is SIT-treated mothers. In our study, we 
observe that offspring from OVA-sensitized and sham treated mothers were 
protected against eosinophilic airway inflammation and allergen-specific 
IgE, indicating an effect of prior sensitization of the mother. Interestingly, 
a trend towards a similar protective effect of prior allergen sensitization of 
the female mice was observed in the study by Mosconi et al, where airway 
inflammation, allergen-specific IgE and Th2 cytokines were all reduced in 
pups born to sensitized compared to non-sensitized mothers, irrespective 
of OVA challenges during lactation 13. These effects, however, were far 
less pronounced than the effect of allergen challenge during lactation, and 
failed to reach statistical significance. Nevertheless, these and our data might 
indicate that IgG responses induced by allergen sensitization also have a, 
albeit limited, contribution to the transfer of tolerance to the pups. Our data 
on the cross-fostering experiment indicate that both placental and breast-milk 
transfer of IgG might contribute to these effects. 
In summary, we have shown here that despite induction and transmission of 
IgG and IC via breast milk from sensitized and OVA-SIT treated mothers 
to the offspring, SIT induced tolerance was not conferred to the offspring 
through the breast milk, although placental transfer of tolerance to allergen-
specific IgE, but not airway eosinophilia could be observed. Our findings also 
indicate that allergen sensitization prior to conception might also contribute to 
allergen tolerance in the pups, and tolerance induction in this manner strictly 
requires contribution of both pre and postnatal transfers. Future experiments 
involving allergen provocation of SIT-treated mothers during pregnancy or 
lactation as well as performing SIT injections during pregnancy or lactation 
might be helpful to elucidate the possibility of SIT induced maternal transfer 
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Allergy is caused by a specific Th2 immune response to innocuous 
environmental antigens and the subsequent production of allergen-specific 
immunoglobulin E (IgE) to these antigens 1;2. The prevalence of allergic 
diseases has continuously increased over the last four decades, especially in 
industrialized countries 3. The underlying causes of this increased prevalence 
of allergic diseases are not understood to date. Epidemiological data indicate 
that increased prevalence of allergic diseases has been associated with 
changes in environmental factors and lifestyle, such as: (i) reduced exposure 
to microbial infection as stated in the hygiene hypothesis 4, (ii) increased 
exposure to perennial allergens 5, (iii) decline in physical exercise and changes 
in diet 5 e.g. increased usage of iron intake by infants in affluent societies6-8. 
However, supportive data for mechanisms underlying each hypothesis is 
lacking to date.
The question whether increased iron intake by infants offers a causal 
explanation for the increased prevalence of allergic diseases has not been 
tested by experimental approaches to date. In our OVA -driven mouse model 
we asked whether increased iron intake can contribute to an increased severity 
of manifestations of experimental allergic asthma. To this end, we evaluated 
whether high levels of orally and parenterally administered iron altered 
the asthma parameters in our mouse model of OVA-driven allergic asthma 
(chapter 2). Surprisingly, we found that high levels of oral iron administration 
in fact reduce the allergen-induced airway eosinophilia, whereas parenteral 
iron administration suppresses allergen-induced airway hyperreactivity 
and reduces airway eosinophilia. We did not find evidence supporting our 
hypothesis that iron administration could augment the manifestation of allergic 
disease. We examined the effects of systemic as well as orally administered 
iron on allergic sensitization and the severity of asthma-like manifestations 
in our mouse model. However, the contribution of increased usage of iron 
supplements to the increased prevalence of allergic diseases in human 
populations, which more likely reflects an increase in allergic sensitization than 
an increased severity of symptoms, remains to be elucidated. Nevertheless, 
our data indicate that in a sensitized individual, increased iron intake might 
have beneficial effects on alleviating the symptoms of the disease.
The importance of a causal treatment for allergic diseases that leads to 
long-lasting relief of the disease symptoms by changing the immunological 
response to the allergen, which is the cause of the disease, is underscored 
by the lack of practical options for preventive measures despite the high 
prevalence of allergic diseases 9. Allergen specific immunotherapy (SIT) 
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is currently the only causal treatment for allergic diseases rendering long-
lasting relief of symptoms. There is requirement for improvement of SIT 10;11. 
A detailed understanding of the mechanisms of action of SIT, a prerequisite 
for the rational improvement of the treatment, is lacking to date. 
Allergen Specific Immunotherapy
Noon and colleagues were the first who documented the clinical efficacy of 
allergen specific immunotherapy (SIT) in alleviating the allergic symptoms 
in 1911 12. This treatment has been in clinical use, ever since, for different 
allergic diseases with vrariable efficacies. SIT is efficacious in allergic rhinitis 
and venom allergies, while its efficacy to suppress manifestations of allergic 
asthma remains variable at best 13-16. There is an unmet medical need for 
improvement of SIT, which requires a detailed understanding of the mechanisms 
by which SIT induces its therapeutic effects. During the last few decades, 
significant progress has been made in our understanding of the SIT-induced 
modifications in immunological and clinical parameters 17-26. For instance, 
increased production of allergen specific IgA and IgG has been reported after 
SIT treatment in allergic patients 27-31. This might indicate a role for blocking 
immunoglobulins which sequestrate the allergen on the one hand and induce 
inhibitory signals through low affinity Fcg-RIIB on the other hand. Besides 
production of immunoglobulins, B cells may also play a tolerogenic role in SIT 
by acquisition of regulatory capacities 32. Increased frequency of peripheral 
FOXP3+ as well as IL-10 producing inducible regulatory T cells (iTreg cells) 
have also been observed after SIT treatment in clinical studies, indicating a 
possible role for a heterogeneous population of iTreg cells in SIT-induced 
allergen tolerance 28;33. In agreement with the induction of IL-10 producing T 
or B regulatory cell subsets, increased plasma levels of IL-10 and increased 
allergen-induced production of IL-10 by PBMCs of allergic individuals was 
observed shortly after the initiation of SIT treatment 34. Production of IL-10 
after SIT, however is not limited to B and T cells and it has been shown that 
monocytes produce IL-10 after SIT as well 35. The long-term efficacy as well 
as the allergen specificity of SIT suggests that long-lived memory B or T cell 
subsets rather than short-lived monocytes govern the SIT-induced allergen-
specific tolerance induction 13;36;37. Collectively, these studies have stressed the 
importance of several subpopulations of innate and adaptive immune cells and 
their mediators. However, due to the limitations of the clinical studies towards 
experimental interventions during treatment, these studies have remained 
largely descriptive in nature. To allow the undisputed identification of those 
immune cell subsets and mediators critically required for the suppression 
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of allergic responses by SIT, we and others have established experimental 
mouse models of allergen-specific immunotherapy38;39. In our model, we treat 
OVA-sensitized mice with allergen injections (SIT treatment), followed by 
allergen provocation by inhalation, to assess suppression of manifestations of 
allergic asthma in comparison to a control group. The value of these models 
has been underscored by the identification of IL10 receptor signaling as an 
event critically required for the suppression of allergic inflammation by IT 
in the mouse model 39. Notwithstanding the fact that the mouse model has 
allowed us to begin to unravel the immunological basis of SIT, the exact 
molecular and cellular mechanism of action has to be elucidated yet. 
In this dissertation we aimed to (i) dissect the mechanism of SIT-mediated 
generation of allergen-specific tolerance in a sensitized host, and to (ii) 
identify efficient approaches to improve the safety or efficacy of SIT. We have 
approached these aims by addressing the following questions:
1) What is the role of B cells and secreted allergen-specific IgG or IgA in SIT-
induced suppression of allergic manifestations upon allergen provocation?
2) Are plasmacytoid dendritic cells during SIT treatment crucially required 
for SIT-induced suppression of allergic manifestations? 
3) What is the role of CD4+FOXP3+ Treg cells during SIT treatment for the 
generation of SIT-induced allergen tolerance?
4) Are CD4+FOXP3+ Treg cells critically required for SIT-induced 
suppression of the manifestation of allergic asthma during allergen 
provocation?
5) Which cell types produce IL-10 during SIT treatment as well as upon 
allergen provocation, and do these cells play a critical role for the 
suppression of allergic manifestations?
6) Can CTLA4-Ig be used as an adjuvant for SIT to improve the efficacy of 
SIT in suppressing the manifestations of allergic asthma?
7) Can TGF-β delivered at the time of SIT treatment improve the efficacy 
of SIT to suppress the manifestations of allergic asthma through the 
generation of iTreg cells?
8) Can SIT-induced allergen tolerance be transferred to the next generation? 
The role of B cells and blocking antibodies in SIT
B cells are the only cells of the immune system that produce and secrete 
antibodies. They play a pivotal role in the pathogenesis of allergic diseases 
by Th2-induced production of allergen specific IgE that binds to mast cells 
and basophils and thereby sensitizes these cells 40. B cells can potentially 
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contribute to the SIT-induced allergen tolerance through two mechanisms. 
The first mechanism entails the production of allergen specific IgG and IgA. 
Increased production of allergen specific IgA and IgG (especially IgG4) has 
been frequently observed after SIT treatment in allergic patients 27-31 and 
in experimental mouse models of SIT 41-43. The observation of increased 
levels of allergen-specific IgG after SIT treatment has lead to the blocking 
IgG hypothesis as an explanation for the mechanism of action of SIT. The 
blocking IgG hypothesis states that allergen specific IgG antibodies have a 
pivotal role in SIT-induced tolerance induction 44;45. These antibodies on the 
one hand can bind to the allergen and block its binding to IgE antibodies, 
thereby preventing IgE cross-linking on effector cells such as mast cells 
and basophils, IgE facilitated antigen presentation by dendritic cells and 
effectively preventing the allergic reaction induced by allergen provocation46. 
On the other hand, IgG can bind to the inhibitory IgG receptor (FcγRIIB) 
on the same effector cells and through the intracellular ITIM motif inhibit 
IgE-induced FceRI signaling upon allergen-mediated cross-linking 47. The 
neutralizing capacity of IgG antibodies for allergen-IgE interactions has been 
elegantly shown by Pree and colleagues 48. These investigators showed that 
SIT with recombinant Bet V1, a major allergen of birch pollen, increases the 
level of IgG in serum, which correlates with reduced binding of allergen-
IgE complex to low affinity IgE receptor, CD23, and thereby to a reduced 
allergen specific T cell response48. Some studies have indeed observed a 
negative correlation between the level of IgG after SIT and improved clinical 
symptoms or skin prick test reaction49-51, while other studies did not 52;53. 
Some studies have suggested that the affinity for the allergen, rather than 
the concentration of immunoglobulin in the serum, determines the beneficial 
effects and neutralizing capacity of SIT-induced IgG antibodies 46;54;55.
The second potential mechanism by which B cells might contribute to SIT is 
by acquiring regulatory properties such as production of IL-10. It has been 
shown that helminth infection can induce such regulatory B cells, and that 
these have suppressive effects on allergic inflammation 32;56 suggesting that 
regulatory B cells may have therapeutic implication in allergic diseases 32. 
In the studies described in chapter 3 of this dissertation we aimed to address 
the role of B cells in SIT-induced allergen tolerance in our mouse model of 
allergic asthma. Since, in parallel to the clinical situation, SIT in our model 
induces strongly increased levels of allergen-specific IgG1 and IgG2a, our 
experimental mouse model efficiently allows these mechanistic studies. 
First, we show that mice lacking the inhibitory FcγRIIB did not display an 
altered sensitivity to suppression of allergic manifestations by SIT, ruling out 
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a critical role for neutralizing IgG antibodies by binding to its inhibitory Fc 
receptor. Moreover, using mice lacking all mature B cells, we show that neither 
regulatory B cells nor the production of allergen-specific IgG is required for 
SIT-induced tolerance in our model. We further showed that local production 
of IgA at the mucosal surfaces, a feature retained in the mature B cell deficient 
mice, is dispensable for the therapeutic effects of SIT by using mice that 
lack the polymeric-immunogobulin receptor that uniquely transports IgA 
across the mucosal barrier. In conclusion, we show that production of allergen 
specific IgG or IgA, or B cell regulatory function is not required for SIT-
induced allergen tolerance in our mouse model. 
These data are in striking contrast to a study taking a similar approach towards 
SIT treatment in a Fel d1-driven mouse model of acute anaphylaxis57. Here, 
the authors show that signaling through FcγRIIB is critical for suppression 
of the systemic, basophil-mediated, anaphylactic response upon i.v. 
administration of the allergen, but not of the tissue mast cell degranulation 
upon local administration of the allergen. In our study using the B cell 
deficient mice, allergen-specific IgE is entirely absent, and consequently the 
asthma manifestations in our model exclusively reflect the allergen-induced 
late phase response induced by Th2 cell activity 58. Hence, we cannot draw 
any conclusions regarding the requirement of blocking IgG or B cell activity 
for the suppression of the early allergic response, unlike the Fel d1 mouse 
study, which exclusively assesses the early allergic response. Taken together, 
production of allergen-specific IgG, as observed in human studies of SIT, 
may not be necessary for suppression of late-phase allergic responses, but 
they might still critically contribute to the effects of SIT on the early phase 
response, and have a limited contribution to the suppression of the late phase 
response by SIT through sequestration of allergen, inhibitory signaling 
through FcγRII and blocking IgE mediated allergen presentation.  
Role of dendritic cells
Antigen presentation is a key step in eliciting an efficient T cell mediate 
immune tolerance. Surprisingly, there is only limited knowledge available 
about antigen presentation during SIT. Classically, SIT is performed by 
subcutaneous administration of the allergen where it can be captured by a 
variety of antigen presenting cells (APCs) including Langerhans cells, dermal 
dendritic cells, skin macrophages and plasmacytoid dendritic cells (pDCs) that 
are recruited to the skin 59-61. Langerhans cells reside in the epidermal layer of 
the skin and show tolerogenic properties in the absence of danger signals 62. 
These cells have high migratory capacities, and might therefore contribute to 
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allergen presentation in secondary lymphoid organs during SIT63. However, 
in SIT allergen is applied to hypodermis layer of the skin which is not the 
anatomical location of the Langerhans cells.  Instead, Langerhans cells reside 
in the epidermis layer of the skin and thus the contribution of these cells to 
tolerance induction might be rather limited 64. Nevertheless, Langerhans cells 
can be found in the hypodermis layer of the skin during their migration from 
epidermis to the regional lymph nodes 65. These migratory Langerhans cells, 
however, undergo a maturation process leading to reduced capacity of antigen 
capture 66. This makes allergen capture by Langerhans cells an unlikely event, 
especially during the low allergen up-dosing phase characteristic of early-
phase SIT treatment. Langerhans cells might, however, contribute to the 
generation of SIT-induced tolerance when other routes of allergen application 
are employed, such as sublingual SIT 67 or SIT with skin patches where the 
patches are applied on the epidermis layer of the skin 68.   
Conventional DCs also have the capacity of inducing immune tolerance 69;70. 
It has been shown that dermal DCs have high migratory capacity in vivo 71 
and have the capacity to generate inducible Tregs in vitro 72 and in vivo 73. 
Dermal DCs (dDCs) also reside in an anatomical compartment that is located 
in the deeper layers of the skin 74, making them more likely candidates for 
the presentation of the subcutaneously administered allergen. Interestingly, 
it has been shown that dDCs preferentially induce FOXP3-IL-10 producing 
regulatory T cells while Langerhans cells induce FOXP3+ regulatory T cells75. 
The role of dermal DCs in the generation of SIT-induced allergen tolerance, 
however, remains to be determined. 
Skin-resident macrophages can possibly play tolerogenic roles during 
antigen presentation 60. It has recently been demonstrated that macrophage-
like cells play a critical role in antigen presentation and tolerance induction 
during sublingual SIT in a mouse model 76. However, the route of antigen 
administration and potentially the mechanism of tolerance induction in 
sublingual SIT are different from subcutaneous SIT. The importance of skin 
macrophages for SIT-induced allergen tolerance has yet to be elucidated.
pDCs also seem to be good candidates for playing a tolerogenic role 
during SIT since these cells can be rapidly recruited to the skin upon skin 
stimulation 61 and they can contribute to allergen tolerance induction through 
at least two mechanisms. The first mechanism is by expression of IDO, 
which has been found to be expressed in particular by pDCs 77. We have 
previously shown that IDO partially contributes to the therapeutic effects of 
SIT in our mouse model 42. The second mechanism of pDC contribution to 
allergen tolerance is by facilitating the generation of IL-10 producing Tr-1 
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cells through expression of ICOS-L 78. We have previously shown that SIT-
induce allergen tolerance in our mouse model is IL-10 dependent 39. In the 
studies described in chapter 4 of this dissertation we investigated the role of 
pDCs in the induction of allergen tolerance during SIT in our mouse model 
of allergic asthma. We show that pDCs contribute to antigen presentation 
during SIT by capturing the subcutaneously applied allergen followed by 
functional antigen presentation in the draining lymph nodes. However, these 
cells play dispensable roles for the induction of allergen tolerance in our 
model as evident by a similar efficacy of SIT in suppressing the manifestation 
of experimental allergic asthma in the presence or absence of pDCs. These 
results indicate that other sub-types of DCs or skin macrophages can play 
a critical role in the generation of allergen tolerance during SIT treatment. 
We also show that the second major population of DCs that capture OVA 
during SIT in our model displays a phenotype similar to dermal DCs. Since 
we found that pDCs are redundant for SIT-induced allergen tolerance, we 
suggest that dDCs play a crucial tolerogenic role during SIT. Yet, it remains 
to be addressed whether antigen presentation leading to tolerance induction 
during SIT is in fact limited to a specific subset of APCs or whether tolerance 
induction is instead a redundant activity, shared by different subsets of APCs 
and merely depends on the activation state of the APC presenting the allergen 
upon the SIT injections.
Role of regulatory T cells
There is a large body of evidence suggesting a pivotal role for regulatory T 
cells (Treg cells) in the induction of SIT-mediated allergen tolerance. Treg 
cells are key players in the induction of peripheral immune tolerance 79. 
Central tolerance ensures that self-reactive T cells are eliminated during T cell 
differentiation in the thymus by the process of negative selection. Peripheral 
tolerance enables the immune system to control the immune responses to 
pathogens, to prevent unnecessary immune reactions to harmless antigens 
and to suppress self reactive T cells that escaped central tolerance induction. 
Peripheral tolerance acts through the induction of T cell anergy and through 
active immune suppression by Treg cells 79-82. 
There is evidence suggesting that SIT generates forkhead box P3 (FOXP3) 
expressing inducible regulatory T cells (iTreg cells) 28;83;84. However, it 
is unknown whether these de novo FOXP3+ Treg cells play a critical role 
in mediating the suppression of allergic manifestations in human patients. 
Moreover, it is not known whether FOXP3+ naturally occurring Treg cells 
(nTreg), a separate lineage of T cells originated from a distinct precursor in 
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thymus, are required for maintaining a tolerogenic microenvironment during 
the SIT treatment, allowing the induction of allergen-specific tolerance. 
In the studies described in chapter 5 of this dissertation we first tested the 
possibility that during SIT, FOXP3+Treg cells are required for the generation 
of SIT-induced allergen tolerance. Regardless of the mechanism by which SIT 
suppressed the manifestation of experimental allergic asthma upon allergen 
provocation, we addressed whether FOXP3+Treg cells are required for the 
induction of this suppressive mechanism. It has been shown that nTreg cells 
can facilitate the generation of iTreg cells, a process known as infectious 
tolerance 85;86. Since nTreg cells express high levels of interleukin-2 receptor 
α-chain (CD25) 80 we used a CD25-depleting antibody at the time of SIT 
injections, thereby applying an approach that has been widely used to study 
the function of nTreg 87-89. Interestingly, we found that depleting nTreg cells 
during SIT partially impaired SIT-mediated suppression of allergen induced 
AHR while it did not influence the suppression of airway eosinophilia or 
serum levels of specific IgE. These findings indicate that the mechanism by 
which SIT suppresses allergen-induced AHR is, at least in part, dependent on 
nTreg cells present at the time of SIT treatment.
One possible mechanism of the contribution of nTreg cells at the time of 
SIT treatment is the generation of TGF-β producing iTreg cells (Th3), 
which contribute to the suppression of AHR upon allergen exposure. This 
explanation is supported by two lines of evidence from literature. First, it 
has been shown that nTreg cells can induce a subset of iTreg cells that show 
TGF-β dependent suppressive effects 86. Second, it has been shown that Treg 
cells engineered to produce TGF-β are capable of suppressing AHR in mouse 
model of OVA-driven asthma 90. Hence, we hypothesize that the induction 
of a TGF-β producing iTreg cells subset during SIT treatment contributes 
specifically to suppression of AHR.    
In chapter 5, we further examined whether SIT generates de novo FOXP3+ 
Treg cells and whether these FOXP3+ Treg cells are critically required for 
SIT-induced suppression of the manifestation of allergic asthma upon allergen 
provocation. We show that SIT generates inducible CD4+CD25+FOXP3+ Treg 
cells as evident by the transient increased number of CD4+CD25+FOXP3+ Treg 
cells only in spleen and blood shortly after the injections. We found that SIT 
increases the number of CD4+CD25+FOXP3+ Treg cells in the spleen and blood 
at 24h but not 96 h after the treatment. These data are in line with observations 
in human studies, where increased number of CD4+CD25+FOXP3+ Treg cells 
was observed in the circulation during venom SIT 28. 
Finally, we demonstrate that SIT-induced suppression of airway eosinophilia 
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but not of AHR and specific IgE is partially mediated by CD4+FOXP3+ Treg 
cells. Here, we used DEREG mice to specifically deplete CD4+FOXP3+ T 
cells, 24 h prior to inhalation challenges in our mouse model of SIT. This 
approach enabled us to selectively deplete CD4+FOXP3+ Treg cells after 
SIT treatment, before inhalation challenges 91. Interestingly, we found that 
depletion of CD4+FOXP3+ Treg cells after SIT abrogated suppression of 
airway eosinophils whereas suppression of AHR and specific serum IgE 
remained intact. These data indicate that airway eosinophilia in our model 
is suppressed by an induced subset of CD4+FOXP3+ Treg cells. In other 
mouse models, FOXP3+ T cells were also found to suppress eosinophilic 
inflammation. For instance, in a mouse model of nasal tolerance induction, 
it has been shown that depletion of CD4+CD25+FOXP3+ Treg cells before 
allergen exposure abrogates the suppression of airway eosinophilia 88. Grainer 
and colleagues have shown that helminth secretions lead to generation of 
CD4+FOXP3+ iTreg cells can effectively suppress airway inflammation in a 
mouse model 92. In a clinical study it was observed that number of circulating 
CD4+FOXP3+ Treg cells negatively correlates with specific IgE in serum and 
eosinophils in allergic patients, suggesting a role for CD4+FOXP3+ Treg cells 
in suppressing the levels of IgE and eosinophils in the human situation, too.
Taken together, we find that CD4+FOXP3+ Treg cells contribute to the 
generation of tolerance towards AHR during SIT, most likely by the induction 
of a FOXP3- TGF-β producing regulatory T cell subset, while SIT generates 
CD4+FOXP3+ iTreg cells that suppress airway eosinophilia upon allergen 
challenge.    
Source of IL-10 production
Interleukin 10 has been suggested to play a crucial role in SIT-induced 
allergen tolerance. Increased IL-10 levels have been frequently observed 
after successful SIT in patients 28;35;93-95. Some studies have reported that SIT 
increases the number of peripheral IL-10+CD4+ T cells 35;93;94 while some 
studies report increased levels of IL-10 in serum 27;95;96. Also in tissue biopsies, 
IL-10+ T cells and APCs have been observed during season in grass-pollen SIT 
treated subjects 97. We have previously shown that neutralizing IL-10 using 
IL-10-receptor neutralizing antibody completely abrogated the therapeutic 
effects of SIT in our model 39, indicating that IL-10 is crucially required for 
SIT-induced allergen tolerance in our model. In the experiments described in 
chapter 6, we tested which cells were producing IL-10 during SIT treatment 
and subsequent allergen provocation, and which of these IL-10 producing 
cells were critical for suppression of allergic inflammation. Here, we found 
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that SIT increased the number of IL-10 producing Th2 cells and CD8+ T cells 
at the time of SIT injections. Depletion of CD8+ T cells, however, indicated 
that these cells were dispensable for suppression of allergic inflammation by 
SIT. Our data demonstrating increased production of IL-10 by Th2 cells are in 
line with the finding of Aslam and colleagues, who showed that SIT initially 
activates Th2 cells which are subsequently gradually suppressed as Treg cells 
are induced 25. 
Interestingly, at the time of allergen challenge, T cell subsets no longer 
produced enhanced IL-10 levels. Instead, we identified a subset of DCs that 
produces IL-10 upon allergen exposure subsequent to SIT in our mouse 
model. This DC subset expressed CD11c and CD11b, identifying it as an 
inflammatory DC, and intermediate levels of MHCII indicating a reduced 
maturation of these cells. By performing adoptive transfer experiments using 
OVA-pulsed DCs from IL-10 knockout mice or from wild-type controls into 
wild-type, OVA-sensitized and OVA-SIT or sham control treated acceptor 
mice, we show that IL-10 production by the allergen-presenting DCs was 
critically required for suppression of allergic airway inflammation at the time 
of allergen provocation in this model. 
In our mouse model of allergic asthma, SIT induces a long-term IL-10 
dependent tolerance that lasts for at least 20 weeks 39. In the experiments 
described in chapter 6 we have observed that IL-10 secretion by DCs is pivotal 
for SIT-induced suppression of airway eosinophilia. Since long-term allergen-
specific memory cannot be maintained by short-lived DCs, we postulate that a 
subset of allergen-specific regulatory T cells instructs the allergen-presenting 
DCs to produce the IL-10 required for suppression of allergic inflammation. A 
similar observation has been made by Kearly and colleagues, who have found 
that transfer of CD4+CD25+ T cells to sensitized mice suppresses allergen-
induced airway inflammation and AHR in an IL-10-dependent fashion, the 
IL-10 secretion from the transferred CD4+CD25+ T cells themselves is in fact 
not required for the observed suppressive effects. 
Overall, we conclude that DC-derived IL-10 mediates SIT-induced suppression 
of airway eosinophilia. However, the short lifespan of DCs and long term 
efficacy of SIT indicates that SIT-induced allergen tolerance is maintained 
by a yet to be identified sub-type of Treg cells.  Given the data described in 
chapter 5, where we show that depletion of FOXP3+ Treg cells at the time of 
allergen challenge, but not of all Treg cells at the time of allergen injections 
is sufficient to suppress eosinophilic airway inflammation, we postulate that 




Improvement of SIT: CTLA4-Ig, a potent adjuvant for SIT
SIT has three main disadvantages, being the need for (i) high doses of the 
sensitizing allergen, and thereby the risk of severe side-reactions, including 
anaphylaxis, (ii) the long-term treatment required for sustained protection, and 
(iii) the variable efficacy in treated patients. Identifying clinically applicable 
adjuvants that increase the efficacy for allergic disorders in which SIT is 
currently not efficacious, or that result in the same efficacy of SIT at lower 
doses of allergen, or that allow a reduced treatment period, are urgently needed. 
In experiments described in chapter 7 we examined whether CTLA4-Ig can 
act as an adjuvant for SIT using our mouse model. Cytotoxic T Lymphocyte 
Antigen 4 (CTLA4) is an inhibitory costimulatory molecule expressed by 
nTreg cells and activated T cells, and has been implicated in terminating T 
cell responses 98. CTLA4-Ig is a fusion molecule consisting of extracellular 
domain of CTLA4 with Fc regions of human or mouse IgG99. CTLA4-Ig has 
tolerogenic effects, and has been used in the treatment of rheumatoid arthritis 
and prevention of allograft rejection in humans 100-102.
Two mechanisms are involved in tolerogenic effects of CTLA4-Ig. First, 
CTLA4-Ig can sequester B7 and thereby block CD28:B7 interactions and 
prevent the T cell costimulatory signal required for acquisition of full effector 
functions 98. Second, CTLA4-Ig can signal into the DC through B7 molecules, 
activate the non-canonical NF-kB pathway and induce the expression of 
IDO99;103;104. 
We tested whether CLTA4-Ig has an adjuvant effect on SIT in our mouse model. 
We found that co-administration of CTLA4-Ig with SIT highly enhances SIT-
induced suppression of AHR, airway eosinophilia and allergen-specific IgE 
in the serum indicating that CTLA4-Ig can act as a potent adjuvant for SIT. 
Testing the effects of co-administration of CTLA4-Ig with SIT in mice lacking 
the indoleamine 2,3 dioxygenase (IDO) gene revealed that although SIT in 
these mice fails to suppress AHR and airway eosinophilia, CTLA4-Ig restores 
and highly enhances the suppressive effects of SIT. These results suggest that: 
First, IDO contributes to the mechanism of induction of allergen tolerance 
confirming our previous findings using a chemical inhibitor of IDO 42. Second, 
the likely mechanism of action for CTLA4-Ig in our model is blocking CD28 
costimulatory signal in CD4+ T cells and not induction of IDO through reverse 
signaling. Since memory Th2 cells in the sensitized host are less dependent 
on CD28 for their activation, blocking CD28-mediated costimulation most 
likely affects naïve CD4+ T cells leading to the induction of clonal anergy 
and regulatory properties in these otherwise activated cells 98;105. It has been 
shown that lack of costimulation leads to the induction of anergized human T 
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cells which show regulatory properties through expression of inducible T cell 
costimulator (ICOS) and IL-10 106. So, co-administration of CTLA4-Ig with 
SIT through blocking CD28-mediated T cell costimulation may enhance the 
induction of anergized CD4+ T cells with regulatory properties that suppress 
the manifestation of experimental allergic asthma upon inhalation challenges. 
Lack of costimulation due to antigen presentation by immature DCs might 
also play a role in the induction of allergen tolerance in SIT without adjuvant. 
Overall, given the high efficacy of CTLA4-Ig in potentiating the effects 
of SIT, and approved clinical application of CTLA4-Ig by Food and Drug 
Administration and its European counterpart we suggest that CTLA4-Ig 
might be used as an adjuvant for SIT in clinical trials. 
Can TGF-β augment the therapeutic effects of SIT?
Increased TGF-β levels in serum have been observed after subcutaneous 
SIT, and TGF-β levels correlate with the alleviation of allergic symptoms 
in human patients 29;107;108. TGF-β can potentially contribute to SIT-induced 
allergen tolerance through four mechanisms. The first two mechanism 
involve facilitating the induction of TGF-β producing Th3 and FOXP3+ 
iTreg cells in the absence of IL-6 109-111 or in the presence of all-trans retinoic 
acid 112. The third mechanism of action of TGF-β is by instructing B cells 
to produce IgA113. The fourth mechanism by which TGF-β can contribute 
to the induction of allergen tolerance is generating tolerogenic properties in 
DCs by induction of IDO 114. While endogenous TGF-β may contribute to 
the therapeutic effects of SIT, we were interested to test whether exogenous 
TGF-β can potentiate the therapeutic effects of SIT. In the studies described 
in chapter 8, we examined whether administration of TGF-β during SIT 
injections could potentiate the effects of SIT, and if so, whether an enhanced 
induction of iTreg cells was observed in our mouse model of allergic asthma. 
Indeed, we found that TGF-β augmented SIT-induced suppression of allergen 
induced airway eosinophilia as well as Th2 cytokines when co-administered 
with suboptimal SIT (2x1 mg OVA-SIT). Interestingly, TGF-β also augments 
the suppressive effects of a 10-fold lower dose of sub-optimal SIT (2x 0.1 
mg OVA-SIT) on airway eosinophilia, OVA-specific IgE in serum and Th2 
cytokines in BAL. Moreover, we found that the enhancing effects of TGF-β 
on SIT is accompanied by an increased level of specific-IgA in the serum and 
an increased percentage of CD4+FOXP3+ Treg cells in the mediastinal lymph 
nodes. The latter effect was observed regardless of antigen administration. 
We observed that sub-optimal SIT increases the levels of TGF-β in the 
serum indicating a role for Th3 cells in the suppression of the manifestation 
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of experimental allergic asthma by SIT alone. However, administration of 
exogenous TGF-β does not seem to enhance the induction of Th3 cells as 
serum TGF-β levels were not further increased. Sub-optimal SIT-induced 
suppression of allergen-specific IgE, airway eosinophilia but not of AHR was 
augmented by co-administration of TGF-β. This suppression was associated 
with increased levels of allergen-specific IgA and percentage of CD4+FOXP3+ 
T cells in draining lymph nodes in our study. While the mechanism of SIT-
induced suppression of allergen-specific IgE remains to be determined, 
suppression of airway eosinophilia seems to be mediated by CD4+FOXP3+ T 
cells revisiting our previous findings that SIT-induced suppression of airway 
eosinophilia is mediated by CD4+FOXP3+ T cells. As we suggested earlier, 
induction of a subset of CD4+FOXP3- T cells which is not augmented by 
administration of exogenous TGF-β might be responsible for the suppression 
of AHR.     
Finally, we found that blocking IL-6 receptor during SIT treatment does not 
enhance the adjuvant effect of TGF-β on suppression of allergic manifestations 
by SIT, indicating that induction of Th17 cells does not seem be an important 
component of SIT in our model. Taken together we provide evidence that 
co-administration of TGF-β with SIT augments the therapeutic effects 
of SIT. Since systemic administration of TGF-β may induce undesirable 
effects, it is suggested that indirect induction of TGF-β in APCs, for instance 
by administration of vitamin D3 75, during SIT-treatment will be useful in 
clinical trials to improve the clinical efficacy of SIT. Interestingly, we have 
previously shown that co-administration of vitamin D3 with SIT potentiates 
the therapeutic effects of SIT through induction of IL-10 and TGF-β 43. 
Absence of maternal transfer of protection by allergen 
immunotherapy in a mouse model of allergic asthma
The prevalence of allergic diseases has been and still is increasing worldwide3. 
There is evidence indicating that asthma is heritable and that offspring born 
to asthmatic mothers have a bigger chance to develop asthma 115;116. Despite 
having a higher susceptibility to the disease, experimental data are now 
indicating that allergic mothers might in fact transfer protection to allergic 
sensitization to their progeny during pregnancy and lactation 117. It has been 
shown that pups born to allergically sensitized mice show reduced level 
of allergen induced airway inflammation, allergen-specific IgE and Th2 
cytokines 117. However, the observed reduction is more far more pronounced 
when mothers received inhalation challenges during lactation 117. Maternal 
transfer of allergen-IgG immune complexes are implicated in this maternal 
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transfer of protection against experimental allergic asthma 117. Interestingly, 
induction of allergen tolerance by SIT is associated with the induction of 
blocking IgG antibodies in humans 45 raising the question whether maternal 
transfer of therapeutic of SIT is possible. While the process of SIT treatment 
is time consuming and requires at least a few years of treatment to show 
efficient suppression of the symptoms of allergic diseases, it will be hitting 
two targets by one bullet if the beneficial effects of SIT can be transferred to 
the next generation through maternal transfer. In the experiments described in 
chapter 9 we examined whether SIT-induced allergen tolerance can be 
transferred to the progeny of the treated mothers through allergen-immune 
complexes in the breast milk. As expected, we found that SIT, induces 
high levels of allergen-specific IgG1 in the serum of treated mothers. We 
discovered that enhanced allergen-specific IgG1 and allergen-immune 
complexes are present in the breast milk of sensitized as well as SIT-treated 
mothers. Interestingly, we observed that induction of experimental asthma 
in the progeny of all OVA-sensitized mice resulted in a lower level of OVA-
specific IgE in the serum compared to the progeny of naïve mice. Surprisingly, 
only progeny of OVA-sensitized Sham-treated but not SIT-treated mice 
showed lower level of airway eosinophilia compared to the progeny of naïve 
mice upon induction of experimental asthma. This is in accordance with the 
study conducted by Mosconi and colleagues, where they showed that allergen 
sensitization in mothers convey a low-level of protection to the progeny 117, 
however, our results indicate that SIT-treatment abrogates this protection 
against airway eosinophilia. Although it was not evaluated directly, one 
reason for this abrogation could the induction of allergen-IgG2a immune 
complexes in the milk in SIT-treated mothers. We have previously shown 
that SIT treatment induces high levels of allergen-specific IgG2a in the serum 
in our model 58. Induction of allergen-IgG2a complexes in the milk might 
abrogate the low-level protection in progeny induced by low concentration 
of allergen-IgG1 complexes. More studies are required to unravel the details 
of allergen tolerance that is transferred to the progeny of SIT-treated mothers. 
It has been shown that allergen-specific IgE responses in offspring are 
strongly inhibited by maternal IgG 118-120. Maternal IgG can be transferred 
to the offspring either via breastfeeding or via  placenta by transfer via Fc 
receptor (FcRn) 121. To assess the impact of transfer of OVA-IgG immune 
complexes through either breastfeeding or placenta, we analyzed the asthma 
manifestations in mice born to sensitized Sham-control or OVA-SIT treated 
mice but weaned by naïve mice, and vice versa. Intriguingly, we found that 
pups born to SIT-treated mothers but weaned by naïve mice show tolerance 
towards the induction of specific IgE in serum. However, this tolerance 
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towards specific IgE is absent in the pups born to naïve mothers and weaned 
by SIT-treated fosters. These results suggest that the placental, rather than the 
milk, route of transfer of allergen-IgG complexes conveys the SIT-induced 
maternal protection towards allergen-specific IgE in the serum. Lack of transfer 
of SIT-induced maternal protection through milk could be due to a relatively 
lower level of allergen-IgG complexes in the milk compared to the study of 
Mosconi and colleagues. The level of allergen-IgG complexes in the milk in 
our study was approximately one third of the levels observed by Mosconi 
and colleagues. These investigators exposed the mothers to airborne allergen 
during lactation while in our study SIT treatment was done preconceptionally 
and there was no further exposure to allergen during pregnancy or lactation. 
Absence of allergen exposure during pregnancy and lactation, not only leads 
to reduced level of allergen-IgG complexes but also reduces the transfer of 
free allergen through the milk which has been shown to transfer protection to 
allergen induced airway inflammation in a TGF-β dependent fashion 122. In a 
study conducted by Polte and colleagues, they observed that preconceptional 
induction of oral tolerance is transferred to the progeny independent of 
breast milk 121. Although this protection remained sufficient in the absence 
of placental IgG transfer in FcRn-deficient mice 121. More studies are needed 
to determine the transferability of effects of SIT from mothers to pups and to 
unravel the possible mechanism of transfer. 
Summarizing conclusion
In our mouse model of SIT, the sequence of events can be virtually divided 
into two phases of action including induction and effector phase. Induction 
phase is defined as the period of SIT-treatment when administration of allergen 
leads to alterations in allergen specific immune response and induction 
of allergen tolerance. Effector phase is the period of allergen provocation 
subsequent to SIT-treatment when the mediators of allergen tolerance 
suppress the manifestation of experimental allergic asthma. We contribute to 
unraveling the mechanisms of SIT-induced allergen tolerance by investigating 
the induction as well as the effector phase of SIT, focusing largely in the 
suppression of the late-phase allergic response, and by evaluating the role of 
B cells, pDCs, CD8+ T cells, CD4+FOXP3+ T cells and IL-10 producing DCs. 
A hypothetical mechanism of action of SIT in our model is demonstrated in 
figure 1. Interestingly, we find no contribution of B cells or blocking IgG to 
the suppression of allergic asthma manifestations (chapter 3), while we do 
observe a dependence on IL-10 (chapter 6) and subsets of regulatory T cells 
(chapter 5). These data are in remarkable conflict to the data presented by 
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the group of Bachmann 57 who showed that blocking immunoglobulins are 
critically required for the suppression of anaphylaxis upon systemic delivery 
of Fel d1 in sensitized and SIT-treated mice. Remarkably, suppression of 
anaphylaxis in this model is entirely independent on the presence of Tregs or 
CD4+ T cells altogether. Since we find a complete redundancy for B cells and 
IgG for the suppression of the allergic inflammation by SIT, we can conclude 
that SIT suppresses the early and the late phase allergic response through 
radically divergent mechanisms: suppression of the early phase response 
requires the presence of blocking Ig and B cells, but is independent on Tregs, 
whereas the situation is reversed for the suppression of the late phase response, 
that is dependent on the presence of Tregs, but entirely independent on B cells 
and blocking IgG. 
The critical antigen-presenting cell during the induction phase of SIT remains 
to be established. By ruling out the role of pDCs we propose that dDCs 
capture the administered allergen and transport it to the skin draining lymph 
nodes during the induction phase. In skin draining lymph nodes allergen is 
presented to CD4+ Th2 cells and naïve Th cells in the presence of nTregs that 
maintain a tolerogenic microenvironment and are relevant for the suppression 
of AHR at the time of allergen challenges. We postulate the hypothesis that 
during this process, the presence of CD4+CD25+FOXP3+ Treg cells lead to 
the generation of CD4+FOXP3- Treg cells that suppress AHR likely through 
expression of TGF-β, ICOS or programmed death-1 (PD-1) in the effector 
phase. The evidence for the possible role of ICOSL or PD-1 has been provided 
by McGreen and Agrawal who showed that transfer of either CD25+ or CD25-
CD4+T cells suppresses allergen induced AHR and airway inflammation in 
a mouse model of allergic asthma, and proposed a role for PD-1 and ICOS 
expressed by CD4+CD25+ Treg cells 123. Moreover, It has been shown that 
ligation of PD-1 or ICOS to their corresponding ligands on DCs induces 
IL-10 secretion in the DC 124. Hansen and colleagues provided evidence for 
the suppressive effects of TGF-β on airway eosinophilia and AHR in a mouse 
model of allergic asthma 90. 
During the induction phase, allergen-specific CD4+CD25+FOXP3+ Treg cells 
are also generated, likely through expression of TGF-β by allergen presenting 
APCs, or through the absence of costimulation. It remains to be established 
whether these cells originate from de novo differentiated naïve T cells or 
from immune deviation of the pre-existing Th2 memory cells. The large 
amounts of allergen required for efficient induction of allergen tolerance 
argues in favor of a model where the pre-existing memory pool of Th2 
cells needs to be saturated, allowing for the concurrent activation of naïve 
210
Chapter 10
T cells that will then adopt a regulatory T cell fate. Our data in chapters 4 
and 6 clearly show the activation of the pre-existing Th2 cells during the 
induction phase. Our data in chapter 5 show that the pre-existing nTregs 
are not required for the induction of this iTreg subset, while our data in 
chapter 7 indicate that full blockage of co-stimulatory activity can further 
enhance the suppression of allergic manifestations. Taken together, 
the cumulative data presented in this thesis strongly argue in favor for 
the de novo induction of iTregs during the induction phase through the 
absence of costimulatory molecules by the relevant APC subset. We 
postulate that these iTreg cells suppress airway eosinophilia by instructing 
CD11bhiCD11chi MHC-IIint DCs to produce IL-10 during the effector phase. 
The IL-10 production by the DCs then critically suppresses the induction of 
a late phase response during the allergen provocation in SIT treated mice, 
resulting in strongly reduced airway eosinophilia and reduced presence and 
activity of Th2 cells. Exogenous TGF-β enhances the generation of de novo 
CD4+CD25+FOXP3+ Treg cells and enhances SIT-induced suppression of 
airway eosinophilia, indicating the possibility for further enhancement of the 




























Figure 1 - Proposed mechanism by which SIT suppresses the manifestation of experimental allergic 
asthma in our mouse model of SIT. Antigen presentation to Th2/naïve CD4+ T cells by dermal dendritic 
cells in the presence of CD4+ FOXP3+ Treg cells leads to the generation of TGF-β producing Th3 Treg 
cells.  These Th3 cells suppress allergen induced AHR. Antigen presentation during induction phase 
also results in the generation of de novo CD4+FOXP3+ Treg cells which suppress airway eosinophilia 
during effector phase. SIT-induced suppressed levels of IgE in the serum could be due to either: (i) 
generation of a subset of CD4+FOXP3- Treg cells during induction phase which suppress the levels of 
allergen-specific IgE in the serum during effector phase, or (ii) induction of anergy in B cells caused by 
high level of antigen administrations during induction phase.
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SIT-induced suppression of allergen-specific IgE in the serum could be 
mediated by a subset of CD4+FOXP3- Treg cells which are generated during 
induction phase, since the levels of allergen-specific IgE in the serum remained 
unchanged in the presence or absence of CD4+FOXP3+ Treg cells. It is also 
possible that administration of high levels of allergen during induction phase 
causes clonal anergy in the allergen-specific B cells. The exact mechanism of 
SIT-induced suppression of specific IgE in the serum remains to be further 
elucidated.
Interesting points to address in the future studies
The followings are interesting points to be addressed in future studies:
•	 Determining the functional role of dermal DCs, langerhans cells and 
skin macrophages during SIT for the induction of allergen tolerance
•	 Identify the exact mechanism of SIT-induced suppression of allergen-
specific IgE in the serum. 
•	 Identify which cell types produce TGF-β during the induction phase 
and whether TGF-β plays a crucial role during the induction phase for 
the therapeutic effects of SIT
•	 The contribution of Programmed Death-1 mediated signaling during 
the effector phase of SIT-induced allergen tolerance
•	 Identifying Treg cell sub-types that mediate SIT-induced allergen 
tolerance
•	 Testing the adjuvant efficacy of CTLA4-Ig in SIT in clinical trials
•	 Identifying the mechanism of transfer of beneficial effects of SIT 
through the milk 
•	 Identifying whether administration of  SIT injections or inhalation 
exposure of SIT-treated mothers during pregnancy leads to the transfer 
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Allergische ziekten zoals hooikoorts en astma zijn chronische 
ontstekingsziekten die worden gekenmerkt door regelmatig terugkerende 
klachten zoals tranende ogen, niezen en benauwdheid, telkens wanneer men in 
contact komt met een allergeen zoals stuifmeel of huisstof. De onderliggende 
oorzaak van deze ziekten is een overdreven reactie van het afweersysteem 
op allergenen waardoor IgE antilichamen worden aangemaakt. Deze IgE 
antilichamen passen als een sleutel op een slot op het betreffende allergeen, 
of anders gezegd ze binden er specifiek aan. Dit IgE wordt geproduceerd door 
de zogenoemde B-cel, een bepaald type witte bloedcel. De geproduceerde 
IgE-antilichamen circuleren in het bloed en binden aan het oppervlak van 
mestcellen die zich in de weefsels, zoals de long en neus, bevinden. Hierdoor 
kunnen deze mestcellen na hernieuwd contact met het betreffende allergeen 
heel specifiek hierop reageren en komt o.a. histamine vrij. Het vrijgezette 
histamine leidt tot de karakteristieke allergische klachten zoals hiervoor 
genoemd. Naast deze acute klachten veroorzaakt chronische blootstelling aan 
een allergeen zoals tijdens het stuifmeelseizoen, chronische ontsteking van de 
luchtwegen (long en neus). Bij astmatische patiënten ontstaat hierbij ook een 
toename van de gevoeligheid van de luchtwegen voor luchtwegvernauwende 
prikkels. Dit laatste wordt hyperreactiviteit genoemd. De ontsteking 
wordt gekenmerkt door de aanwezigheid van grote aantallen eosinofiele 
granulocyten en wordt daarom ook wel eosinofiele ontsteking genoemd. Uit 
onderzoek bij mensen en muizen is de laatste decennia duidelijk geworden 
dat zowel de aanmaak van IgE-antilichamen als de chronische klachten 
van ontsteking en hyperreactiviteit worden gedirigeerd door een bepaald 
type witte bloedcel, de type 2 T-helper-cel, kortweg Th2-cel genoemd. Th2 
cellen worden gekarakteriseerd door het aanmaken van cytokinen zoals 
interleukine-4 (IL-4), IL-5 en IL-13 die betrokken zijn bij IgE aanmaak door 
B-cellen, eosinofiele ontsteking en luchtweg hyperreactiviteit.
Allergeen immunotherapie
Ruim een eeuw geleden werd allergeen specifieke immunotherapie (SIT; 
ook wel hyposensibilisatie of allergeen vaccinatie genoemd) voor het 
eerst toegepast voor de behandeling van hooikoorts. Het principe van deze 
behandeling is grotendeels nog steeds hetzelfde. Uit een ruwe grondstof 
(stuifmeel afkomstig van gras) wordt een extract gemaakt, het SIT preparaat. 
De behandeling met deze SIT preparaten bestaat uit een opdoseringsfase van 
wekelijkse onderhuidse injecties met een toenemende dosis van het allergeen 




deze eerste fase volgt een onderhoudsfase die bestaat uit maandelijkse injecties 
met deze hoogste dosis die wordt voortgezet gedurende drie tot vijf jaar. SIT 
wordt toegepast bij allergische ziekten zoals hooikoorts en allergisch astma, en 
kan leiden tot vermindering van de allergische klachten. Het voordeel van SIT 
in vergelijking met alle andere behandelingen voor allergieën (o.a. steroïden 
en antihistaminica) is dat de werkzaamheid van SIT aanhoudt gedurende een 
zeer lange tijd (> 15 jaar) na het stopzetten van de therapeutische behandeling. 
Dit langdurig onderdrukken van allergische klachten ondanks blootstelling 
aan allergeen wordt tolerantie genoemd. Belangrijke andere aspecten van SIT 
zijn de verminderde kansen op sensibilisatie voor andere allergenen en op 
het ontwikkelen van astma bij allergische kinderen. Belangrijke nadelen van 
SIT zijn de variabele effectiviteit, de duur van de behandeling en de vereiste 
klinische monitoring tijdens de opdoseringsfase om in te kunnen grijpen bij 
ernstige allergische reacties. Deze nadelen hebben er helaas toe geleid dat 
deze behandeling nog steeds niet op grote schaal wordt toegepast. Er is dus 
alle reden om SIT te verbeteren zowel wat betreft de effectiviteit alsook de 
veiligheid en de duur van de behandeling zodat deze behandeling aantrekkelijk 
wordt voor een grote groep allergische patiënten.
Over het werkingsmechanisme van allergeen immunotherapie in het lichaam 
bestaat nog veel onduidelijkheid. In de loop van de 20e eeuw is de rol van 
blokkerende IgG antilichamen, de inductie van T-cel anergie, een verschuiving 
van een Th2-cytokine respons naar een Th1 respons en de inductie van bepaalde 
regulerende T-cellen nader onderzocht. Het is echter nog steeds noodzakelijk 
om meer te weten te komen over het precieze werkingsmechanisme van 
allergeen immunotherapie om deze behandeling ook effectief en veilig toe 
te kunnen gaan passen bij allergische astmapatiënten. Hiervoor is enkele 
jaren geleden in ons laboratorium een muismodel voor allergisch astma 
ontwikkeld waarin de verschillende astmatische verschijnselen door allergeen 
immunotherapie onderdrukt konden worden. Muizen kunnen astmatisch 
worden gemaakt door deze dieren te sensibiliseren middels intraperitoneale 
injecties met het model allergeen ovalbumine en een paar weken later de 
luchtwegen herhaaldelijk bloot te stellen aan een nevel van hetzelfde allergeen 
(“provocatie”). Bij deze dieren wordt een door Th2-cellen gereguleerde 
afweerreactie waargenomen met een toename van allergeen-specifiek IgE in 
het serum, een verhoogde hoeveelheid eosinofielen in de longen en de long 
lavage vloeistof, en hyperreactiviteit voor diverse luchtwegvernauwende 
stimuli. Door het toepassen van allergeen immunotherapie ná de sensibilisatie 
maar voorafgaande aan de inhalatieprovocatie, is het mogelijk de astmatische 
verschijnselen te onderdrukken. In dit proefschrift zijn de resultaten 
beschreven van experimenten die als doel hadden meer te weten te komen over 
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het werkingsmechanisme van allergeen immunotherapie met als uiteindelijk 
doel te komen tot een verbeterde immunotherapie voor de behandeling van 
allergische patiënten, inclusief astma. 
Is er een rol voor IgG en IgA in allergeen immunotherapie? 
(hoofdstuk 3) 
B-cellen zijn de enige cellen van het afweersysteem die antilichamen aanmaken 
en uitscheiden en spelen een belangrijke rol in de pathogenese van allergische 
ziekten door de aanmaak van IgE antilichamen. B-cellen dragen mogelijk bij 
aan de tolerantie voor allergeen na SIT door twee mechanismen. Ten eerste 
neemt de bloedspiegel van allergeen-specifieke IgG en IgA antilichamen in 
het bloed sterk toe na SIT, zowel in de mens als in ons muismodel. Deze 
waarnemingen hebben geleid tot de zogenaamde “blokkerende antilichamen” 
theorie. Deze IgG antilichamen zouden de binding van het allergeen aan 
IgE kunnen blokkeren en daardoor allergische reacties kunnen afremmen. 
Daarnaast kunnen deze IgG antilichamen mogelijk via remmende IgG 
receptoren (FcγRIIB) allergische reacties onderdrukken. Ten tweede kunnen 
B-cellen een regulerende functie aannemen door de aanmaak van het 
afweeronderdrukkende interleukine-10 (IL-10).
In de experimenten beschreven in hoofdstuk 3 hebben we de rol van B-cellen 
in de tolerantie na SIT onderzocht in ons muismodel. Ten eerste toonden wij 
aan dat in muizen die de remmende IgG receptor niet hebben, SIT evengoed 
werkt als in kontrole muizen met deze receptor. Ten tweede toonden wij aan 
dat in muizen die geen B-cellen hebben, SIT evengoed werkt om de eosinofiele 
ontsteking te onderdrukken als in muizen die wel B-cellen hebben. Tenslotte 
toonden wij aan dat in muizen die IgA niet kunnen transporteren naar de 
mucosale oppervlakken zoals het slijmvlies de longen, SIT evengoed werkt 
om de eosinofiele ontsteking te onderdrukken als in kontrole muizen.
Samenvattend kan dus geconcludeerd worden dat de aanmaak van 
specifiek IgG en IgA alsook regulerende B-cellen niet essentieel zijn voor 
de ontstekingsonderdrukkende werking van SIT. Wij kunnen echter niet 
uitsluiten dat deze mechanismen een rol spelen in de remming van mestcel 
activatie of luchtweg hyperreactiviteit na SIT.
Is er een rol voor plasmacytoide dendritische cellen in 
allergeen immunotherapie? (hoofdstuk 4)
Dendritische cellen (DCs) zijn onderdeel van het afweersysteem en bevinden 
zich overal in het lichaam waar ze voortdurend lichaamsvreemde materialen 




Hierna zoeken de DCs T-cellen op in lymfeklieren en presenteren de 
opgenomen materialen aan deze T-cellen. Behalve deze presenterende rol 
hebben DCs ook een dirigerende rol doordat ze stofjes aanmaken die bepalen 
wat de T-cel vervolgens moet gaan doen. Dat kan betekenen dat de T-cel de 
Th2 cytokinen gaat produceren zoals bij allergische personen maar ook dat de 
T-cel een afweeronderdrukkende rol aanneemt. Deze afweeronderdrukkende 
T-cellen worden kortweg Treg cellen genoemd. Het is opmerkelijk dat er 
nagenoeg niets bekend is over de soort DCs en hun specifieke rol bij de 
tolerantie die optreedt na SIT.
Er zijn verschillende soorten DCs en één daarvan wordt de plasmacytoide DC 
genoemd (pDC). Het is algemeen bekend dat pDCs een belangrijke rol spelen 
bij de inductie van Treg cellen en tolerantie. Een van de manieren waarop 
de pDC dit doet is door gebruik te maken van een enzym, indoleamine 2,3 
dioxygenase (IDO), dat het aminozuur tryptofaan omzet in kynurenine en 
andere metabolieten. Voorheen is door ons aangetoond dat na remming van dit 
IDO enzym, de tolerantie die optreedt na SIT in ons muismodel grotendeels 
afwezig is. 
In hoofdstuk 4 laten we zien dat pDCs in belangrijke mate het allergeen 
opnemen na SIT waarbij het allergeen onderhuids wordt ingespoten. Hierna 
gaan deze DCs naar de lymfeklier om het allergeen aan T-cellen te presenteren. 
Echter als we deze pDCs uitschakelen, door het inspuiten van een antilichaam 
waardoor deze cellen dood gaan, en vervolgens SIT geven dan treedt nog 
steeds tolerantie op voor de allergische klachten in ons muismodel. Dit 
experiment toont aan dat de pDC geen kritieke rol speelt bij de tolerantie na 
SIT. Verder onderzoek is nodig om vast te stellen welke soort DC wél van 
kritisch belang is voor de tolerantie na SIT.
Zijn Treg cellen betrokken bij allergeen immunotherapie? 
(hoofdstuk 5)
Uit studies naar het werkingsmechanisme van SIT bij allergische personen 
blijken Treg cellen toe te nemen in het bloed na SIT. Of deze Treg cellen ook 
betrokken zijn bij de allergie onderdrukkende werking van SIT is moeilijk zo 
niet onmogelijk vast te stellen in de mens. In de muis bestaat deze mogelijkheid 
wel. In hoofdstuk 5 tonen wij in ons muismodel aan dat Treg cellen toenemen 
in het bloed en in de milt kort na de SIT injecties. Vervolgens hebben wij 
onderzocht of het uitschakelen van Treg cellen van invloed is op het ontstaan 
van de tolerantie na SIT. Hierbij is gebruik gemaakt van een zogenaamde 
“knock-out” muis en door antilichamen die de Treg cellen elimineren. Hieruit 
blijkt dat de rol van Treg cellen in de tolerantie na SIT complex is. Ze spelen 
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namelijk wel een rol bij de onderdrukking van de eosinofiele ontsteking maar 
niet bij de luchtweghyperreactiviteit en IgE antilichaam productie.
IL-10 producerende dendritische cellen zijn essentieel voor 
allergeen immunotherapie. (hoofdstuk 6)
Uit studies naar het werkingsmechanisme van SIT bij allergische personen 
blijkt de productie van het afweeronderdrukkende cytokine IL-10 door T-cellen 
verhoogd te zijn. Voorheen hebben wij in het allergische muismodel voor SIT 
aangetoond dat IL-10 een kritische rol speelt in de allergie onderdrukkende 
werking van SIT. In hoofdstuk 6 hebben wij nu in detail onderzocht welke 
lymfocyten en andere afweercellen IL-10 produceren na SIT. We hebben 
aangetoond dat kort na SIT het aantal IL-10 producerende CD8 lymfocyten 
toeneemt in de milt. Om een rol van deze IL-10 producerende CD8 lymfocyten 
bij SIT aan te tonen dan wel uit te sluiten, hebben wij de CD8 lymfocyten 
geëlimineerd kort vóór de SIT injecties. Dit bleek echter geen gevolg te 
hebben voor de tolerantie na SIT en kan dus geconcludeerd worden dat deze 
IL-10 producerende CD8 lymfocyten geen rol spelen bij SIT.
Aangezien IL-10 in staat is afweerreacties direct te onderdrukken, hebben wij 
in SIT behandelde muizen onderzocht welke cellen er nu IL-10 produceren 
lokaal in de long na de blootstelling aan het allergeen. Opmerkelijk genoeg 
vonden wij dat het niet de T-cellen zijn die verhoogd IL-10 maken, maar er 
bleek een groep van DCs te zijn die verhoogd IL-10 maakt indien de muizen 
SIT hebben ontvangen. Om te onderzoeken of deze IL-10 producerende DCs 
daadwerkelijk van belang zijn voor de allergie onderdrukkende werking 
van SIT in het muismodel, hebben wij gebruik gemaakt van zogenaamde 
adoptieve overdrachtstudies. In deze studies krijgen DCs in een reageerbuis 
allergeen aangeboden dat vervolgens wordt opgenomen. Deze DCs worden 
dan vervolgens in de luchtpijp van een allergische muis toegediend alwaar 
ze lokaal in de long de Th2 cellen activeren die dan de eosinofiele ontsteking 
veroorzaakt. Door nu DCs te gebruiken die al dan niet in staat zijn IL-10 
te produceren, konden wij aantonen dat IL-10 geproduceerd door allergeen-
presenterende DCs essentieel is voor de remming van de eosinofiele ontsteking 
na SIT. Omdat DCs een relatief kort leven hebben in het lichaam en de 
tolerantie na SIT langdurend aanhoudt, vermoeden wij dat er een bepaalde, 
nog niet nader bekende, T-cel moet zijn na SIT die deze DCs instrueert om 
IL-10 te gaan produceren. Het is heel goed mogelijk dat deze T-cel een Treg 
cel is waarvan we in hoofdstuk 5 hebben laten zien dat die betrokken is bij 
de onderdrukking van de eosinofiele ontsteking. Het is van belang om op te 




neus IL-10 producerende cellen zijn aangetoond die grotendeels niet bestaan 
uit T-cellen maar overeen lijken te komen met allergeen-presenterende cellen. 
Verder onderzoek zal nodig zijn om aan te tonen dat dit werkingsmechanisme 
van SIT in de muis ook plaatsvindt in allergische patiënten na SIT.
CTLA4-Ig is een potent adjuvans voor allergeen 
immunotherapie. (hoofdstuk 7)
SIT bij de mens heeft een drietal nadelen. (i) De noodzaak van toediening van 
een hoge dosis allergeen. (ii) De noodzaak van langdurige onderhoudsinjecties 
van 3-5 jaar. (iii) De grote variatie in de allergie onderdrukkende werking tussen 
verschillende patiënten. Daarom is er een grote behoefte om SIT te verbeteren 
en één van de mogelijkheden is door gebruik te maken van een adjuvans. 
Een adjuvans is een stof die de werking van SIT sterk bevordert terwijl deze 
stof alléén geen langdurende allergie-onderdrukkende werking heeft. In 
hoofdstuk 7 hebben wij onderzocht of het molecuul CTLA4-Ig bruikbaar is 
als adjuvans voor SIT in ons muismodel. Van CTLA4-Ig is aangetoond dat 
het tolerantie kan bevorderen op twee manieren. (i) CTLA4-Ig kan binden 
aan de receptor B7 op DCs en daarmee voorkomen dat het molecuul CD28, 
aanwezig op T-cellen, kan binden met deze receptor waardoor deze T-cellen 
langdurig inactief worden. (ii) CTLA4-Ig kan na binding aan de receptor 
B7 op DCs de hoeveelheid van het enzym IDO in deze DCs verhogen. Wij 
laten in het muismodel zien dat het toedienen van CTLA4-Ig tegelijk met 
SIT leidt tot een sterke verbetering van de allergie-onderdrukkende werking 
van SIT op de hyperreactiviteit, eosinofiele ontsteking en IgE aanmaak. 
Hetzelfde experiment uitgevoerd in muizen die het enzym IDO missen, liet 
een even sterke verbetering van SIT zien wat aantoont dat het enzym IDO 
niet betrokken is bij deze versterkende werking van SIT door CTLA4-Ig. 
Hoewel we dit niet formeel hebben aangetoond, ligt het dus voor de hand 
dat het werkingsmechanisme van CTLA4-Ig komt door het blokkeren van de 
B7 receptor waardoor T-cellen langdurig inactief kunnen worden. Aangezien 
het gebruik van CTLA4-Ig voor klinische toepassingen is toegestaan door 
de Europese en Amerikaanse autoriteiten (FDA, EMEA) zou een klinische 
studie naar de adjuvans werking CTLA4-Ig voor SIT in allergische patiënten 
van groot belang kunnen zijn. 
TGF-β bevordert de allergie-onderdrukkende werking van 
allergeen immunotherapie. (hoofdstuk 8)
Er is gerapporteerd dat de bloedspiegel van het afweeronderdrukkende 
cytokine TGF-β toeneemt na SIT in allergische patiënten. TGF-β kan op 3 
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verschillende mogelijkheden een rol spelen in de tolerantie na SIT. (i) TGF-β 
kan het aantal Treg cellen doen toenemen. (ii) TGF-β kan B-cellen aanzetten 
tot de productie van IgA antilichamen waarvan bekend is dat het een allergie-
onderdrukkende werking kan hebben. (iii) TGF-β kan de hoeveelheid van 
het enzym IDO in DCs verhogen. In hoofdstuk 8 waren wij in het bijzonder 
geïnteresseerd om te vast te stellen of TGF-β ook bruikbaar is als een adjuvans 
voor SIT in ons muismodel. Het bleek dat het toedienen van TGF-β tegelijk 
met SIT leidt tot een sterke verbetering van de allergie-onderdrukkende 
werking van SIT op de eosinofiele ontsteking en IgE aanmaak maar niet op 
de hyperreactiviteit. Dit ging gepaard met een duidelijke verhoging van de 
bloedspiegel van specifiek IgA antilichaam en een toename van het percentage 
Treg cellen in lymfeklieren. Dit laatste lijkt in overeenstemming met onze 
eerdere conclusie dat Treg cellen betrokken zijn bij de onderdrukking van 
eosinofiele ontsteking na SIT. Omdat systemische toediening van TGF-β 
ongewenste bijwerkingen zou kunnen hebben, zou het van belang kunnen 
zijn om te trachten DCs aan te zetten tot de aanmaak van TGF-β, door 
bijvoorbeeld de toediening van de actieve vorm van vitamine D. In dit kader 
is het interessant om te noemen dat wij voorheen al hebben aangetoond dat 
vitamine D als adjuvans de werking van SIT sterk bevordert. 
Afwezigheid van maternale overdracht van tolerantie na 
allergeen immunotherapie. (hoofdstuk 9)
In muismodellen van allergisch astma is aangetoond dat via de moedermelk 
allergenen en allergeen-specifieke IgG antilichamen kunnen worden 
overgebracht naar de pups, wat bij kan dragen aan de inductie van tolerantie 
tegen het allergeen in de pups. Omdat de serum spiegels van de allergeen-
specifieke IgG antilichamen bij SIT sterk verhoogd zijn, hebben we onderzocht 
of de tolerantie die SIT wordt geïnduceerd ook overdraagbaar is via de 
moedermelk. We konden inderdaad aantonen dat de moedermelk van SIT 
behandelde muizen allergenen en specifieke IgG antilichamen bevatte. Dit 
gaf echter maar een zeer beperkte bescherming tegen de aanmaak van IgE in 
de pups, en geen bescherming tegen eosinofiele luchtwegontsteking. Vreemd 
genoeg waren pups van moeders die wel allergisch waren maar niet behandeld 
met SIT wel enigszins beschermd tegen eosinofiele luchtwegontsteking, 
ook al was er geen aanwezigheid van specifieke IgG antilichamen in de 
moedermelk van deze muizen. In onze experimenten waren de spiegels 
van de specifieke IgG antilichamen in de moedermelk aanzienlijk lager dan 
bekend uit gepubliceerd onderzoek. Dit komt waarschijnlijk omdat wij in 




niet aan allergeen hebben blootgesteld, wat in de voorgaande studies van 
andere onderzoekers wel het geval was. In de toekomst zullen we verder 
gaan onderzoeken wat nu precies de bijdrage is van de neutraliserende IgG 
antilichamen in de moedermelk aan de bescherming in de pups, en of SIT van 
de moeder hier nu een extra bescherming kan bieden voor het nageslacht.
Conclusies
In ons onderzoek hebben we laten zien dat SIT de verschillende aspecten 
van een allergische reactie op meerdere manieren onderdrukt. De meeste 
vooruitgang hebben we geboekt in het ontrafelen van het mechanisme 
waarmee SIT de allergische ontsteking remt. Wij hebben aangetoond dat 
neutralizerende IgG antilichamen en IL-10 productie door B cellen van 
belang zijn voor de onderdrukking van de eosinofiele ontsteking van de 
luchtwegen na SIT. Daarentegen zijn Treg cellen en de productie van IL-10 
door antigeen-presenterende cellen tijdens een allergeen-provocatie juist wel 
belangrijk voor de onderdrukking van de eosinofiele luchtwegontsteking. We 
hebben ook laten zien dat deze Treg cellen niet al aanwezig hoeven te zijn 
tijdens de SIT behandeling, maar dat er juist door de SIT behandeling meer 
Treg cellen uitgroeien. Wij denken dus dat de SIT behandeling zelf nieuwe 
Treg cellen induceert, die bij allergeen provocatie vervolgens belangrijk zijn 
om de allergeen-presenterende cellen aan te zetten tot IL-10 productie, wat 
essentieel is voor het onderdrukken van de allergische ontsteking. We hebben 
ook aangetoond dat aanpassingen van de SIT behandeling die de uitgroei 
van Treg cellen verhogen sterk kunnen bijdragen aan de effectiviteit van 
SIT. Hierin liggen dus mogelijkheden voor toekomstige verbetering van de 
klinische behandeling met SIT.
Dutch version re-reviewed by Drs. D.K.J Willemsen, for typing errors.
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